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Amyloidogenic peptides are considered central pathological factors in neurodegenerative 
diseases; however, their roles in the pathologies of the diseases have not been fully understood. 
Amyloidogenic peptides have indicated their multiple faces on formation, aggregation, and 
accumulation that portray the complexity of the intrinsically disordered protein stemming from their 
convoluted structure and heterogeneous nature. Although the latest research suggests oligomeric forms 
of amyloidogenic peptides as toxic species towards neurodegeneration, their direct involvements in the 
pathologies and the corresponding mechanistic details remain rudimentary. Therefore, novel chemical 
approaches to modify amyloidogenic peptides at the molecular level would be useful in advancing our 
comprehension of those aspects and the subject. 
In Chapter 1, we briefly introduce outline and discuss possible therapeutic targets in Alzheimer’s 
disease. In Chapter 2, the design of an Ir(III) complex, Ir-1, is described as a chemical tool for oxidizing 
amyloidogenic peptides upon photoactivation and subsequently modulating their aggregation pathways. 
Biochemical and biophysical investigations illuminate that the oxidation of representative 
amyloidogenic peptides [i.e., amyloid- (A), -synuclein, and human islet amyloid polypeptide] is 
promoted by light-activated Ir-1, which can alter the conformations and aggregation pathways of the 
peptides. In Chapter 3, effective chemical strategies for modifications of A peptides implemented by 
a single Ir(III) complex are illustrated. Such peptide variations can be achieved by our rationally 
designed Ir(III) complexes leading to the significant modulation of the aggregation pathways of A40 
and A42 as well as the production of toxic A species. 
Amyloidogenic peptides can coordinate to metal ions, including Zn(II), which can subsequently 
affect the peptides' aggregation and toxicity, leading to neurodegeneration. Unfortunately, the detection 
of metal–amyloidogenic peptide complexation has been very challenging. In Chapter 4, we report the 
development and utilization of a probe (A-1) capable of monitoring metal–A complexation based on 
Förster resonance energy transfer (FRET). Moreover, as the FRET signal of Zn(II)-added A-1 is 
drastically changed when the interaction between Zn(II) and A-1 is disrupted, the Zn(II)-treated probe 
can be used for screening a chemical library to determine effective inhibitors against metal–A 
interaction. 
Overall, we demonstrate chemical tactics for modifications of amyloidogenic peptides in an 
effective and manageable manner utilizing the coordination capacities and/or photophysical properties 
of chemical reagents. Our approaches will provide the foundation for developing effective and efficient 
methods for elucidating fundamental properties of pathological factors at the molecular level and 
assisting in identifying therapeutic candidates against neurodegenerative disorders. 
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Et2O   Diethyl ether 
EtOAc   Ethyl acetate 
EXAFS   Extended X-ray absorption fine structure 
FBS   Fetal bovine serum 
FDA   Food and Drug Administration 
FRET   Förster resonance energy transfer 
FTD   Frontotemporal dementia 
FTIR   Fourier-transform infrared spectroscopy 
GABA   Aminobutyric acid 
Gel/Western blot  Gel electrophoresis with Western blotting 
GSK3   Glycogen synthase kinase 3 
hAChE   Human acetylcholinesterase 
HBTU   2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HDACs   Histone deacetylases 
HEPES   4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
HFIP   1,1,1,3,3,3-Hexafluoro-2-propanol 
hIAPP   Human islet amyloid polypeptide 
HOAt   1-Hydroxy-7-azabenzotriazole 
XVII 
HOBt   1-Hydroxy-benzotriazole 
HPLC   High-performance liquid chromatography 
HRMS   High-resolution mass spectrometry 
ICT   Isothermal titration calorimetry 
IM-MS   Ion mobility mass spectrometry 
IRF   Instrument response function 
JNK   c-Jun N-terminal kinase 
Kd   Binding affinities 
LTP   Long-term potentiation 
MALDI-TOF  Matrix-assisted laser desorption/ionization time-of-flight 
MAO   Monoamine oxidase 
MAPs   Microtubule-associated proteins 
MCI   Mild cognitive impairment 
MEM   Minimum essential medium 
MS   Mass spectrometry 
MS2   Tandem mass spectrometry 
MTs   Metallothioneins 
MTT   3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
MWs   Molecular weights 
N2a   Neuro-2a 
NADPH oxidase  Nicotinamide adenine dinucleotide phosphate oxidase 
Nap   N-Naphthylethylenediamine 
NFTs   Neurofibrillary tangles 
NMDA   N-Methyl-D-aspartate 
NMDAR  N-Methyl-D-aspartate receptor 
NMR   Nuclear magnetic resonance 
PAS   Peripheral anionic site 
PBS   Phosphate-buffered saline 
PD   Parkinson’s disease 
PDB   Protein data bank 
PDEIs   Phosphodiesterases inhibitors 
PDEs   Phosphodiesterases 
pGlu-A  Pyroglutamate A 
PHFs   Paired helical filaments 
PIPES   Piperazine-N,N’-bis(2-ethanesulfonic acid) 
PLA2s   Phospholipase A2 
XVIII 
PPAR   Peroxisome proliferator activator receptor  
ptau   Hyperphosphorylated tau 
ROS   Reactive oxygen species 
S.E.M.   Standard errors of mean 
sAPP   Soluble amyloid precursor protein  
SAXS   Small-angle X-ray scattering 
SDS   Sodium dodecyl sulfate 
SFs   Straight filaments 
SHG   Second harmonic generation 
SOD   Superoxide dismutase 
SOFAST-HMQC 2D band-selective optimized flip-angle short transient heteronuclear 
multiple quantum correlation 
SPPS   Solid phase peptide synthesis 
SPR   Surface plasmon resonance 
SPs   Senile plaques 
TBS   Tris-buffered saline 
TCSPC   Timecorrelated single-photon counting 
TEM   Transmission electron microscopy 
TFA   Trifluoroacetic acid 
ThT   Thioflavin-T 
TLC   Thin layer chromatography 
TNF   Tumor necrosis factor 
TNF   Tumor necrosis factor  
TRAIL   Tumor necrosis factor-related apoptosis-inducing ligand 
TRAIL-R1  Tumor necrosis factor-related apoptosis-inducing ligand receptor 1 
TRAIL-R2  Tumor necrosis factor-related apoptosis-inducing ligand receptor 2 
Tris   Tris(hydroxymethyl)aminomethane 
UV-vis   Ultraviolet-visible spectroscopy 
XANES   X-ray absorption near edge structure 
XAS   X-ray absorption spectroscopy 
ZIPs   Zinc-regulated transporters, iron-regulated transporter-like proteins 
ZnT   Zinc transporter 
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1.1.1. Neurodegenerative Diseases 
Neurodegenerative diseases are characterized by the progressive loss of neuronal function. Despite a 
herculean effort, neurodegenerative diseases remain incurable. Research is revealing parallels between 
Alzheimer’s disease (AD), the most prevalent form of dementia which accounts for ca. 60−80% of 
cases,1 and other neurodegenerative diseases, including Parkinson’s disease (PD)2 and amyotrophic 
lateral sclerosis (ALS).3 As the global population ages and the number of individuals expected to 
develop neurodegenerative conditions increases, the search for an effective cure is becoming 
progressively more urgent. 
An obstacle to drug discovery can in part be attributed to the multifactorial nature of most 
neurodegenerative illnesses. Although the specifics vary, several unifying threads that run through 
multiple neurodegenerative diseases have been identified. Proteopathy is one recurrent aspect, generally 
in the form of misfolded and aggregation-prone proteins and peptides, which may occur concurrently 
with defects in their clearance (Figure 1.1).4−6 AD is characterized by the deposition of senile plaques 
(SPs) and neurofibrillary tangles (NFTs), composed of the aggregates of amyloid- (A) and 
hyperphosphorylated tau (ptau), respectively.7,8 
Another prominent theme is metal ion dyshomeostasis in the brains of patients suffering from 
neurodegeneration.8−12 Under normal conditions, metal ions play several critical roles in the brain. They 
are cofactors for numerous enzymes with important catalytic activities (e.g., energy production) and 
serve as active participants in metal-dependent neurotransmission. Therefore, the proper regulation of 
metal ions is necessary for normal neuronal function. In neurodegenerative diseases, elevated or 
lowered levels as well as miscompartmentalization of metal ions are observed, leading to dysregulation 
of various downstream processes (Figure 1.1). One important consequence of metal ion dyshomeostasis 
[especially, redox-active Cu(I/II) and Fe(II/III)] is oxidative stress caused by reactive oxygen species 
(ROS) overproduced from Fenton-like reactions.10,13 In addition, metal ions are coordinated to 
amyloidogenic peptides (e.g., A) and consequently modify their aggregation pathways.14−16 Other 
pathological features common to several neurodegenerative diseases include mitochondrial 
dysfunction,17−19 elevated oxidative stress,20 defects in energy metabolism,21,22 aberrant axonal 
transport,23−25 and pervasive, sustained chronic inflammation (Figure 1.1).7,26 Thus, these pathological 
elements could trigger neuronal loss, alter neurotransmitter levels, and lower the capacity for signal 
transduction precipitating the progressive decline of cognitive and/or motor function and eventual death. 
Based on their inter-related roles in the pathogenesis of AD, metal ions and other inter-related 




Figure 1.1. Multifactorial nature of neurodegenerative diseases. (a) Proteopathy of wild-type (wt) or 
mutant intra- or extracellular unfolded proteins/peptides. Unfolded monomers partially fold and 
aggregate into oligomers and fibrils. Oligomers may interact with various organelles (e.g., mitochondria) 
or cell membrane disrupting Ca(II) homeostasis and signaling. (b) Dyshomeostasis of metal ions that, 
depending on the disease, can bind to misfolded proteins/peptides affecting their aggregation or 
accumulate in the brain or spinal cord. (c) Elevated oxidative stress resulting from redox-active metal 
ions (i.e., Cu and Fe) via Fenton-like reactions or ROS escaping from damaged mitochondria. ROS can 
attack cellular proteins, nucleic acids, and lipids causing oxidative damage. (d) Mitochondrial 
dysfunction and defects in energy metabolism that can occur as a consequence of protein/peptide 
aggregates. (e) Aberrant axonal transport from hyperphosphorylated microtubule binding proteins, 
mutant tubulin proteins, or mutant motor proteins. (f) Pervasive, sustained chronic inflammation with 
reactive microglia and astrocytes as well as altered inflammatory signaling pathways. 
 
Current therapeutic strategies are palliative and only manage symptoms for a short duration of 
time before cognitive abilities or motor function continue to degenerate. At present, for instance, widely 
administered treatments for AD are acetylcholinesterase inhibitors (AChEIs) which curb acetylcholine 
(ACh) degradation and thus maintain levels of neurotransmission.27 This approach, however, invariably 
fails, and patients eventually succumb to deteriorating cognitive health. Development of efficacious 
drugs for neurodegenerative illnesses has been challenging because their precise etiology is not 
completely identified. A thorough comprehension of disease etiology would be beneficial to aid the 
discovery of effective therapeutics capable of targeting the root cause of neurodegenerative conditions 
in a disease-modifying manner. For example, the amyloid cascade hypothesis, the most widely held AD 
hypothesis, posits that the aggregates of A peptides, produced in the brain, are the primary cause of 
neurodegeneration.28 Drugs altering the production, clearance, and aggregation of A have been 
developed and many have entered clinical trials. None, however, has successfully yielded significant 
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benefits, although some improvements were observed.29 These failures have prompted a reexamination 
of the hypothesis suggesting that other factors, in addition to A, may be mutually operating in 
neurodegeneration.30 Another hurdle is timely treatment because neurodegeneration begins prior to 
disease onset and diagnosis. Intervening at this stage could halt further damage, but it may not be able 
to reverse the deterioration, which has already occurred. Compounded with these problems are 
challenges that come from treating a condition in the brain, which is generally nonregenerative, highly 
heterogeneous, and insulated by the blood-brain barrier (BBB). 
Taken together, the multifaceted nature of neurodegenerative diseases suggests that an effective 
treatment might require a multipronged approach to simultaneously combat several pathological 
features. Towards this aim, numerous chemical tools capable of targeting and regulating pathological 
aspects of neurodegenerative disorders have been rationally designed, and studies have been conducted 
to assess their efficacies. This chapter describes possible therapeutic targets in AD-affected brains to 
advance our understanding of the etiology fo the disease. 
 
1.2. Alzheimer’s Disease (AD) 
In 1906, Alois Alzheimer introduced the world to a devastating disease widely known today as AD.31 
AD is a progressive neurodegenerative disease responsible for 60 to 80% of dementia cases.1,32 
According to the World Alzheimer Report, 47 million people worldwide were affected by AD in 2015 
and this number is projected to increase to 75 million by 2030.1 With the aging world population, the 
social and economic impact of AD is expected to rise significantly.33 Since the discovery of AD, a great 
deal of progress has been made towards understanding its pathogenesis; however, we have yet to 
pinpoint its causative factors or fully elucidate its pathology. More importantly, there are no treatments 
for AD that can cure or halt its progression. Current AD therapies either temporarily relieve symptoms 
by inhibiting acetylcholinesterase (AChE) to maintain the levels of ACh and cholinergic transmission 
or regulating the activation of N-methyl-D-aspartate (NMDA) receptors. Five AD treatments approved 
by the Food and Drug Administration (FDA) are available to relieve the symptoms of AD (Table 1.1): 
(i) three AChE inhibitors (i.e., donepezil, galantamine, and rivastigmine); (ii) an NMDA receptor 
(NMDAR) antagonist (i.e., memantine); (iii) a mixture of donepezil and memantine. The imminent 
amplification of the socioeconomic impact of AD and the lack of an effective treatment illustrate the 
urgent necessity to identify the underlying AD pathogenesis. 
Loss of short-term and long-term memory is the most widely recognized AD symptom. 
Throughout the progression of AD, patients manifest a general decline in mental ability: language and 
motor skills, sensory information processing, and memory formation and retrieval.34 The anatomical 
hallmarks of AD include the shrinkage of the hippocampus and cortex.35 Histopathologically, AD 
compromises SPs and NFTs composed primarily of A and tau, respectively.28,36,37 Along with its 
proteopathy, metal ion dyshomeostasis, imbalance between the production and removal of ROS, and 
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loss of cholinergic transmission are also implicated in AD pathology. Several hypotheses have arisen in 
an attempt to identify the principal pathological factors in AD: (i) amyloid cascade hypothesis; (ii) tau 
hypothesis; (iii) metal ion hypothesis; (iv) oxidative stress hypothesis; (v) cholinergic hypothesis. Thus, 
therapeutics targeting singular pathological factors presented in these hypotheses have proven 
ineffective, inferring the intricate nature of AD pathogenesis. Consequently, the contemporary direction 
concerning AD etiopathology increasingly appreciates its complexity and has transitioned from 
focusing on individual pathological components to illuminating the interrelations among multiple 
pathological factors. 
 
Table 1.1. Currently available AD treatments. 





All Stages 1996 AChE 
Galantamine 
 















aDonepezil, 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one; galantamine, (4aS,6R,8aS)-
5,6,9,10,11,12-hexahydro-3-methoxy-11-methyl-4aH-[1]benzofuro[3a,3,2-ef][2]-benzazepin-6-ol; memantine, 3,5-
dimethyl-tricyclo[3.3.1.13,7]decan-1-amine; rivastigmine, (S)-3-[1-(dimethylamino)ethyl]phenyl-N-ethyl-N-
methylcarbamate. bAChE, acetylcholinesterase; BuChE, butyrylcholinesterase; NMDAR, N-methyl-D-aspartate receptor. 
 
1.2.1. Amyloid- (A) and Tau 
AD proteopathy is portrayed by two highly recognized AD hypotheses: the amyloid cascade and tau 
hypotheses. The amyloid cascade hypothesis posits that A, a proteolytic product of amyloid precursor 
protein (APP), is the causative factor in the course of AD pathology.36 Genetic studies support the 
pertinence of A in the pathogenesis of AD. Numerous AD genes are shown to influence A pathology 
(e.g. APOE, APP, PSEN1, and PSEN2).38 A common polymorphism, ε4, within APOE is reportedly 
associated with the late onset of AD. This mutation is characterized by elevated A aggregation and 
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reduced A clearance.39,40 Genetic variants in APP are connected with early onset familial AD.41 
According to an AD mutation database, 51 APP gene mutations are believed to be linked to the increased 
A42:A40 ratio as well as the production and aggregation of A leading to AD.38,41 PSEN1 and PSEN2 
mutations are indicated to be involved in the pathology of AD with 219 and 16 variants identified, 
respectively.41 Genetic mutations to PSEN1 and PSEN2 are shown to enhance the A42:A40 ratio.38 
Responsible for the production of A, APP processing can be categorized into nonamyloidogenic 
and amyloidogenic pathways.42−44 In nonamyloidogenic APP processing, the soluble APP (sAPP) 
and the C-terminal fragment  (CTF) are formed by -secretase cleavage.42−44 Subsequent cleavage 
of CTF by -secretase results in the generation of p3, a nonamyloidogenic peptide. Amyloidogenic 
APP processing is initiated by -secretase cleavage [e.g., -site APP cleaving enzyme (BACE1)] 
producing sAPP and CTF.42−44 The generated CTF is then cleaved by -secretase at multiple sites 
within the transmembrane domain, producing a range of A monomers with 38 to 43 amino acid 
residues.42−45 
A peptides possess a propensity to aggregate, which is a subject of intensive research. As an 
intrinsically disordered protein, A lacks stabilized secondary or tertiary structures; however, it can 
exist in partially folded states depending on genetic mutations and external factors (e.g., pH, 
temperature, peptide concentration, and intermolecular interactions).46 During on-pathway aggregation, 
composed of a nucleation phase followed by an elongation phase, monomeric A species oligomerize 
through interactions between their self-recognition sites and hydrophobic C-terminal regions (Figure 
1.2).43 These metastable A oligomers can further aggregate into protofibrils and fibrils which exhibit 
a -sheet conformation.46 Fibrils have been reported to contribute to the accumulation of A oligomers 
through fragmentation and secondary nucleation.47,48 Due to their prominent presence in extracellular 
SPs, fibrils were initially thought to be responsible for the neurotoxicity found in AD.49,50 A lack of the 
correlation between SP load and the extent of neurodegeneration, however, led to the reevaluation of 
this notion.36 Recent studies have supported an alternative concept of structured A oligomers as 
potential toxic species.51−54 The toxic mechanisms of structured A oligomers have been proposed to 
arise from their interactions with membranes and membrane receptors and the disruption of intracellular 
processes [e.g., induction of endoplasmic reticulum (ER) stress, lysosomal leakage, mitochondrial 
dysfunction, and signal interruption].46,55 Furthermore, A transmissibility through a seeding effect has 
been suggested as a means to spread its toxicity, possibly to remote areas, through cell-to-cell 
transmission mechanisms.56,57 Overall, the amyloid cascade hypothesis presents potential therapeutic 




Figure 1.2. Schematic representation of the on-pathway aggregation of A. During the nucleation phase, 
A monomers aggregate to oligomers through interactions between their self-recognition sites (LVFFA; 
highlighted in bold and underlined in the amino acid sequence of A). Structured A oligomers are 
implicated as potential toxic species. Oligomeric A species are further transformed into protofibrils 
and fibrils. Fragmentation of preformed fibrils, along with secondary nucleation, also contributes to the 
formation of A oligomers. 
 
NFTs, the second prominent histopathological feature of AD, are mainly found within neurons 
and predominantly contain aggregates of the tau protein.123,144 Proponents of the tau hypothesis links 
the toxicity in AD to the pathogenicity of tau, whose NFT burden correlates more accurately with 
neurodegeneration than A plaque load.37,60 Tau, a phosphoprotein, belongs to the family of 
microtubule-associated proteins (MAPs) that stabilize microtubules, promote, among other functions, 
anterograde (nucleus to periphery) and retrograde (periphery to nucleus) axonal transport, and sustain 
dendrite structure.61 Thus, properly functioning tau is essential to neuronal trafficking and synapse 
architecture. 
Tau is encoded by a single gene on chromosome 17 that gives rise to six isoforms varying in 
length from 352 to 441 amino acids, which are all found aggregated and hyperphosphorylated in 
NFTs.37,58 Tau hyperphosphorylation causes a loss-of-function, which hinders its ability to bind to 
microtubules, inducing the deterioration of axonal trafficking and dendrite structure leading to 
microtubule depolymerization.37,58,62 pTau aggregation occurs in stages, as for A, first into oligomers 
and amorphous tangles that mature into paired helical filaments (PHFs) and straight filaments (SFs). 
Similar to A fibrils, PHFs and SFs also contain a cross- structural feature but additionally include a 
-helix motif.63 Other proteins [e.g., normal tau and alternative MAPs (MAP1/2)] and post-
translationally modified and truncated tau/ptau are coaggregated with PHFs and SFs.64 A greater 
understanding of tau’s aggregation pathway may prove useful in the development of tau-targeting 
therapeutics. Noble et al. linked the initiation of tau aggregation to cyclin-dependent kinase-5 (cdk5) in 
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a transgenic (Tg) mouse model.65 Further research regarding tau phosphorylation and aggregation in 
AD is necessary to determine their cause-and-effect relationship leading to neuronal degradation and 
suggest prospective therapeutic approaches. 
Gain-of-toxic function from tau is suspected to arise from ptau oligomers rather than from NFTs 
or SFs. Recent studies on the tau oligomers have increasingly supported their role in the early pathology 
of AD since they could disrupt anterograde axonal transport and impair long-term potentiation (LTP) in 
Tg mice.66,67 For the above-mentioned reasons, the modulation of abnormal hyperphosphorylation and 
aggregation of tau presents a potential approach for drug discovery. Aside from AD, the diseases, known 
as tauopathies [e.g., sporadic corticobasal degeneration, progressive supranuclear palsy, and 
frontotemporal dementia (FTD)], have been linked to tau, suggesting a mutual connection among 
multiple neurodegenerative diseases.68 
Increasing evidence indicates a link between the amyloidogenic proteopathy and tauopathy in 
AD.69 Tau and ptau have been reported to directly and indirectly interact with A. In a perspective 
article introducing the amyloid cascade hypothesis, A was accountable for the formation of NFTs.36 
The parallel between A and tau with respect to the toxicity of oligomeric forms has led to the 
suggestion that the oligomeric species of A and tau may synergistically act to induce neurotoxicity 
and synaptic dysfunction.69−72 Moreover, the disruption of calcium homeostasis, glycogen synthase 
kinase 3 (GSK3), cdk5, and free fatty acids have been implicated as bridging factors between A and 
tau.36,62,65,73,74 The interrelationship of A and tau appears to be complex, and further clarification would 
benefit from agents capable of interacting with both of them. 
 
1.2.2. Metal Ions 
Metal ions are involved in biologically vital processes, such as signal transmission, catalysis, 
stabilization of proteins’ structures, and metabolism.10,75 The functions of the essential first-row 
transitions metals (e.g., Fe, Cu, and Zn) have been widely studied. These metal ions are strongly 
regulated across the BBB due to their pertinent role in biologically essential processes.76 Therefore, the 
dysregulation of these regulatory mechanisms could lead to disease. In fact, previous studies have 
demonstrated the colocalization of the above-mentioned metal ions in SPs from AD patients’ brain 
tissue.8,10 The metal ion hypothesis posits that the dyshomeostasis and miscompartmentalization of 
metal ions contribute to AD pathology.77 In this section, we discuss metals’ functionality, toxicity, 
homeostasis, and binding to A, as well as the pathological implications of metal−A. 
Among essential transition metals, Zn is the second-most abundant in biological systems.78 
Available in both protein-bound and labile forms in the body, Zn(II) is a d10 metal ion that does not 
possess a biologically relevant redox activity.78 Zn(II) sites in proteins are tetrahedral or distorted 
tetrahedral, and as a transition metal ion with borderline hardness, Zn(II) binds to nitrogen (N), oxygen 
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(O), and sulfur (S) donor atoms of amino acid residues.79,80 Zn(II) is heterogeneously distributed 
throughout the brain with relatively high concentrations observed in the hippocampus, amygdala, 
neocortex, and olfactory bulb areas.81 Protein-bound Zn(II) [e.g., zinc finger proteins and Cu/Zn 
superoxide dismutase1 (SOD1)] accounts for over 90% of the total Zn(II) content of the brain. The 
remaining labile pools of Zn(II), primarily localized within synaptic vesicles of glutaminergic neurons, 
have been indicated in LTP.78,82 The interactions of Zn(II) with -aminobutyric acid (GABA) receptors 
and NMDARs and its extracellular release following neuronal stimulation have led researchers to 
propose its involvement as a neurotransmitter and secondary messenger.83−85 
Cu, the third-most abundant transition metal in the human body, is found in protein-bound [e.g., 
cytochrome c oxidase (CcO), Cu/Zn SOD1, ceruloplasmin, and dopamine  monooxygenase (DM)] 
and labile forms.78,86 As a redoxactive metal, Cu acts as a critical cofactor involved in enzymatic 
functions, including the biochemistry of dioxygen (O2).78,87 The two major oxidation states of Cu are 
+1 and +2. Cu(I) exists under intracellular reducing conditions, while Cu(II) is likely to be present under 
oxidizing conditions. Cu(I) and Cu(II) are considered soft and borderline acids, respectively, and bind 
to N, O, and S donor atoms. Cu(I), like Zn(II), is a d10 metal ion with preferred coordination numbers 
2, 3, or 4, indicating linear, trigonal planar, or (distorted) tetrahedral geometries, respectively. As a d9 
metal ion, Cu(II) can be coordinated to 4, 5, or 6 ligands, with square planar, square pyramidal, or 
(axially distorted) octahedral geometries, respectively.88 
Cu(I)-/Cu(II)-coordinated proteins can be categorized into two groups based on their relation to 
metal ions: (i) proteins utilizing the redox chemistry of Cu(I)/Cu(II) to carry out specific functions (e.g., 
SOD1 and CcO) and (ii) proteins involved in the Cu transport [e.g., CTR1, ATP7, and CCS].9,89 Cu 
adopts important roles in the brain. In order to compensate for the high level of O2 metabolism in the 
brain and the potential accidental release of ROS, neurons and glia require Cu for antioxidant enzymes 
(e.g., SOD1). Cu is also associated with the homeostasis of neurotransmitters, neuropeptides, and 
dietary amines by acting as a cofactor for DM, peptidylglycine -hydroxylating monooxygenase, 
tyrosinase, and amine oxidases.78 Micromolar Cu is released into the extracellular space upon neuronal 
depolorization.90 Although the role of Cu in signal transmission is not fully understood, previous reports 
suggest that micromolar Cu is capable of antagonizing NMDA, GABA, and glycine receptors.91 In 
addition, exogenous Cu is reported to affect K(I) and Ca(II) channels.78 Further research regarding the 
link of labile Cu(II) to neurotransmission is necessary to gain a better understanding of its 
neurophysiological role. 
Fe, known for its role in O2 transport and metabolism, is the most abundant transition metal in 
the human body.92,93 Like Cu, the utility of Fe as a redox-active component manifests the basis of its 
enzymatic involvement. Fe is an essential element of enzymes (e.g., heme proteins, nonheme proteins, 
and Fe SOD1) responsible for a spectrum of biological functions, such as electron transfer, O2 chemistry, 
gene regulation, and regulation of cell growth and differentiation.94 The resting state of Fe in enzymes 
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is mainly found as Fe(II) and Fe(III), while higher oxidation states can be observed as intermediatesin 
catalytic cycles.78 Labile Fe(II) and Fe(III) are reported to exist in pools at intracellular concentrations 
of up to 100 M,78 but the nonenzymatic role of Fe in neurobiology has not been clearly identified. 
Metal ion homeostasis, balancing functionality against toxicity, is a critical aspect in the proper 
functioning of biological systems.78,95 Zn(II) homeostasis is managed by proteins, such as SLC30A (zinc 
transporter 3; ZnT-3), Zinc-regulated transporters, iron-regulated transporter-like proteins (ZIPs), and 
metallothioneins (MTs).78,96−98 ZIP transporters bring Zn(II) into the cytoplasm, while zinc transporter 
(ZnT), voltage-gated calcium channels, and NMDARs are shown to mediate the extracellular release of 
Zn(II).9 Greenough and co-workers implicated the expression of presenilins, a component of -secretase, 
as a major contributor toward the control of Zn(II) and Cu(I)/Cu(II) in the brain.99 The dysregulation of 
Zn(II) can lead to excitotoxicity that may induce cell death via the upregulated activity of glutamate 
receptors, ROS generation, and overactivation of nitric oxide (NO) signaling.98,100,101 Cu(I)/Cu(II) 
homeostasis is regulated by proteins, such as CCS, CTR1, ATP7A, COX17, and Cu metabolism COMM 
domaincontaining protein 1 (COMMD1) domain.9,89 On the basis of its redox activity, the dysregulation 
of Cu(I) and Cu(II) can cause the overproduction of ROS leading to oxidative stress. In addition, due 
to its imperative roles in enzymes, such as SOD1, CcO, and DM, the colocalization of Cu in amyloid 
plaques may result in Cu-deficient proteins, causing irregularity in biological functions. Similar to Cu, 
the notable redox reactivity of Fe makes it a double-edged sword, enabling a wide range of biological 
functions but generating ROS, whose release can induce toxicity if unregulated and left unchecked. Fe 
homeostasis is controlled by different types of proteins, including Fe transporters [e.g., divalent metal-
ion transporter-1 (DMT1), ferroportin-1, mitoferrin-1, and ZIP14],102 heme transporters (e.g., HRG1 
and FLVCR1),103,104 Fe chaperones (e.g., PCBPs), ferrireductases, hepcidin, ferritin, and transferrin.105 
The essential function of metals in the brain coupled with the detrimental effects of their 
dysregulation suggests that metal ion dyshomeostasis could lead to disease.8,9,10,86,106−111 In 1994, Bush 
et al. discovered the relevance of metal ions in AD pathogenesis.112 They reported the induction of A40 
fibrillization in the presence of Zn(II),112 launching intense research into the binding of transition metal 
ions to Aβ.15 Moreover, highly concentrated Cu(I/II), Zn(II), and Fe(II/III) (ca. 400, 1000, and 900 M, 
respectively) were found within SPs compared to healthy age-matched controls, reinforcing their 
interaction with A in vivo and possible involvement in AD pathogenesis.113 Since binding of Zn(II), 
Cu(I/II), and Fe(II) to A modifies its aggregation, the investigations of molecular-level interactions 
between metal ions and A can be challenging. Researchers circumvented this issue by employing A16 
or A28 that bind Cu(II) and Zn(II) without significant aggregation.114−131 The proposed coordination of 
Zn(II), Cu(I/II), and Fe(II) to A is summarized in Table 1.2 and Figure 1.3. 
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Amino Acid Residues 





N-terminal NH2, (D1 or E3),  
(D1-A2 or H6-D7; Carbonyl from the Amide 
Group), H6, and (H13 or H14) 
NMR 129 





A6-14 H13 and H14 EXAFS 123 
A10-14 H13 and H14 EXAFS 123 
A16 H13 and H14 EXAFS, EPR 124 
A16 H13 and H14 NMR, XANES 125 




A40 H13 and H14 EXAFS, EPR 124 
Cu(II) 
A16 
pH 6.5: H6, (H13 or 14),  
N-terminal NH2, (D1; Side-chain Carboxylate 
Group), and (D1-A2; Carbonyl from the Amide 
Group) 
 
pH 9.0: N-terminal NH2, (D1-A2; N from the 
Amide Group), (A2-E3; Carbonyl from the 
Amide Group), and (H6, H13, and H14) 
EPR 134 
A16 
pH 6.3: N-terminal NH2, (D1-A2; Carbonyl from 
the Amide Group), H6, and (H13 or H14); 
 
pH 8.0: (A2-E3; Carbonyl from the Amide 
Group), H6, H13, and H14 
EPR 127 
A16 
pH 6.3: D1, (D1-A2; Carbonyl from the Amide 
Group), H6, and (H13 or H14); 
 
pH 8.0: (A2-E3; Carbonyl from the Amide 
Group), H6, H13, and H14 
EPR 128 
A28 pH 5.5: H6, Y10, H13, and H14 NMR, EPR 119 
A28 
pH 7.4: N-terminal NH2,  
H6, H13, and H14 
EPR 138 
Zn(II) 
A16 R5, H6, H13, and H14 ESI-MS 114 
A16 D1, H6, H13, and H14 NMR 115 
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A16 
H6, H13, H14, and (E11; Side-chain Carboxylate 
Group) 
NMR 116 
A16 A11-14 Residues (E11 and H14) SPR, ESI-MS 117 
pA16 (S8) 
H6, D7, Phosphorylated S8, 






H6, E11, (H13 or H14), (D1, E3, or D7), and N-
terminal NH2 
NMR, XAS 131 
D7H-A10 
(D1-A2; Carbonyl from the Amide Group), E3, 




A28 H6, H13, and H14 NMR, EPR 119 
A28 H6, H13, and H14 NMR, CD 120 
A28 
N-terminal NH2, H6, H13, (H14, and/or E11), and 
(Y10 for Conformational Rearrangement) 
NMR 121 




Figure 1.3. Examples of metal coordination to A. Each metal [Zn(II) and Cu(II)] coordination is 
published in refs 131 and 134, respectively. Possible fifth ligands on the metal centers are not indicated 
in this figure. 
 
Numerous studies have focused on possible binding modes of Zn(II) and A.114−122,131,132 On the 
basis of previous findings, the feasible Zn(II) binding sites in A are primarily composed of 4−6 ligands: 
H6, H13, and/or H14 with additional candidates that include D1 (N-terminal NH2 or side chain 
carboxylate), E3, R5 (backbone amide), D7, Y10, E11, or water molecules.8,106,108,114−116,119,120,132,133 In 
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addition, Y10 is implicated in a Zn(II)-dependent conformational rearrangement under membrane-
mimicking environments.121 Kulikova et al. reported that phosphorylated residues may be involved in 
Zn(II) binding based on studies with A containing phosphorylated S8 (pA). Proposed binding 
residues are the phosphate group, the imidazole ring of H6, and a backbone carbonyl group of either 
H6 or D7.118 This binding mode stimulates peptide dimerization with an additional Zn(II) coordinated 
to two pairs of E11 and H14 from two separate peptide subunits.118 This observation of Zn(II)-induced 
dimerization provides insight into the initiation of metal-induced A aggregation. 
Recently, an unprecedented coordination of Zn(II)−A10 was presented with the Taiwanese 
mutation D7H using a suite of structural characterization methods.122 The 1:1 stoichiometry was 
confirmed via nuclear magnetic resonance (NMR) and isothermal titration calorimetry (ITC). 
Additionally, the formation of the proposed complex [Zn2(D7H-A10)2], which consisted of a binuclear 
Zn(II) core where both ions were bound to two D7H-A10 peptides, was validated by mass spectrometry 
(MS) and isotope-edited NMR.122 The NMR investigations revealed that the carbonyl group (D1-A2), 
carboxyl group (E3), H6 (from one polypeptide chain), and H7 (from the second polypeptide) were 
bound to Zn(II).122 These observations were theoretically refined and supported by extended X-ray 
absorption fine structure (EXAFS) spectroscopy.122 
The Cu(II)−A binding mode occurs in two forms, components I and II (Figure 1.3), depending 
on the pH (i.e., pH 6.5 and pH ≥ 8, respectively).8,106,119,127,128,133−137 At pH ≥ 8, component II is 
predominant with three main potential binding configurations of Cu(II)−A: (i) 3N1O coordination 
{e.g., for 3N, [H6, D1 (N-terminal NH2), and D1-A2 (deprotonated backbone amide)] or (H6, H13, and 
H14); for 1O, carbonyl backbone oxygen (A2-E3)},127,128,134 (ii) 4N coordination with three histidines 
(H6, H13, and H14) and either N-terminal amino group or deprotonated backbone amide,138,139 or (iii) 
5N1O coordination with potential binding sites: N-terminal NH2, the N donor atom from the D1-A2 
backbone, carbonyl backbone from A2-E3, H6, H13, and H14.134 
Component I is the prevalent Cu(II) binding mode with A under physiological conditions. 
Several reports have proposed 3N1O coordination involving: (i) the N-terminal primary amino group 
of D1, an O donor atom from a carbonyl backbone between D1 and A2, H6, and either H13 or H14 or 
(ii) D1 (N-terminal amine), D1-A2 (a carbonyl backbone), and two histidines among H6, H13, and H14, 
with the possibility of an additional coordination with D1 (carboxylate).8,106,108,127,128,133−136 Dorlet et al. 
reported the observation of a 5-coordination mode using electron paramagnetic resonance spectroscopy 
(EPR) in conjunction with specific isotopic labeling.134 They detected and identified a 3N2O 
coordination site in A consisted of two histidines (H6 and either H13 or H14), the N-terminal NH2, 
the carbonyl group between D1 and A2, and the carboxylate group of D1. The carbonyl and carboxylate 
groups from D1 were reported in the equatorial and axial positions, respectively. The exact binding 
atoms of D1 in A is controversial. The N-terminal NH2, the carboxylate, and the amide backbone have 
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all been suggested to be possible binding atoms from D1.127,128,134 Moreover, the involvement of Y10 
via conformational rearrangement of Cu(II)−A at pH 6.9 has been suggested.119 Previous studies 
demonstrated that the pH-dependent oxidation state of the A-bound Cu dictates the coordination 
geometry of the complex.124,140 When Cu K-edge X-ray absorption spectroscopy (XAS) was applied to 
Cu(II)−A, a square-planar Cu(II) center with mixed N/O ligation, including imidazole groups of 
histidine ligands, was indicated.124,141 After reduction of Cu(II)−A, the EXAFS data fit best a linear 
two-coordinate geometry with two imidazole ligands, possibly H13 and H14, coordinated to 
Cu(I)−A.123−126,141 Studies of the Fe(II)−A binding via NMR demonstrated a coordination composed 
of the N-terminal NH2 (D1), a carboxylate from either D1 or E3, a carbonyl group from D1-A2 or H6-
D7, and two N donor atoms from H6 and either H13 or H14.129 There is limited information regarding 
the binding of Fe(III)−A.129,130 
Determination of binding affinities of metal−A complexes at different conditions can be 
valuable, especially towards the development of therapeutics with metal chelating capabilities. 
Comparative studies regarding binding affinities of metal−A to novel metal chelators may allow 
researchers to estimate their ability to target labile metal ions and metal−A versus metal ions from 
metalloproteins essential for biological functions. The reported range of Kd for Zn(II) and A is 
10−9−10−6 M.8,108,132,135,142−148 The presented Kd values for metal−A are dependent on the experimental 
conditions and techniques, such as ITC, fluorescence spectroscopy, and potentiometry.108,110,132,143−146 
For Cu(II)−A, the Kd value was calculated to be 10−11−10−7 M, while Cu(I)−A showed 10−15−10−8 M 
in Kd.8,107,132,135,138,142,144−146,149−160 Cu(II) seems to exhibit stronger binding to A than Zn(II). Fe(II) 
forms less stable complexes (Kd = ca. 10−5 M), compared to those of Cu(II) or Zn(II).145 The reported 
Kd values of Zn(II)−A, Cu(I/II)−A, and Fe(II)−A are summarized in Table 1.3. The propensity of 
A to aggregate poses a challenge in studying its metal binding properties. As a solution, researchers 
have been utilizing various A fragments with slower aggregation kinetics. Although soluble A 
fragments enable the study of metal binding and coordination, various conformations of the full-length 
A (e.g., monomers, oligomers, and fibrils) are expected to exhibit different metal coordination 
environments.146,159 On the basis of currently available literature, a wide range of binding affinities is 
reported because metal binding to A is dependent on A species, techniques, and experimental 
conditions (e.g., buffer composition, temperature, concentrations, and peptide purity). 
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(x 10-6 M) 
Conditionsa Technique Reference 
Fe(II) A40 76 (± 20) 
10 mM Tris, pH 7.4, 




2.7 (± 2.1) 
x 10-9 
20 mM N-Ethylmorpholine, pH 7.0 UV-Vis 154 
H6A-A16 
8.9 (± 3.7) 
x 10-9 
20 mM N-Ethylmorpholine, pH 7.0 UV-Vis 154 
H13A-A16 
1.1 (± 0.7) 
x 10-8 
20 mM N-Ethylmorpholine, pH 7.0 UV-Vis 154 
H14A-A16 
1.0 (± 0.8) 
x 10-8 
20 mM N-Ethylmorpholine, pH 7.0 UV-Vis 154 
A42 
5.4 (± 0.9) 
x 10-2 
100 mM HEPES, pH 7.4 UV-Vis 154 
Cu(II) 
A16 47 (± 5) 
100 mM Tris, pH 7.4, 
150 mM NaCl  
Fluorescence 149 
A16 0.1 H2O, pH 7.8 Fluorescence 150 
A16 0.09 
50 mM HEPES, pH 7.4, 100 mM 
NaCl 
ITC 151 
A16 0.7 x 10-3 
20 mM HEPES, pH 7.2, 
150 mM NaCl  
ITC 158 
A16 0.3 x 10-3 
20 mM PIPES, pH 7.4, 
160 mM NaCl 
ITC 160 
A4-16 8 (± 2) 
100 mM Tris, pH 7.4,  
150 mM NaCl 
Fluorescence 149 
A28 0.1 H2O, pH 7.8 Fluorescence 138 
A28 28 (± 5) 
100 mM Tris, pH 7.4,  
150 mM NaCl 
Fluorescence 149 
A28 0.07 
50 mM HEPES, pH 7.4, 100 mM 
NaCl 
ITC 151 
A28 0.4 (± 0.1) 10 mM Phosphate, pH 7.2 Fluorescence 156 
A28 2.5 (± 0.2) 10 mM HEPES, pH 7.2 Fluorescence 156 
A28 1.2 (± 0.1) 10 mM Phosphate, pH 6.5 Fluorescence 156 
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A40 1.6 (± 0.9) 
10 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 145 
A40 11 (± 1) 
100 mM Tris, pH 7.4,  
150 mM NaCl 
Fluorescence 149 
A40 ca. 8 
50 mM Phosphate, pH 7.4,  
100 mM NaCl 
Fluorescence 152 
A40 0.5 (± 0.2) 
10 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 144 
A40 1.2 (± 0.4) 
20 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 144 
A40 3.8 (± 0.9) 
50 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 144 
A40 30 (± 6) 
100 mM Tris, pH 7.4,  
100 mM NaCl  
Fluorescence 144 
A40 0.6 (± 0.2) 
20 mM HEPES, pH 7.4, 100 mM 
NaCl  
Fluorescence 144 
A40 2.5 (± 0.6) 
100 mM HEPES, pH 7.4, 100 mM 
NaCl 
Fluorescence 144 
A40 0.9 x 10-3 
20 mM HEPES, pH 7.2, 
160 mM NaCl 
ITC 155 
A40 0.4 x 10-3 
20 mM HEPES, pH 7.4, 
160 mM NaCl 
ITC 155 
A40 1.6 5 mM Phosphate, pH 7.3 NMR 157 
A40 5.2 x 10-4 
20 mM PIPES, pH 7.4,  
160 mM NaCl 
ITC 160 
F4W-A40 0.6 (± 0.2) 
10 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 155 
A42 2.0 (± 0.8) 
10 mM Tris, pH 7.4,  
100 mM NaCl  
Fluorescence 155 
A42 0.8 (± 1.0) 




A16 22 (± 15) 
20 mM Tris, pH 7.4, 
100 mM NaCl 
ITC 153 
A16 14 (± 5) 
20 mM HEPES, pH 7.4, 
100 mM NaCl 
UV-Vis 153 
A16 9 50 mM HEPES, pH 7.1 UV-Vis 148 
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A28 6.6 (± 0.2) 10 mM HEPES, pH 7.2 Fluorescence 132 
A28 1.1 (± 0.1) 10 mM Phosphate, pH 7.2 Fluorescence 132 
A28 3.2 (± 0.1) 10 mM Phosphate, pH 6.5 Fluorescence 132 
A28 12 (± 5) 
20 mM HEPES, pH 7.4, 
100 mM NaCl 
UV-Vis 143 
A28 10 (± 8) 
20 mM Tris, pH 7.4, 
100 mM NaCl 
ITC 143 
A40 1.2 (± 0.03) 10 mM Phosphate, pH 7.2 NMR 132 
A40 300 (± 100) 
10 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 145 
A40 7 (± 3) 
20 mM Tris, pH 7.4, 
100 mM NaCl 
ITC 143 
A40 7 (± 3) 
20 mM HEPES, pH 7.4, 
100 mM NaCl 
UV-Vis 143 
A40 65 (± 3) 
20 mM HEPES, pH 7.4, 100 mM 
NaCl 
Fluorescence 144 
A40 124 (± 32) 
20 mM HEPES, pH 7.4, 100 mM 
NaCl 
UV-Vis 144 
A40 60 (± 14) 
10 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 144 
A40 184 (± 30) 
100 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 144 
A40 fibrils 9 (± 6) 
20 mM HEPES, pH 7.4, 
100 mM NaCl 
UV-Vis 143 
F4W-A40 90 (± 30) 
10 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 145 
A42 57 (± 28) 
10 mM Tris, pH 7.4,  
100 mM NaCl 
Fluorescence 145 
A42 7 (± 3) 
20 mM HEPES, pH 7.4, 
100 mM NaCl 
UV-Vis 143 
A42 91 (± 16) 
20 mM HEPES, pH 7.4, 100 mM 
NaCl 
Fluorescence 144 
A42 6.2 (± 0.9) 20 mM HEPES, pH 7.4 ITC 147 
aTris, tris(hydroxymethyl)aminomethane; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; PIPES, piperazine-
N,N′-bis(2-ethanesulfonic acid); PBS, phosphate-buffered saline.  
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The influence of transition metal ions on A aggregation has also been examined in depth since 
the first description of Zn(II)-dependent A40 aggregation.11,112,161 At physiological pH, Cu(II) and 
Fe(II/III) also promote A40 aggregation,161,162 although induction by Cu(II) requires a slightly acidic 
condition (e.g., pH 6.8).163 Even trace metal ions (< 0.8 M) are sufficient to stimulate A40 aggregation, 
resulting in less structured aggregates.164,165 Metal-induced A aggregation is shown to be rapid, and it 
could result in the production of nonfibrillar, amorphous aggregates depending on the ratio of metal to 
A (vide infra). A mixture of A42:Cu(II) in a 1:5 ratio resulted in a diminished fluorescence intensity 
of thioflavin-T (ThT), and smaller-sized aggregates as determined by atomic force microscopy (AFM), 
relative to A42 only.166 This observation was extended to other metal ions, including Zn(II) and 
Fe(II).167 Ultrafast spectroscopic techniques demonstrated an immediate interaction within milliseconds 
between micromolar Zn(II) and A40 showing resultant nonfibrillar peptide aggregates that were 
possibly toxic.168 A detailed study suggested that Zn(II)−A40 species might inhibit fibril formation by 
disrupting fibril elongation.169 Interaction of Cu(II) with A40 (pH 6.7) was also observed on a time 
scale of subseconds with the formation of amorphous Cu(II)−A species.170 Likewise, Fe(III) was 
observed to retard A42 fibrillization by redirecting the aggregation pathways towards unstructured, less 
toxic Fe(III)−A aggregates.171 Although the precise nature of metal−A conformations is uncertain, 
the measurements by circular dichroism spectroscopy (CD) propose that their transition may involve 
the generation of -enriched structures, distinct from the fibrillar -sheet conformation.172 
Metal ions appear to increase the proportion of soluble oligomers compared to fibrils.173−175 Since 
structured soluble oligomers are associated with toxicity,176,177 this may constitute a potential 
mechanism of toxicity that arises from metal−A species. Addition of Cu(II) to A yielded soluble 
toxic oligomers enriched in a -sheet configuration.174 In another report, Cu(II) and Zn(II) triggered the 
production of transient A oligomers.175 While Zn(II) developed annular A protofibrils without 
undergoing a nucleation process, Cu(II) and Fe(III) prevented the formation of fibrils by lengthening 
the nucleation phase.175 
The relative ratio of metal ions to A also impacts the aggregation pathways of A.178,179 
Increasing the relative amount of Cu(II) to A40 from 0.1 to 0.6 causes a shift from fibrillar structures 
to amorphous granular aggregates.178 Another study examined a wider Cu(II):A40 range from sub- to 
supra-stoichiometric amounts.179 The Cu(II):A ratio was found to affect the aggregation kinetics and 
aggregate morphology, deviating from fibrillar to nonfibrillar with increasing Cu(II):A proportions. 
Structures of Cu(II)−A aggregates were dynamic. The transient and impermanent nature of metal−A 
species has made their structural characterization difficult. Still, progress towards an understanding of 
their general characteristics has been made. A small-angle X-ray scattering (SAXS) study examined the 
generation of A oligomers at extremely short time scales by combining the technique with in-line rapid 
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mixing.180 Modeling of the scattering data can approximate oligomers’ size (i.e., diameter), molecular 
weight, and polydispersity. 
Although the aggregation kinetics, species distribution, and toxicity of metal−A species have 
been extensively studied, their precise mechanism of toxicity has been still uncertain. Recently, 
Matheou et al. illustrated the distinct influence of substoichiometric Cu(II) on the aggregation pathways 
of A40 and A42.181 While fibrillization was favored for A40, oligomeric and protofibrillar forms of 
A42 were observed in the presence of Cu(II). These species could cause leakage from lipid vesicles in 
a manner reminiscent of metal-free A oligomers.182 Mutations of A may also impact its aggregation 
properties in the presence of metal ions and may be one mechanism linking familial forms of AD to 
pathogenesis. The Taiwanese mutation (D7H) led Zn(II)- and Cu(II)-induced aggregates of both A40 
and A42 from fibrillar forms to smaller-sized oligomers.183 The pathogenic A2V mutation imparted 
different A aggregation kinetics and metal binding properties in response to addition of Cu(II).184 The 
Cu(II)−AA2V complex showed a preference for the component I configuration of the Cu(II) center. 
On the basis of cumulative experimental and theoretical evidence, metal ions have been 
considered potential therapeutic targets in AD. The utilization of metal chelators has demonstrated their 
potential as AD treatments, but further optimization of metal chelators is necessary to develop effective 
therapeutics.185,186 Moreover, fine-tuning metal binding affinities (Kd) of compounds to specifically 
target metal ions bound to A without disrupting vital enzymatic activities is an important parameter 
for rational design. 
 
1.2.3. Oxidative Stress 
O2 is indispensable to aerobic organisms. In metabolic systems, ROS are generated from endogenous 
processes, such as O2 metabolism and cellular signaling, while exogenous ROS can be produced from 
environmental stress (e.g., ionizing radiation and heat exposure).187−189 Biologically relevant ROS 
include superoxide anion radical (O2
•−), hydroxyl radical (•OH), hydrogen peroxide (H2O2), 
hydroperoxyl radical (•O2H), singlet oxygen (1O2), peroxide (O22−), and hydroxide ion (OH−). A 
membrane-bound enzyme, nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), 
found in cell membranes, mitochondria, and ER, is responsible for substantial intracellular ROS 
production.190,191 NADPH oxidase generates superoxide anion radicals (O2
•−) by transferring electrons 
from NADPH within the cell across the membrane.190,192 ROS are necessary for a variety of cellular 
functions, including receptor-mediated signaling pathways and transcriptional activation.193−199 In 
addition, ROS plays a critical role in cellular homeostasis through regulation of apoptosis. ROS control 
apoptotic signaling initiated via two pathways:198,200 (i) ROS-triggered death receptors [e.g., Fas (CD95 
or APO-1), tumor necrosis factor (TNF) receptor 1, TNF-related apoptosis-inducing ligand (TRAIL) 
receptor 1 (TRAIL-R1 or DR4), and TRAIL receptor 2 (TRAIL-R2 or DR5)] can mediate the extrinsic 
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pathway of apoptosis by clustering and forming lipid-raft-derived signaling platforms, suggested as a 
major mechanism of apoptotic signaling,200,201 and (ii) ROS are associated with mitochondrial 
permeabilization by generating pores in the mitochondrial outer membrane, which stimulates the release 
of proapoptotic proteins [e.g., members of the B-cell lymphoma 2 (Bcl-2) gene family and BAX (Bcl-
2 associated X)] that are essential for the activation of apoptosis.198,200,202−204 
Various types of ROS can be found in cellular environments.193,194 Prominent biological ROS are 
hydroxyl radical (•OH), O2
•−, and H2O2. Hydroxyl radicals are produced by Fenton-like reactions.8,142 
Due to its relatively short half-life (10−9 s), •OH is known to be involved in “site-specific” reactions in 
the vicinity of its formation site.205,206 O2
•−, the product of the one-electron reduction of O2, is generated 
by multiple systems in organisms of animals and plants (e.g., xanthine oxidase and NADPH 
oxidase).188,192,194,207 O2
•− can react with many substrates by converting into other species.111,194,195 O2
•− 
is capable of transforming into •OH by the Haber-Weiss reaction, which generates •OH from H2O2 and 
O2
•−.207 Both •OH and O2
•− can initiate lipid peroxidation that can lead to apoptosis.8,107,188,195,207,208 H2O2 
is a common byproduct of diverse enzymatic reactions, including those involving SOD.107,111,188,194,195,209 
H2O2 is related to a broad range of biological processes: (i) immune response; (ii) oxidative biosynthesis, 
such as tyrosine crosslinking mediated by peroxidases; (iii) cellular signaling in mediating mitogenic 
signaling pathways.195,209,210 
Under normal conditions, the levels of the above-mentioned ROS are regulated by innate 
antioxidant defenses.10,111,190,211−213 Pathological conditions, however, can elicit an imbalance between 
the production and removal of ROS, resulting in elevated ROS levels.9,111,195 Oxidative stress is 
characterized by dysregulation of ROS and the resultant cellular damage through the oxidation of lipids, 
proteins, and DNA.86,111,189,193−195 Oxidative stress in biological systems has been strongly implicated as 
a causative factor for a wide spectrum of diseases and aging.9,111,195 Thus, maintaining proper ROS load 
is important to the preservation of biological homeostasis. 
Oxidative stress is believed to be involved in neurodegenerative diseases, including 
AD.9,10,86,110,111,142,187−189,208,211,213,214 Oxidative stress is a prevailing component in the manifestation of 
multiple pathological factors (e.g., A, metal ions, and metal−A) as well as toxic mechanisms of these 
factors.142,107,215 Three major aspects are connected with oxidative stress to AD pathology: (i) A 
production and accumulation;211,215−218 (ii) metal ion dyshomeostasis;219 (iii) mitochondrial 
dysfunction.111,187,189,193,194,214,215 Researchers have suggested that oxidative stress enhances A 
production by decreasing the activity of -secretase while increasing the activity of - and -
secretases.211,215 In addition, oxidative stress could activate the pathway of c-Jun N-terminal kinase 
(JNK), which could modulate the expression of -secretase.211,215 The generated A accumulates in the 
brain and forms SPs, a hallmark of AD.86,109 
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Pathological factors of AD (e.g., metal ions, A, and tau) are suggested to be involved in redox-
active processes capable of inducing oxidative stress via ROS generation.10,106,220 Multiple in vitro and 
in vivo studies report that A peptides trigger oxidative stress.221−236 A Tg C. elegans worm model 
expressing human A42 exhibited enhanced oxidative stress as evidenced by elevated carbonyl levels 
associated with the oxidation of proteins.233,237 I31 and M35 in A are proposed to be potentially 
responsible for oxidative damage (vide infra).228,229,231,237 Especially, M35 is reported as a critical amino 
acid residue for ROS production.221,223,230 The -helical conformation in the C-terminal region of A 
allows the S atom of M35 to interact with the O atom from the carbonyl of I31,229,231,236 which could 
result in the formation of the methionine sulfuranyl radical (MetS•).228,236,238 A can also act as a source 
of ROS and initiate lipid peroxidation by producing carbon-centered radicals.231,236 Moreover, 
oligomeric A has been observed to increase the generation of ROS directly by activating NADPH 
oxidase and indirectly through NMDARs by stimulating the release of arachidonic acid, a retrograde 
messenger involved in modulating synaptic plasticity.232,239 
The dysregulation of redox-active metal ions, including Cu(I/II) and Fe(II/III), in the central 
nervous system (CNS) is observed in the AD-affected brain.240−243 Furthermore, these metal ions are 
able to produce ROS through Fenton-like reactions.244,245 Overproduction of ROS by metal ions can 
result in oxidative stress that causes neuronal death in the brain.10,213,214 Moreover, Zn(II), a redox-inert 
metal ion, indirectly increases ROS levels.246−250 Mitochondrial uptake of labile Zn(II) from the 
cytoplasm through the calcium uniporter can alter mitochondrial polarization and disrupt the electron 
transport chain leading to the formation of ROS, such as O2
•−.246−250 
Along with the individual impact of metal ions and A on ROS production, metal−A species 
have been observed to generate ROS. Redox-active metal ions associated with A [i.e., Cu(I/II)−Aβ 
and Fe(II/III)−A] can generate ROS via Fenton-like reactions, similar to redox-active metal 
ions.10,251,252 In vitro studies demonstrate that Cu(I/II)−A or Fe(II/III)−A can overproduce ROS 
leading to oxidative stress.8,10,213,251,253,254 ROS generation mediated by Cu(I/II)−A has been widely 
studied.86,129,136,255,256 Cu(I/II)−A is indicated to catalytically form ROS. In the presence of a reductant 
(e.g., ascorbate), Cu(II)−A could be reduced to Cu(I)−A and transfer an electron to O2 to yield 
O2
•−.86,255,257 Then, a hydroperoxyl radical (•O2H) can be formed via electron/proton transfer, finally 
resulting in the production of H2O2 (vide supra).8,10,259 The generated H2O2 can then react with either 
Cu(I)−A or Cu(II)−A affording •O2H or •OH through Fenton-like reactions.8,86,258 Spectroscopic and 
spectrometric studies presented that the D1, H13/H14, and M35 residues in A may be involved in the 
electron transfer between Cu(I/II) and A responsible for ROS generation.221,230,255,259−263 
Oxidative stress can damage cells by disrupting cell signaling and causing mitochondrial 
dysfunction.111,181,189,193,215 Mitochondrial function is vulnerable to oxidative stress; however, 
paradoxically, the mitochondrial respiratory chain is a major source of intracellular ROS.193,215,264 
22 
Mitochondrial respiratory complexes could generate ROS, such as O2
•− and H2O2, and the increased 
concentrations of these ROS could produce •OH and react with biomolecules, including lipids and 
proteins.8,188,195,207,265 Biological systems are observed to protect themselves from oxidative stress by 
maintaining appropriate levels of ROS with endogenous defensive systems.107,111,187,193−195 For example, 
(i) Cu/Zn SOD1 binds to Cu and Zn to catalyze the dismutation of O2
•− into either O2 and 
H2O2;9,86,111,188,208 (ii) another important antioxidant is glutathione that is converted to its oxidized form 
(i.e., glutathione disulfide) upon interaction with ROS;188,194 (iii) catalases catalyze the decomposition 
of H2O2 to H2O and O2.209,210 Thus, the imbalance between ROS production and removal could occur 
by deficient antioxidant defense, inhibition of electron flow, or exposure to xenobiotics.265 
Oxidative stress is indicated to play an underlying role in the pathology of AD based upon the 
impact of ROS on the production and aggregation of A, metal ion homeostasis, and mitochondrial 
dysfunction. These pathological features could contribute back to oxidative stress through ROS 
generation in direct and indirect manners. Thus, the utilization of antioxidants to reduce the level of 
ROS offers a potential approach for drug discovery in AD. The strategy of regulating ROS only with 
antioxidants, however, has not been successful in clinical trials, possibly due to the multifaceted nature 
of AD pathology.266 
 
1.2.4. Cholinesterases (ChEs) 
The cholinergic hypothesis proposes that the degeneration of cholinergic neurons and the associated 
loss of cholinergic neurotransmission in the cerebral cortex are contributors to the deterioration of 
cognitive function observed in the brain of AD patients.267,268 ACh, the neurotransmitter in cholinergic 
transmission responsible for learning and memory in the CNS, is a cationic agonist of muscarinic and 
nicotinic receptors.269,270 ACh production from choline and acetyl coenzyme A (acetyl-CoA) is catalyzed 
by choline acetyltransferase (ChAT) in neurons.271 Cholinergic transmission is initiated by the ACh 
release from the presynapse into the synaptic cleft, where ACh diffuses and binds to postsynaptic 
receptors. Subsequently, ChEs, serine hydrolases abundant in the synaptic cleft, rapidly terminate signal 
transmission by converting ACh into acetate and choline. To complete the cycle of cholinergic 
transmission, the presynaptic neuronal reuptake of catabolic products occurs to produce ACh. 
Cholinergic deficits from decreased ACh levels are a characteristic of the brain affected by AD.272 As 
the main culprit of this phenomenon, ChEs have been widely studied as a therapeutic target for AD 
leading to the development of AChEIs for AD treatment (Table 1.1). There are two main types of ChEs: 
(i) AChE and (ii) butyrylcholinesterase (BuChE). AChE is responsible for the majority of the ChE 
activity in healthy human brains, while the remaining is accounted for by BuChE.273,274 AChE has been 
a therapeutic target in AD based on its role in hydrolyzing the majority of ACh in the brain.275,276 
The active site of AChE is located at the bottom of a gorge, a narrow cavity lined with 14 highly 
conserved aromatic residues.277 The active site of human AChE (hAChE) is composed of an esteratic 
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site containing the catalytic triad (i.e., S200, H440, and E327), and an anionic site, where the quaternary 
ammonium of ACh binds through cation− interactions. Analysis of the crystal structure of AChE 
revealed that the anionic site, which binds the quaternary trimethylammonium choline moiety of the 
substrate via cation− interactions, is in fact uncharged and hydrophobic due to the presence of 
numerous aromatic residues.278−280 The cumulative system of intermolecular interactions and geometric 
constraints of the active site gorge may contribute to the substrate specificity and rapid enzyme kinetics 
of AChE through mechanisms, such as aromatic guidance.280,281 In addition, the peripheral anionic site 
(PAS), located near the rim of the gorge, has been reported to transiently bind to substrates as an 
initiating step of the catalytic process.282,283 Szegletes et al. reported that binding of ACh to the PAS of 
AChE led to accelerated hydrolysis.283 
BuChE can also hydrolyze ACh.284,285 BuChE also possesses the overall structure, the amino acid 
sequence, and the catalytic mechanism similar to AChE.286 While AChE is specific for ACh, BuChE 
can hydrolyze a range of esters and amides, in addition to ACh. One explanation for this disparity in 
substrate specificity is the size difference of their active-site gorges. The reported active-site gorge of 
BuChE (ca. 500 Å) is much larger than that of AChE (ca. 300 Å).287 Furthermore, BuChE lacks the PAS 
that contributes towards AChE’s activity.288 The distinct structural characteristics of the two ChEs 
present a parameter to consider when compounds capable of inhibiting the activity of either AChE, 
BuChE, or both are rationally designed.289 The physiological and pathological roles of BuChE remain 
unclear. Specific inhibitors for AChE and BuChE may help determine their impact on cholinergic 
transmission and AD pathogenesis. Thus, the potential therapeutic benefits of targeting BuChE, 
explored less than AChE, could provide a valuable direction for AD research. 
In recent years, the lack of success in halting AD progression with ChE inhibitors (ChEIs) has 
led researchers to reevaluate the cholinergic hypothesis. A comparative study monitoring the levels of 
cholinergic markers in human subjects with mild cognitive impairment (MCI) and severe late stage of 
AD suggested that cholinergic dysfunction may be influential during the later stages of the disease.290 
Compensatory responses, such as upregulation of ChAT in the frontal cortex and hippocampus, have 
been proposed as resistance mechanisms working against the transition from MCI to AD.291 Based on 
the current direction in understanding AD pathology, reassessment of the cholinergic hypothesis focuses 
on the interrelationships between ChEs and other pathological factors, including A, tau, metal ions, 
and ROS.292−298 Both AChE and BuChE have been found to be colocalized with A aggregates in SPs.299 
Moreover, evidence has indicated that AChEs could affect A aggregation299−302 and toxicity via 
interactions between the PAS and A.292,299 For example, the complexation of AChE and A, at the 
hydrophobic PAS of AChE could accelerate A aggregation.299,301 Further research is needed to fully 
elucidate the pathological relationships between ChEs and other pathological elements. 
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1.2.5. Additional Targets 
In this section, we briefly introduce additional pathological factors in AD that may serve as therapeutic 
targets in the design of multifunctional molecules. Glutamate is a central excitatory neurotransmitter in 
the mammalian cortex.303 Glutamate receptors, primarily located in the CNS, are involved in synaptic 
plasticity, learning, and memory.304,305 There are two types of glutamate receptors: metabotropic and 
ionotropic. Ionotropic glutamate receptors form ion channel pores that allow the nonselective flux of 
cations upon activation by binding of glutamate.306 Among the ionotropic glutamate receptors, 
NMDARs, named according to its selective binding of NMDA, have been researched for their role in a 
range of CNS disorders.307 A majority of NMDARs are tetramers composed of two NR1 subunits, 
forming the channel, and two NR2A, NR2B, NR2C, or NR2D subunits.308 The physiological and 
pharmacological properties of NMDARs vary depending on the combination of NR1 and NR2 
subunits.309 Under normal conditions, the NMDAR channel is blocked by Mg(II) in a voltage-dependent 
manner, which can be activated to control the influx of cations [e.g., Na(I), K(I), and Ca(II)].310 The 
depolarization of NMDARs under pathological conditions is proposed to lead to the loss of Mg(II) from 
the channel, resulting in its overactivation.311 Dysregulation of NMDAR activation contributes towards 
the pathology of the disease via cellular Ca(II) dyshomeostasis.312,313 Therefore, the modulation of 
NMDARs has been suggested as a strategy to develop potential therapeutics for CNS-related disorders. 
Memantine, an uncompetitive NMDAR antagonist for AD treatment approved by the U.S. FDA (Table 
1.1), has exhibited its effectiveness in attenuating cognitive decline in moderate to severe AD cases.314 
The utilization of NMDARs as a target in the past has been challenging due to adverse side effects, a 
consequence of nonspecific NMDAR recognition.315 Nonetheless, the success of memantine has proven 
its therapeutic potential, and a more specific approach to antagonize NMDARs targeting the neurons 
affected by AD could be advantageous.314 Furthermore, fine-tuning various parameters to inhibit 
NMDARs through the derivatization of uncompetitive NMDAR antagonists could provide insight into 
the invention of multifunctional molecules as potential drugs for AD. 
Monoamine oxidase (MAOs), a family of enzymes that oxidatively deaminates monoamines, are 
linked to the pathogenesis of PD since they regulate dopaminergic and serotonergic 
neurotransmission.316−319 The commonalities and correlated onsets between AD and PD have led 
researchers to investigate the role of MAOs in the pathology of AD. MAOs, found on the outer 
mitochondrial membrane, are divided into two isoforms, MAO-A and MAO-B, which exhibit 
overlapping substrate specificities against dopamine, tyramine, and tryptamine.320 MAO-A, however, 
is capable of deaminating serotonin, melatonin, norepinephrine, and epinephrine, whereas MAO-B is 
mainly responsible for breaking down phenethylamine. MAO-catalyzed reactions produce H2O2 and 
ammonia as byproducts.316 Thus, the overactivity of MAOs enhances the generation of H2O2 possibly 
leading to oxidative stress.316 Inhibition of MAOs has been studied as a promising approach to treat 
AD.321 
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Phosphodiesterases (PDEs), composed of 12 families of enzymes responsible for the hydrolysis 
of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), play a role 
in the regulation of intracellular signaling cascades, LTP, and synaptic plasticity.322−324 Various members 
of PDEs have been implicated in a wide range of disorders, including AD and PD.322 Specifically, the 
change in the expression of PDE4, PDE7, and PDE8 has been indicated in the AD-affected brain.322−324 
PDE inhibitors (PDEIs) have been shown to control signaling pathways by elevating the levels of cAMP 
and cGMP with subsequent activation of the cAMP response element binding (CREB) protein.325,326 
Such activation of the CREB protein is involved in LTP and synaptic plasticity.327,328 Incorporation of 
the inhibitory activity against specific PDEs in the rational design of multifunctional molecules could 
be an effective means to construct them into potential drugs for AD. Furthermore, a link between PDEs 
and tau has been suggested through the direct relation between cAMP and protein kinase A associated 
with the phosphorylation of tau.329,330 
Apolipoprotein E (ApoE) is recognized as a major determinant in lipoprotein metabolism, 
cholesterol homeostasis, and cardiovascular disease.331 Research regarding the connection between 
ApoE polymorphisms and AD led to the discovery of ApoE4 as a strong genetic factor.332−334 ApoE 
isoforms (i.e., ApoE2, ApoE3, and ApoE4) have only one or two different amino acid residues; however, 
they exhibit distinct biological functions.335 For example, the ApoE4 allele is strongly implicated in 
sporadic AD, while ApoE2 is observed to be linked to neuroprotection.334,336,337 
The direct and indirect relationships between ApoE4 and A are controversial with research 
supporting both ApoE’s pathological (for ApoE4) and remedial roles (possibly, for ApoE2) in AD. 
ApoE’s effect on A deposition and neuritic degradation was shown to be specific for the isoform. For 
example, an increase in the A burden, fibrillogenesis, and neuritic plaque formation through binding 
to ApoE4 was greater than that of ApoE3 binding.338 Hashimoto et al. presented that ApoE increased 
the levels of A oligomers in an isoform-dependent manner (ApoE2 < ApoE3 < ApoE4).339 In addition, 
ApoE4-expressing astrocytes were indicated to enhance amyloidogenic processing of APP in neurons, 
and the lack of ApoE4 reduced A deposition in Tg mice overexpressing human APPV717F.340 On the 
other hand, Jiang et al. reported the capability of ApoE to promote the proteolytic degradation of A in 
an isoformdependent manner, where ApoE4 impaired A proteolysis, relative to ApoE2 and ApoE3.341 
Upregulated at the sites of elevated inflammation, ApoE3 and ApoE4 were reported to block glial 
secretion of TNF, implying its connection to inflammatory processes.342 Further research to identify 
ApoE’s multifactorial role in AD would be valuable to gain a better understanding to find a direction 
for developing effective therapeutics. One approach is to inhibit the interactions between ApoE4 and 
AD pathological factors (e.g., A) using small molecules. Chen et al. indicated that small molecules 
able to control the intramolecular interactions between the amino- and carboxyl-terminal domains of 
ApoE4 could eliminate its detrimental effects in vitro.343 A recent study displayed a link between ApoE4 
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and tau pathology, further cementing the involvement of ApoE4 in AD pathogenesis.344 Knock-in of 
human ApoE4 into a mouse model of tauopathy (1N4R P301S tau) resulted in exacerbated ptau 
pathology compared to that of ApoE2 and ApoE3, while knockout of ApoE had a protective effect.344 
ApoE4/P301S mice further displayed more neurodegeneration and neuroinflammation than 
ApoE2/P301S and ApoE3/P301S mice, and ApoE knockout mice were once more protected from these 
pathological changes.344 The isoform-dependent genetic implications of ApoE indicate an aspect of AD 
in connection to A and tau, suggesting its therapeutic potential to be considered for the design of 
multifunctional compounds as possible drug candidates. 
Pyroglutamate A (pGlu-A) is a variation of A with an N-terminal pyroglutamate residue 
implicated for its toxicity.345−348 Glutaminyl cyclase is a catalytic enzyme responsible for the pGlu 
modification of A.349 Glutaminyl cyclase has been gaining the attention of researchers as a potential 
therapeutic target for AD due to its upregulation in the areas of the brain affected by AD and its potential 
contribution toward A-mediated toxicity.346,348−350 Overexpression of glutaminyl cyclase has been 
shown to induce behavioral deficits in Tg mice, whereas glutaminyl cyclase knockout improved the 
behavioral phenotype in 5xFAD mice.346 Increasing evidence supporting the effectiveness of inhibiting 
glutaminyl cyclase implies a tactic that could be valuable to consider in the design of multifunctional 
molecules as potential therapeutics.348,350,351 
Neuroinflammation is a biological response of the nervous tissue initiated in reaction to 
detriments (e.g., infection and traumatic brain injury).352 Pathological events of AD, including A 
accumulation and tau hyperphosphorylation, are reported to invoke inflammatory responses in 
vulnerable regions of the AD-affected brain.353 Gliosis and activated glial cells are two major 
histopathological signs of neuroinflammation in AD.353 Previous studies suggest that the direct and 
indirect damage from inflammation may exacerbate the pathological processes through a positive 
feedback loop.353 The interconnected inflammation pathways can be activated by A aggregates354 and 
NFTs355 through classical and alternative complement pathways.353 
 
1.3. Conclusions 
Multiple aspects of AD presented thus far represent a large portion of the research effort devoted toward 
determining the factors responsible for neurodegeneration observed in AD. Although a great deal of 
work has been dedicated to the cause, it is still unclear if the pathological elements mainly indicated in 
the AD-affected brain serve as causative factors of the disease or are the products of unidentified 
upstream events. The number of potential pathological components [e.g., peroxisome proliferator 
activator receptor  (PPAR),356,357 phospholipase A2 (PLA2s),358,359 cyclophilin D (CypD),360,361 GD3 
synthase,362 plasminogen activator,363,364 dickkopf1 (DKK1),365 calpain,366,367 and histone deacetylases 
(HDACs)368], speculated to play a role in AD pathology, represent the gap between our understanding 
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of the disease and its complexity. On the basis of diverse potential pathological targets and their 
suggested interconnections towards the pathogenesis of AD, the development of chemical tools would 
be valuable for understanding and modifying pathogenic factors in neurodegenerative diseases. 
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Amyloidogenic peptides are found in human degenerative diseases [e.g., amyloid- (A) for 
Alzheimer’s disease (AD), -synuclein (-Syn) for Parkinson’s disease (PD), and human islet amyloid 
polypeptide (hIAPP) for type II diabetes].1–6 Amyloidogenic peptides have aggregate-prone properties 
to form -strand fibrils through oligomeric conformations, and their aggregation has been suggested to 
be linked to the pathogenesis of degenerative disorders.1–6 Thus, a variety of approaches have been 
developed to regulate or suppress the aggregation pathways of amyloidogenic peptides.2,7–12 Among 
such methods, peptide modifications, including peptide oxidation, have been recently implicated as a 
strategy suitable for modulation of amyloidogenic peptide aggregation (Figure 2.1a).13–23 
To trigger the oxidation of peptides, some chemical reagents, such as metal ions, have been 
utilized.14,24–27 Metal ions are frequently used for peptide oxidation; however, they require harsh 
additional oxidants.14,24–27 In addition, chemical reagents capable of generating oxidants from O2 upon 
photoactivation have been developed for use as photosensitizers in various fields because light is a 
readily accessible resource.13,28–40 A series of organic molecules, such as riboflavin, rose bengal, 
methylene blue, and porphyrins, have been used as photoinduced reagents;13,29–35 however, (i) many of 
them have relatively lower quantum yields than those of photoactivatable transition-metal complexes;41–
44 and (ii) some organic agents are less stable, which potentially indicates their degradation upon 
irradiation.28,36 Photoactivatable metal complexes present relatively high quantum yields, structural 
stability, and tunable geometries and properties upon ligand substitution.28,36 Due to these beneficial 
aspects, multiple metal complexes have been designed and mediated for photoinduced oxidation of 
peptides.37–40 One inorganic complex, [Ru(bpy)3]2+ (bpy = 2,2’-bipyridine), has been frequently 
employed for oxidative modifications of peptides through light exposure.38–40 To achieve peptide 
oxidation, this ruthenium(II) complex still needs an additional electron acceptor (e.g., ammonium 
persulfate), however, which could lead to cytotoxicity and limit its applications.38–40,45 Thus, robust 
inorganic complexes able to efficiently oxidize peptides simply by light introduction without the 
assistance of harsh additives would be of significant value for gaining a greater understanding of 
peptide-related chemistry and biology. 
Herein, we report an iridium(III) complex, Ir-1 (Figure 2.1b), as a chemical tool for the oxidation 
of amyloidogenic peptides with the subsequent control of their aggregation under mild conditions that 
only include readily available O2 and visible light. Ir-1 was rationally designed as such a tool through 
incorporating the general properties of Ir(III) complexes previously reported for various applications, 
including photoactivation, formation of reactive oxygen species (ROS) upon light exposure, and 
relatively stable octahedral geometry, as well as relatively easy introduction of a ligand containing a 
structural moiety, suggested to be important for interactions with amyloidogenic peptides, on the Ir(III)  
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Figure 2.1. Schematic description of amyloidogenic peptide aggregation and chemical structures of Ir-
1 and 1. As shown in (a), oxidation of amyloidogenic peptides could control their aggregation pathways. 
(b) Synthetic routes to Ir-1. 
 
center.28,46–53 Representative amyloidogenic peptides (i.e., A, -Syn, and hIAPP) were indicated to be 
noticeably oxidized upon treatment of Ir-1 with photoactivation under aerobic conditions, as monitored 
by electrospray ionization mass spectrometry (ESI-MS), and their oxidation sites (as potential sites, 
methionine, histidine, and tyrosine residues) were identified by tandem MS (ESI-MS2). Even with 
oxidative modifications of a few residues in these amyloidogenic peptides, the aggregation pathways 
were noticeably modulated, resulting in distinct morphological features (e.g., smaller-sized or 
amorphous peptide species, instead of fibrils). Taken together, our rational design and investigations 
into Ir-1 illustrate the potential of transition metal complexes as chemical tools for the oxidative 
modification of amyloidogenic peptides simply by employing light and O2. In addition, our studies 
corroborate that small changes in amyloidogenic peptides, such as oxidation at a few specific residues, 
are able to transform overall peptide aggregation pathways; this suggests novel and viable directions 
for amyloid management (Figure 2.1a). 
 
2.2. Results and Discussion 
2.2.1. Rational Design of Ir-1 for Oxidation of Amyloidogenic Peptides 
For the oxidation of amyloidogenic peptides simply upon photoactivation under mild conditions, Ir-1 
(Figure 2.1b) was rationally designed as a chemical tool by taking into account the characteristics found 
in previously reported photoactivatable Ir(III) complexes, as well as specificity for amyloidogenic 
peptides: (i) photoproperties with relatively low-energy radiation (i.e., visible light) ;49,50 (ii) the ability 
to produce ROS [e.g., singlet oxygen (1O2)] from redundant O2, which is responsible for peptide 
oxidation, upon photoactivation;28,48 (iii) robust octahedral coordination, which can provide relative 
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structural stability without any structural modifications when light is introduced;48 (iv) strong spin-orbit 
coupling of the Ir(III) center, which could facilitate electronic transitions without the assistance of 
additional electron acceptors;49,50 and (v) incorporation of a ligand (1) containing a dimethylamino 
group, suggested to be crucial for interactions with amyloidogenic peptides,46,47 onto the Ir(III) center 
(Figure 2.1b). 
Ir-1 was obtained in relatively high yield (ca. 80%) through previously known two-step 
procedures with slight modifications, as depicted in Figure 2.1b.54 Moreover, Ir-1 is easily 
photoactivatable under mild conditions [e.g., excitation with visible light { (463 nm) = 5.78 (± 0.12) 
× 103 M-1 cm-1; Table 2.1} and aerobic conditions] as shown by its quantum yield for phosphorescence 
[p = 0.41 (± 0.02); Table 2.1]. The ability of Ir-1 to generate singlet oxygen (1O2) from triplet dioxygen 
(3O2) was also confirmed by determining the quantum yield of 1O2 [s = 0.25 (± 0.03); Table 2.1]. 
Overall, an octahedral Ir(III) complex, Ir-1, was constructed as a photoactivatable tool to oxidize 
amyloidogenic peptides without the need for harsh conditions through relatively easy synthetic routes 
with a high yield, and demonstrated to generate oxidants (i.e., 1O2) from readily accessible O2. 
 
Table 2.1. Photophysical properties of Ir-1. 
 Ir-1 
ex, max (nm) 463 
em, max (nm) 600 
 [M-1cm-1; 463 nm; 
in H2O (1% v/v DMSO)] 
5.78 (± 0.12) x 103 
Lifetime (ns) 238 
p 0.41 (± 0.02) 
s 0.25 (± 0.03) 
 
2.2.2. Oxidative Modifications of Amyloidogenic Peptides by Ir-1 
To investigate whether the oxidation of amyloidogenic peptides by Ir-1 under aerobic conditions would 
occur with light activation, three amyloidogenic peptides (i.e., A, -Syn, and hIAPP found in AD, PD, 
and type II diabetes, respectively) were chosen as representative amyloidogenic peptides, and the 
resultant monomeric peptide species upon treatment with Ir-1 were first monitored by means of ESI-
MS (Figure 2.2). These three amyloidogenic peptides were observed to be oxidized with the addition 
of lightactivated Ir-1 under aerobic conditions. Without light, even in the presence of Ir-1, all 
amyloidogenic peptides were in nonoxidized forms (Figure 2.2, middle, gray). In the case of A40, the 




Figure 2.2. Oxidation of amyloidogenic peptides by Ir-1 upon light activation. Mass spectrometric 
analyses of amyloidogenic peptides [(a) A40, (b) -Syn, and (c) hIAPP] upon treatment with Ir-1 in 
the presence of light. Oxidized peptide ions are indicated with red asterisks, and the number of asterisks 
indicates the number of oxygen atoms incorporated into the peptides. Conditions: [peptide] = 100 M; 
[Ir-1] = 500 M; pH 7.4; 37 °C; 1 h; no agitation; 1 sun light for 10 min (for samples treated with light); 





Figure 2.3. ESI-MS spectra for A40 with 1 in the absence (top) and presence (bottom) of light. 
Conditions: [A40] = 100 M; [1] = 500 M; pH 7.4; 37 °C; 1 h; no agitation; 1 sun light for 10 min 
(for the samples treated with light); aerobic conditions. 
 
incorporation of one oxygen atom into the peptide (Figure 2.2a, bottom, blue). Notably, ligand 1 alone 
was not able to oxidize A40 (Figure 2.3). Similar to A40, doubly oxidized -Syn with a 32 Da increase 
in mass, relative to that of the native peptide, was indicated; this suggested the introduction of two 
oxygen atoms into the peptide (Figure 2.2b, bottom, blue). Slightly different from both A and -Syn, 
singly oxidized monomeric hIAPP presented a 14 Da difference in mass from nonoxidized peptides 
(Figure 2.2c, bottom, blue). A 14 Da increase in mass could result from the addition of one oxygen atom 




Figure 2.4. Oxidation of A40 dimers by Ir-1 upon photoactivation. (a) ESI-MS spectra for +5-charged 
dimers with Ir-1 in the absence and presence of light. The oxidized dimers are only detected by Ir-1 
with light exposure (bottom, blue). The number of red asterisks indicates the number of oxygen atoms 
incorporated into A40 dimers. (b) ATDs for nonoxidized (top and middle) and tetraoxidized dimers 
(bottom). Each ion selected for IM-MS analysis is indicated with gray arrows in (a). The oxidized dimer 
incorporated with four oxygen atoms presents the higher abundance in the distribution with short drift 
time (bottom) than that of nonoxidized A40 (top and middle), which implies that structural compaction 
can be induced by oxidation. Conditions: [A40] = 100 M; [Ir-1] = 500 M; pH 7.4; 37 °C; 1 h; no 




Figure 2.5. ESI-MS spectra for oligomeric A40 with Ir-1 in the absence and presence of light. The +z-
charged n-mer is denoted as nz+. Peak annotations for oxidized oligomers are highlighted in red. 
Conditions: [A40] = 100 M; [Ir-1] = 500 M; pH 7.4; 37 °C; 1 h; no agitation; 1 sun light for 10 min 
(for the samples treated with light); aerobic conditions. 
 
Second, we examined whether amyloidogenic peptide oligomers (focusing on A oligomers) by 
Ir-1 could be oxidized with light activation under aerobic conditions. From the samples containing A 
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and Ir-1 upon exposure to light and O2, the oxidation of both dimers and larger oligomers was revealed 
(Figures 2.4a and 2.5). As demonstrated in Figure 2.4a, multiple oxygen atoms (e.g., for dimers, up to 
seven oxygen atoms) were indicated to be incorporated into the oxidized oligomers. 
Moreover, structural changes to monomeric and oligomeric peptide species accompanied by 
oxidation were probed by means of ion mobility mass spectrometry (IM-MS), which enabled to 
characterize conformations based on the mobility of ions passing through a cell filled with neutral gas.56 
In the case of A monomers, there was no remarkable difference in arrival time distributions (ATDs) 
between singly oxidized and nonoxidized A40 monomers (Figure 2.6). Distinguishable from A 
monomers, a change in the IM-MS data of A40 dimers upon oxidation was presented at two dominant 
ATDs, centered at 10.80 and 15.55 ms, respectively (Figure 2.4b). Nonoxidized A40 dimers exhibited 
greater dominance in the larger ATD, whereas the oxidized dimers had the opposite tendency, which 
suggested that peptide oxidation could lead to structural compaction in the dimers. Although structural 
details of oxidized dimers have not been elucidated, their structural compaction might assist in 
modulating peptide aggregation because previous studies indicated that conformationally compact A 
species could alter peptide aggregation pathways to form amorphous aggregates.8–11 
 
 
Figure 2.6. IM-MS spectra for +3-charged A40 monomers. ATD for nonoxidized (top and middle) and 
singly oxidized monomeric A40 (bottom). There is no significant difference between ATD of 
nonoxidized A40 (top and middle) and that of singly oxidized A40 upon addition of Ir-1 in the presence 
of light (bottom). 
 
Furthermore, the oxidation of a nonamyloidogenic structured protein, ubiquitin, was also 
investigated when Ir-1 was added with light under aerobic conditions. Ubiquitin was selected as an 
archetypal structured protein because all secondary structures (e.g., -helix, -strand, and random coil) 
could be found in ubiquitin.57 Ubiquitin treated with Ir-1 was shown to be oxidized with light exposure 
under aerobic conditions (Figure 2.7, bottom, blue); however, oxidized ubiquitin was significantly less 
abundant than the oxidized forms of intrinsically disordered amyloidogenic peptides (i.e., A40, -Syn, 
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and hIAPP). Overall, oxidative modifications of amyloidogenic peptides, lacking ordered structures, 
are more readily achieved over structured peptides by Ir-1 under mild conditions, including light and 
O2, which could direct structural compaction; this supports the utilization of Ir-1 as a photoactivatable 
tool for the oxidation of amyloidogenic peptides. 
 
 
Figure 2.7. ESI-MS spectra for ubiquitin with Ir-1 in the absence and presence of light. The number of 
red asterisks indicates the number of the oxygen atoms incorporated into the peptide. The oxidized 
ubiquitin peaks are magnified and indicated in the dotted box. Conditions: [ubiquitin] = 100 M; [Ir-1] 
= 500 M; pH 7.4; 37 °C; 1 h; no agitation; 1 sun light for 10 min (for the samples treated with light); 
aerobic conditions. 
 
2.2.3. Identification of Oxidation Sites in Amyloidogenic Peptides 
The resultant oxidized amyloidogenic peptides, produced by the addition of Ir-1 with light exposure 
under aerobic conditions, were further studied by ESI-MS2 to determine the oxidation sites in the 
peptides.10,11 The fragment ions generated by selectively applying collisional energy to the singly and 
doubly oxidized amyloidogenic peptides were analyzed (Figure 2.8). First, the oxidation sites in A40 
were identified. The singly oxidized fragments, highlighted in red, were observed in b fragments, which 
were cleaved from the N-terminus (Figure 2.8b). All b fragments smaller than b13 existed as nonoxidized 
forms, whereas those larger than b34 represented only oxidized fragments. Methionine 35 (M35) is 
known to be the most readily oxidizable amino acid in A.22 If oxidation occurred only at M35, all 
fragments smaller than b35 would not be oxidized (Figure 2.8a); however, oxidized b fragments were 
indicated to be smaller than b35, which implied the existence of other oxidation sites (Figure 2.8b). 
Based on previously reported studies, other possible oxidation sites could be histidine residues (i.e., 
H13, H14).26,59 In the ESI-MS2 spectrum for doubly oxidized A40, there was no oxidized fragment 
smaller than b13 (Figure 2.8d). Because fragments from b13 to b34 only existed in singly oxidized forms 
(highlighted in red in Figure 2.8), this region would include one oxidation site, possibly H13 or H14. 
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All fragments larger than b34 were doubly oxidized (denoted in green), which implied the incorporation 
of one oxygen atom into M35 to generate a sulfoxide form (Figure 2.8c and d). 
 
 
Figure 2.8. Identification of the oxidation sites in A40. (a and c) The peptide sequence and annotation 
for ESI-MS2 and (b and d) ESI-MS2 spectra for singly and doubly oxidized A40. Singly and doubly 
oxidized b fragments (N-terminal fragment ions) or y fragments (C-terminal fragment ions) are denoted 
in red and green, respectively. The peaks assigned as triangles (b16 and b17) indicate that the loss of a 
water molecule occurs at serine, threonine, glutamate, or aspartate residues in these fragment ions.58 
 
For further analysis of the oxidation sites in A, A40 treated with Ir-1 in the absence and 
presence of light was evaluated by 2D band-selective optimized flip-angle short transient heteronuclear 
multiple quantum correlation (SOFAST-HMQC) NMR spectroscopy (Figures 2.9). In the absence of 
light, minimal chemical shift perturbations (CSPs) of uniformly 15N-labeled A40 appeared upon 
incubation with Ir-1 (Figure 2.9c), which implied no significant interaction of Ir-1 with the peptide. 
Following exposure of the A samples containing Ir-1 to light, a dramatic increase in the CSPs at V12, 
D23, and M35 was observed (Figure 2.9d). A noticeable change in the CSP of M35 suggests that there 
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are interactions near M35, which is consistent with observation monitored by ESI-MS2. In the case of 
histidine residues, although they were not well resolved within the spectra due to peak overlap, the 
enhanced CSP of V12, proximately located to H13 or H14, could be expected, which proposed oxidative 
modifications at H13 or H14, as shown in our ESI-MS2 studies. Notably, in the NMR spectra, D23 was 
adjacent to M35 with some overlap, so the shift of M35 might affect its CSP. Thus, our NMR data 
support that A40 is oxidized at specific sites (potentially, M35, H13, and H14) by Ir-1 upon light 
stimulation under aerobic conditions. 
 
 
Figure 2.9. SOFAST-HMQC NMR studies of uniformly 15N-labeled A40 monomer upon treatment 
with Ir-1 with and without light. (c and d) The chemical shift perturbations (CSPs) for each spectrum 
[in the (a) absence or (b) presence of light], relative to the spectrum of A40 without Ir-1, were calculated. 
Conditions: [15N-labeled A40] = 80 M; [Ir-1] = 160 M; pH 7.4; 37 °C; ambient light for 1 h (for 
samples treated with light); aerobic conditions. *Residues could not be resolved for analysis. 
 
Potential oxidation sites in the other amyloidogenic peptides (i.e., -Syn and hIAPP), when 
treated with Ir-1 in the presence of light under aerobic conditions, were also investigated by means of 
ESI-MS2 (Figure 2.10). When the collisional energy was applied at doubly oxidized -Syn (Figure 
2.10a and b), no oxidation was found in small N-terminal fragments; this reflects that oxidation at M1 
and M5 rarely occurs. The C-terminal fragment y13 was detected in a nonoxidized form, but b119 was 
present in both oxidized and nonoxidized forms. One oxidation site existed between P120 and M127, 
and the most plausible location was M127. Since singly oxidized b116 and b119 ions were relatively 
abundant, M116 was also estimated to be possibly oxidized. There were oxidized fragments smaller 
than b116, such as b63, b65, and b66, which implied that there were oxidation sites other than M116 and  
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Figure 2.10. Identification of oxidation sites in -Syn and hIAPP. Sequences of (a) -Syn and (c) hIAPP. 
ESI-MS2 spectra for (b) doubly oxidized -Syn, and (d) singly and (e) doubly oxidized hIAPP. 
Nonoxidized, singly oxidized, and doubly oxidized fragments are indicated in black, red, and green, 
respectively. 
 
M127. Based on our investigations for oxidation sites in A40, the histidine residue in -Syn (i.e., H50) 
could be an oxidation site. Additionally, in the ESI-MS2 spectra of singly and doubly oxidized hIAPP 
(Figure 2.10c–e), peptide oxidation was observed in fragments larger than b18; this was indicative of 
H18 as a potential oxidation site. Fragments between b18 and b32, however, appeared in both oxidized 
and nonoxidized forms, which suggested that there was another oxidation site apart from H18. In the 
spectrum of doubly oxidized hIAPP (Figure 2.10e), no doubly oxidized ion was displayed other than 
the whole peptide itself, which possibly revealed that Y37 might be the second oxidation site. 
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Previous studies proposed that methionine, histidine, and tyrosine residues in amyloidogenic 
peptides were susceptible to oxidative modification, which could affect their aggregation 
behavior.17,20,22,60 Particularly, oxidative modifications of methionine residues have been reported to 
inhibit -strand formation of amyloidogenic peptides.20,22,60 Incorporation of oxygen atoms into 
methionine residues could provide partial negative charges and further enhance the polarity of 
peptides.15,20,60 In the case of A, the increased polarity of oxidized M35 could reduce hydrophobic 
contacts in the C-terminal region and destabilize a -strand structure in which M35 proximately 
interacts with the aromatic ring of F19.20,60 Along with a change in polarity, greater structural disorder 
and reduced helicity were also found in methionine-oxidized -Syn.15,61 Specifically, oxidation at M116 
and M127 presumably disrupts -Syn aggregation because these residues are suggested to mediate 
long-range interactions with the central hydrophobic regions.62 Other important oxidation sites are 
histidine residues. Due to its structural features, such as an imidazole ring and two protonation states, 
histidine has versatile roles in multiple interactions (e.g., cationic– interactions, – stacking, 
hydrogen– interactions, coordination, and hydrogen bonding).63 Depending on pH, histidine can 
present different protonation states that have effects on the molecular behavior of amyloidogenic 
peptides, including aggregation, through alteration of the strength of interactions.63,64 In addition, 
histidine is known as a metal binding site in amyloidogenic peptides.65–69 Binding of metal ions [e.g., 
Cu(II), Zn(II)] to peptides is shown to accelerate amyloidogenic peptide aggregation or induce the 
formation and stabilization of toxic oligomeric aggregates.2,66,67,70 Upon the formation of 2-oxo-
histidine, metal binding affinities were reported to be substantially decreased; thus, oxidative 
modifications of histidine residues might destabilize complexes of amyloidogenic peptides with metal 
ions.69,71 Collectively, methionine, histidine, and/or tyrosine residues, the potential oxidation sites of A, 
-Syn, or hIAPP, which were suggested to be essential for the properties and aggregation of these 
amyloidogenic peptides, were indicated by our MS and NMR studies. Oxidative modifications are 
present at a few specific residues in amyloidogenic peptides, which might be able to modulate their 
aggregation pathways potentially through altering intra- or intermolecular interactions critical for -
strand formation (see below). 
 
2.2.4. Aggregation Behavior Influenced upon Oxidation of Amyloidogenic Peptides by Light-
Activated Ir-1 
2.2.4.1. Change in the Size Distribution 
To investigate whether peptide oxidation could transmute the aggregation of amyloidogenic peptides, 
two inhibition (Figures 2.11a and 2.12a) and disaggregation (Figure 2.13a) experiments8–11 were carried 
out mainly with A (two major isoforms, A40 and A42). Size distributions of the resultant A40 and 
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A42 species treated with Ir-1 were evaluated by gel electrophoresis with Western blotting (gel/Western 




Figure 2.11. Effects of Ir-1 and 1 on peptide aggregation pathways. (a) Scheme of the inhibition 
experiments. (b) Analyses of the resultant A40 and A42 species generated from various conditions 
[aerobic (left) and anaerobic (right) conditions] by gel/Western blot with an anti-A antibody (6E10). 
Lanes: (C) A40 or A42; (1) A40 or A42 + 1; (Ir-1) A40 or A42 + Ir-1. (c and d) TEM images of the 
samples from (b) and the light-treated samples containing -Syn or hIAPP with and without Ir-1 (scale 
bar = 1 m). Conditions: [peptide] = 25 M; [Ir-1 or 1] = 50 M; pH 7.4; 37 °C; 24 h; constant agitation; 
1 sun light for 10 min (for samples treated with light). 
 
 
In the inhibition studies (Figure 2.11a), when fresh A40 was incubated with Ir-1 in the presence 
of light under aerobic conditions, various molecular weights (MWs) of peptide species were visualized 
in the gel/Western blot (Figure 2.11b, left). Distinct from the result with light exposure, Ir-1 could not 
generate diverse sizes of A aggregates without light. In addition, when the ligands, 1 and 2-
phenylquinoline (Figure 2.1b), were not coordinated to the Ir(III) center, they had no noticeable effect 
on A aggregation, even with light under aerobic conditions (Figures 2.11b and 2.12). When Ir-1 was 
incubated with fresh A42, similar reactivity trends were presented to those with A40 (Figure 2.11b, 
right). Diverse MW distributions of A42 species were shown with both Ir-1 and light. Furthermore, the 
inhibition experiments were conducted in the absence of O2 to verify if A aggregation could be 
influenced upon oxidation of peptides by oxidants generated by O2 with light-activated Ir-1. A 
aggregation pathways were not indicated to be varied under anaerobic conditions, even in the presence 




Figure 2.12. Effect of the ligand (2-phenylquinoline, Figure 2.1) on A40 aggregation. (a) Scheme of 
the inhibition experiment. (b) Analysis of the resultant A40 species visualized by gel/Western blot with 
an anti-A antibody (6E10). Lanes: (C) A40; (2) A40 + 2-phenylquinoline; (Ir-1) A40 + Ir-1. (c) TEM 
images of the samples from (b) (scale bar = 200 nm). Conditions: [A40] = 25 M; [2-phenylquinoline 
or Ir-1] = 50 M; pH 7.4; 37 °C; 24 h; constant agitation; 1 sun light for 10 min (for the samples treated 
with light). 
 
Moreover, in order to disassemble preformed A40 aggregates or redirect their further aggregation 
upon oxidation with Ir-1 in the presence of light and O2, the disaggregation experiment was carried out 
(Figure 2.13). Similar to the inhibition studies, preformed A40 aggregates were observed with a wide 
range of sizes only after treatment with Ir-1 upon light exposure in the presence of O2. Overall, our 
gel/Western blot results from both inhibition and disaggregation experiments suggest that 1) Ir-1 is able 
to transmute A aggregation pathways only with light activation under aerobic conditions; and 2) the 
overall structure of Ir-1 over individual structural components (e.g., ligand 1) is essential to alter A 
aggregation in the presence of both light and O2. Combining the results with the control of light and O2, 
it is demonstrated that A oxidation, triggered by photoactivated Ir-1 with O2, could direct the 
modulation of peptide aggregation pathways. 
 
 
Figure 2.13. Effects of Ir-1 and 1 on the disassembly of preformed A40 aggregates. (a) Scheme of the 
disaggregation experiment. (b) Analysis of the resultant A40 species was visualized by gel/Western blot 
with an anti-A antibody (6E10). Conditions: [A40] = 25 M; [Ir-1 or 1] = 50 M; pH 7.4; 37 °C; 24 
h; constant agitation; 1 sun light for 10 min (for the samples treated with light); aerobic conditions. 
Lanes: (C) A40; (1) A40 + 1; (Ir-1) A40 + Ir-1. 
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2.2.4.2. Morphological Changes of Amyloidogenic Peptides 
The degree of regulating the aggregation pathways of amyloidogenic peptides was also monitored 
through morphological changes visualized by transmission electron microscopy (TEM) (Figure 2.11c 
and d). From the TEM analyses, the resultant peptides upon treatment with both Ir-1 and light under 
aerobic conditions were observed to be smaller, while either structured fibrils or large aggregates were 
indicated without light. In the case of A40, the treatment of the peptide with Ir-1 induced the formation 
of short and thin fibrils in the presence of both light and O2 (Figure 2.11c). Additionally, the 
morphologies of -Syn and hIAPP were also transformed to smaller amorphous aggregates when Ir-1 
was added with exposure of both light and O2, instead of large aggregates or fibrils produced in the 
absence of Ir-1 (Figure 2.11d). Therefore, along with the gel/Western blot data, our TEM studies imply 
that the aggregation of amyloidogenic peptides could be transfigured upon treatment with light-
activated Ir-1 under aerobic conditions. 
 
2.3. Conclusions 
Several strategies for understanding and suppressing the aggregation of amyloidogenic peptides, found 
in amyloid-related disorders and suggested to be linked to their pathogenesis, have been developed. 
One of the tactics would be related to oxidative modifications of the amino acid residues essential for 
properties and aggregation behaviors of peptides. For the oxidation of amyloidogenic peptides, an 
inorganic complex, Ir-1, was rationally designed to be a chemical tool that has a relatively stable 
framework and is capable of generating oxidants (e.g., 1O2) from readily accessible O2 simply upon 
photoactivation employing low-energy radiation. 
On the basis of our biochemical and biophysical analyses, Ir-1 is shown to significantly induce 
oxidative modifications of amyloidogenic peptides, such as A, -Syn, and hIAPP, followed by 
alteration of their aggregation pathways. Peptide oxidation by photoactivated Ir-1 is more noticeable 
for amyloidogenic peptides over well-structured nonamyloidogenic peptides. By MS and NMR, the 
oxidation sites are indicated to be potentially located at methionine, histidine, and/or tyrosine residues 
in these amyloidogenic peptides. Through minor alterations at a few specific residues in peptides by 
photoactivated Ir-1 under mild conditions, their aggregation pathways can be modulated. Overall, our 
rational design and fundamental investigations of Ir-1 demonstrate the promise of an inorganic complex 
in being developed as a chemical tool for oxidative modifications of amyloidogenic peptides with the 
subsequent control of their aggregation. Such a tool will assist in advancing our fundamental 
understanding towards amyloidogenic peptides, as well as providing insight into developing effective 
approaches for amyloid management. 
 
2.4. Experimental Section 
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2.4.1. Materials and Methods 
All reagents were purchased from commercial suppliers and used as received, unless otherwise noted. 
Compound 1 (1 = methyl 4-(dimethylamino)picolinate)72 and the cyclometalated chloridebridged Ir(III) 
dimer ([Ir(C^N)2(-Cl)2])73 were prepared by following previously reported procedures. The prepared 
Ir-1 was characterized by NMR, FTIR, HRMS, and elemental analyzer on an Agilent 400-MR DD2 
NMR spectrometer, Varian Cary 620/670 FTIR spectrometer (UNIST Central Research Facilities, Ulsan, 
Republic of Korea), Bruker maXisTM HD Ultra-high resolution Q-TOF LC MS/MS system (HRMS; 
The Cooperative Laboratory Center of Pukyong National University, Busan, Republic of Korea), and 
Thermo Flash 2000 (UNIST Central Research Facilities, Ulsan, Republic of Korea), respectively. A40 
and A42 were purchased from Anygen (A40 = DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIG-
LMVGGVV, A42 = DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA; Nammyun, 
Jangseong-gun, Republic of Korea). -Syn and hIAPP were obtained from Anaspec and Peptron, 
respectively [-Syn = MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKE-
GVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGA
PQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA (Fremont, CA, USA); hIAPP = 
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNKCNTATCATQRLANFLVHSSNNFGAILSS
TNVGSNTY-NH2 (Daejeon, Republic of Korea)]. Ubiquitin was purchased from Sigma Aldrich 
(ubiquitin = MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLS-
DYNIQKESTLHLVLRLRGG; St. Louis, MO, USA). Double-distilled H2O (ddH2O) was obtained 
from a Milli-Q Direct 16 system (Merck KGaA, Darmstadt, Germany). Irradiation with 1 sun was 
obtained with a Newport IQE-200 solar simulator (Irvine, CA, USA). ESI-MS and IM-MS analyses 
were performed by using a Waters Synapt G2-Si quadrupole time-of-flight ion mobility mass 
spectrometer equipped with an ESI source (DGIST Center for Core Research Facilities, Daegu, 
Republic of Korea). NMR studies of A with Ir-1 were conducted on a Bruker Avance 600 MHz 
spectrometer equipped with a TCI triple-resonance inverse detection cryoprobe. The data was processed 
by using TOPSPIN 2.1 (Bruker) software and assignments were made by using SPARKY 3.1134 
software. Anaerobic reactions were performed in a N2-filled glove box (Korea Kiyon, Bucheon-si, 
Gyeonggi-do, Republic of Korea). TEM images were taken by using a JEOL JEM-1400 transmission 
electron microscope (UNIST Central Research Facilities, Ulsan, Republic of Korea). Photophysical 
properties were measured by using an Agilent Cary 100 UV/Vis spectrophotometer and a Varian Cary 
Eclipse fluorescence spectrophotometer (UNIST Central Research Facilities, Ulsan, Republic of Korea). 
Timecorrelated single-photon counting (TCSPC) was performed for lifetime measurements with a 
Ti:sapphire laser Mira900 (Coherent, Santa Clara, CA, USA), monochromator Acton series SP-2150i 
(Princeton Instruments, Acton, MA, USA), and TCSPC module PicoHarp 300 (PicoQuant, Berlin, 
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Germany) together with MCP-PMT R3809U-59 (Hamamatsu, Shizuika-ken, Japan) and fitted by 
PicoQuant FluoFit software (UNIST Central Research Facilities, Ulsan, Republic of Korea). 
 
2.4.2. Synthesis of Ir-1 
2-Phenylquinoline (680 mg, 3.3 mmol) was added to a solution of IrCl3·nH2O (500 mg, 1.7 mmol) in a 
mixture of 2-methoxyethanol and H2O (3:1). The solution was heated at reflux under N2 (g) for 24 h. 
After cooling to room temperature, brown precipitates were obtained by treatment with additional H2O. 
The crude product (cyclometalated chloride-bridged Ir(III) dimer, [Ir(C^N)2(-Cl)2]) was washed with 
hexanes and cold diethyl ether several times, dried, and used without further purification.73 
A mixture of the cyclometalated chloride-bridged Ir(III) dimer (353 mg, 0.28 mmol), 1 (150 mg, 
0.83 mmol), and Na2CO3 (294 mg, 2.8 mmol) was dissolved in 2-ethoxyethanol. The mixture was 
heated at reflux under N2 (g) for 12 h. After cooling to room temperature, the solution was concentrated, 
followed by the addition of H2O. The organic phase was extracted with CH2Cl2 three times. The 
collected organic solution was dried with Na2SO4 and the solvent was removed under reduced pressure. 
The crude materials were purified by column chromatography (SiO2, 50:1 CH2Cl2/CH3OH, Rf = 0.6) to 
give the product as a red powder (340 mg, 80%). FTIR (neat):  = 3057, 2021, 1608, 1516, 1437, 1381, 
1338, 1163, 1028, 762 cm-1; UV/Vis (H2O): max () = 463 nm (5.78 (± 0.12) × 103 M-1 cm-1). 1H NMR 
(400 MHz, CDCl3):  = 8.79 (d, J = 8.0 Hz, 1H), 8.13 (t, J = 8.0 Hz, 1H), 8.07 (m, 3H), 7.92 (dd, J = 
8.0 Hz, 1H), 7.80 (dd, J = 8.0 Hz, 1H), 7.70 (dd, J = 8.0 Hz, 1H), 7.67 (dd, J = 8.0 Hz, 1H), 7.51 (m, 
2H), 7.42 (d, J = 8.0 Hz, 1H), 7.39 (ddd, 1H) 7.26 (ddd, 1H), 7.03 (m, 2H), 6.95 (m, 2H), 6.89 (dd, J = 
8.0 Hz, 1H), 6.72 (m, 1H), 6.60 (dt, J = 6.8 Hz, 1H), 6.30 (m, 2H), 2.87 ppm (s, 6H); 13C NMR (100 
MHz, CDCl3):  = 173.0, 171.1, 169.2, 154.4, 151.8, 151.4, 148.7, 147.8, 147.0, 145.9, 145.1, 138.1, 
136.3, 134.8, 129.4, 128.5, 126.0, 125.2, 121.5, 120.5, 116.1, 109.7, 108.8, 39.1 ppm; HRMS: m/z calcd 
for C38H29IrN4NaO2 [M + Na]+: 789.1812; found: 789.1814; elemental analysis calcd (%) for 
C38H29IrN4O2·0.5CH3OH: C 59.14, H 4.00, N 7.17; found: C 59.00, H 4.01, N 7.19. 
 
2.4.3. Photophysical Properties of Ir-1 
Absorption and emission spectra were measured by UV-Vis and fluorescence spectrophotometers using 
a solution of Ir-1 (20 M in 20 mM HEPES, pH 7.4, 150 mM NaCl; final 1% v/v DMSO) at 298 K. 
Moreover, the quantum yield for phosphorescence (p) was calculated using [Ir(2-
phenylquinoline)2(2,2’-bipyridine)](PF6) (ref = 0.31; 20 M in 2-MeTHF solution) as a reference 
based on previously reported procedures.74 The quantum yield of singlet oxygen (1O2) (s) was 
determined according to the method reported previously.75 Solutions containing Ir-1 (10 M) and 1O2 
substrate [9,10-anthracenediyl-bi(methylene)dimalonic acid (ABDA, 100 M)] were irradiated with 40% 
of 1 sun light. The absorbance of ABDA was obtained every 1 min up to 5 min. [Ru(bpy)3]2+ was 
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employed as a reference material (s = 0.18).76 s values were determined according to the following 
equation: 







For measurement of the lifetime, time-correlated single photon counting (TCSPC) was performed. 
The second harmonic (SHG = 420 nm) of a tunable Ti:sapphire laser with ca. 150 fs pulse width and 76 
MHz repetition rate was used as an excitation source. The emission was spectrally resolved by using 
some collection optics and a monochromator. The TCSPC module with a MCP-PMT was employed for 
ultrafast detection. The total instrument response function (IRF) for fluorescence decay was less than 
150 ps, and the temporal time resolution was less than 10 ps. The deconvolution of the actual 
fluorescence decay and IRF was fitted by using the FluoFit software to deduce the time constant 
associated with an each exponential decay. 
 
 
Figure 2.14. ESI-MS2 of nonoxidized amyloidogenic peptides: (a) A40, (b) -Syn, and (c) hIAPP. 
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2.4.4. Electrospray Ionization Ion Mobility Mass Spectrometry (ESI-IM-MS) 
A40, -Syn, hIAPP, and ubiquitin (100 mm) were incubated with Ir-1 or 1 (500 M) in 100 mM 
ammonium acetate (pH 7.5) at 37 °C without any agitation. Incubated peptides were diluted 10-fold 
and then injected into a mass spectrometer. The capillary voltage, sampling cone voltage, and source 
temperature were set to 2.8 kV, 70 V, and 40 °C, respectively. The backing pressure was adjusted to 3.2 
mbar. Ion mobility wave height and velocity were adjusted to 10 V and 450 ms-1, respectively, and gas 
flow for the helium cell and ion mobility cell was set to 120 and 30 mLmin-1, respectively. Tandem MS 
(MS2) analyses were additionally performed on the nonoxidized (Figure 2.14) and singly/doubly 
oxidized peptides. The ESI parameters and experimental conditions were same as those reported above. 
Collision-induced dissociation was conducted by applying the collision energy in the trap and adjusting 
LM resolution to 15. More than 200 spectra were obtained for each sample and averaged for analyses. 
To estimate collision cross-section values for obtained IM-MS data, calibration was also performed by 
following previously reported procedures (Figure 2.15).77 
 
 
Figure 2.15. Calibration for the estimation of collision cross section values (D). Calibration was 
performed following the previously described procedure.77 (a) Fitting plot to present a linear correlation 
between published collision cross section values of calibrant proteins and corrected drift time (DT”). 
All IM-MS results of calibrants were obtained in the same experimental parameters with those of A40. 
Published collision cross section values of calibrants could be found in previous reports.78–79 (b) 
Experimentally obtained cross section values for nonoxidized and oxidized A40. The IM-MS spectra 
for +5-charged dimers and +3-charged monomers are shown in Figures 2.4 and 2.6, respectively. 
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2.4.5. Mass Spectrometric Analyses 
Oxidized A40, -Syn, hIAPP, and ubiquitin were observed upon incubation with Ir-1 under aerobic 
conditions in the presence of light by using a Waters Synapt G2-Si Q-ToF mass spectrometer equipped 
with an ESI source. Only major charge states of all peptides (+3 for A40 and hIAPP, +9 for -Syn, and 
+5 for ubiquitin) were selected and shown in all mass spectra. Generally, exact mass should be 
calculated based on monoisotopic mass; however, in the present study, the oxidized peaks were assigned 
based on m/z values of the most abundant peaks because monoisotopic mass values of -Syn could not 
be well resolved without a high-resolution mass spectrometer. For example, +3-charged A40 was most 
dominantly found in ESI-MS (Figure 2.2a). Upon treatment of Ir-1 and light, the singly oxidized A40 
ions were abundantly observed at 1449.6 m/z, corresponding to a 16 Da increase in mass from the 
nonoxidized A40 peak at 1444.2 m/z (Figure 2.2a, bottom; blue). In the case of +9-charged -Syn at 
1607.8 m/z, the singly oxidized peak was not well defined due to overlap with sodiated ions at 1610.2 
m/z. With the treatment of Ir-1 and light, doubly oxidized -Syn was found at 1611.3 m/z, which 
indicated an approximate 32 Da increase in mass (Figure 2.2b, bottom; blue). The +3-charged hIAPP 
presented an oxidized peak at 1306.9 m/z, indicating a 14 Da difference in mass from nonoxidized ions 
with 1302.2 m/z upon treatment with Ir-1 and light (Figure 2.2c, bottom; blue). Different from A40 and 
-Syn, singly oxidized hIAPP indicated a 14 Da increase in mass. In the ESI-MS spectra of ubiquitin, 
the +5 charge state was most abundantly detected (Figure 2.7). Singly and doubly oxidized ubiquitin 
were found at 1717.2 and 1720.3 m/z, respectively, which were approximately 16 and 32 Da increases 
in mass from nonoxidized ubiquitin centered at 1713.9 m/z (Figure 2.7, bottom; blue). 
 
2.4.6. Peptide Aggregation Experiments 
Peptide aggregation experiments were conducted as previously published.80 Amyloid- (A) or -
synuclein (-Syn) was dissolved with ammonium hydroxide (NH4OH, 1% v/v, aq), aliquoted, 
lyophilized, and stored at -80 °C. A stock solution (ca. 200 M) was prepared by re-dissolving A or 
-Syn with NH4OH (1% w/v, aq, 10 L) followed by dilution with ddH2O. In the case of hIAPP, the 
peptide was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, purchased from Tokyo Chemical 
Industries Inc., Ltd., Tokyo, Japan) at a concentration of 100 M to remove preformed aggregates. After 
the treatment with HFIP for 2 h at the room temperature, hIAPP aliquots were prepared by evaporating 
the solvent. The peptide concentration in solution was determined by measuring the absorbance of the 
solution at 280 nm ( = 1450 M-1cm-1 for A40;  = 1490 M-1cm-1 for A42;  = 5400 M-1cm-1 for -Syn; 
 = 1280 M-1cm-1 for hIAPP). 
For inhibition experiments, the peptide (25 M; 20 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), pH 7.4, 150 mM NaCl) was first treated with Ir-1 or 1 (50 M; 1% v/v 
final DMSO concentration) followed by exposure to 1 sun light for 10 min. The resulting samples were 
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incubated at 37 °C for 24 h with constant agitation. For disaggregation experiments, the peptide was 
initially incubated at 37 °C for 24 h with steady agitation. Ir-1 or 1 was added afterward followed by 
an additional 24 h of incubation at 37 °C with constant agitation. For the experiments under anaerobic 
conditions, all samples were prepared following the same procedure described above for aerobic 
samples in a N2-filled glovebox. 
 
2.4.7. 2D NMR Spectroscopy 
2D band-selective optimized flip-angle short transient heteronuclear multiple quantum coherence 
(SOFAST-HMQC) NMR was applied to the sample containing uniformly-15N-labeled A40 and Ir-1 at 
10 °C.81 Uniformly-15N-labeled A40 (rPeptide, Bogart, GA, USA) was dissolved in 1% NH4OH and 
lyophilized to ensure the absence of preformed aggregates. The peptide was re-dissolved in 3 mL of 
DMSO-d6 (Cambridge Isotope, Tewksbury, MA, USA) and in buffer to a final peptide concentration of 
80 M (20 mM d11-Tris, pH 7.4, 50 mM NaCl, 10% v/v D2O). Ir-1 was then titrated into the peptide 
solution from a 20 mM stock in DMSO-d6. Following the completion of each titration (up to 2 equiv, 
160 M) the solution was exposed to ambient light within the NMR tube for 1 h and another spectrum 
was recorded. Each spectrum was obtained using 320 complex t1 points and a 0.1 sec recycle delay on 
a Bruker Avance 600 MHz spectrometer. The data were processed using TOPSPIN 2.1 (Bruker) and 
assignment was performed using SPARKY 3.1134 using published assignments as a guide.82–84 







2.4.8. Gel Electrophoresis with Western Blotting (Gel/Western Blot) 
The resultant A species from both inhibition and disaggregation experiments were analyzed by gel 
electrophoresis followed by Western blotting (gel/Western blot) using an anti-A antibody (6E10).80 
Each sample (10 L; [A40 or A42] = 25 M) was separated using a 10-20% gradient Tris-tricine gel 
(Invitrogen, Grand Island, NY, USA). The gel was transferred to a nitrocellulose membrane and blocked 
with a bovine serum albumin (BSA) solution (3% w/v; Sigma, St. Louis, MO, USA) in Tris-buffered 
saline (TBS; Fisher, Pittsburgh, PA, USA) containing 0.1% Tween-20 (TBS-T; Sigma-Aldrich) for 3 h 
at room temperature. The membrane was treated with the A monoclonal antibody (6E10; Covance, 
Princeton, NJ, USA; 1:2,000; BSA, 2% w/v, in TBS-T) for overnight at 4 °C and then incubated with a 
horseradish peroxidase-conjugated goat anti-mouse secondary antibody (1:5,000; Cayman Chemical, 
Ann Arbor, MI, USA) in 2% BSA in TBS-T solution for 1 h at room temperature. A species were 
visualized using the self-made ECL solution (2.5 mM luminol, 0.20 mM p-coumaric acid, and 0.018% 
H2O2 in 100 mM Tris, pH 8.6). 
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2.4.9. Transmission Electron Microscopy (TEM) 
Peptide samples for TEM were prepared following the previously reported methods.80 Glow discharged 
grids (Formvar/Carbon 300-mesh; Electron Microscopy Sciences, Hatfield, PA, USA) were treated with 
the resultant peptide (5 L) for 2 min at room temperature. Excess sample was removed with filter 
paper, and the grids were washed with ddH2O three times. Each grid was stained with uranyl acetate 
(1% w/v ddH2O; 5 L) for 1 min. Uranyl acetate was blotted off, and grids were dried for 20 min at 
room temperature. Images of samples were taken by a JEOL JEM-1400 transmission electron 
microscope (120 kV, 25,000× magnification). 
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A substantial amount of research efforts has been dedicated towards identifying the association of 
amyloidogenic peptides with the pathologies of neurodegenerative diseases. Among these 
amyloidogenic peptides, amyloid- (A), a proteolytic product of the amyloid precursor protein found 
in the AD-affected brain with a self-aggregation propensity, has been implicated as a pathological factor 
in Alzheimer’s disease (AD).1–4 As the main component of senile plaques, A accumulation is a major 
pathological feature of AD.1–3,5 Recent development in A research (e.g., clinical failures of A-directed 
therapeutics) has led to the re-evaluation of the amyloid cascade hypothesis.6 A pathology, however, 
remains a pertinent facet of the disease with indication of A oligomers as toxic species responsible for 
disrupting neuronal homeostasis.1–3,7 Furthering our elucidation of A pathology presents an 
investigative challenge arising from its heterogeneous nature and intrinsically disordered structure.1,2 
To overcome this obstacle and advance our understanding of A-related contribution towards AD, in 
this study, we illustrate chemical approaches to modify A peptides at the molecular level using 
transition metal complexes. 
Transition metal complexes are capable of harnessing a wide range of chemical and biological 
functionality, including peptide modifications (e.g., hydrolytic cleavage and peptide oxidation).8–37 In 
particular, the ability of transition metal complexes to alter peptides stems from their properties, such 
as capacity for peptide coordination.17–29,36,37 Herein, we report effective chemical strategies for 
modifications of A peptides using a single Ir(III) complex in a in a photo-dependent manner (Figure 
3.1). A modifications, achieved by our rationally engineered Ir(III) complexes, include two events: (i) 
complexation with A in the absence of light; (ii) A oxidation upon coordination and photoactivation, 
which can significantly regulate their aggregation and toxicity. Through our overall multidisciplinary 
studies, presented in this work, we demonstrate the feasibility of developing new chemical tactics for 
modifications of amyloidogenic peptides using transition metal complexes, useful for identifying their 
properties, such as aggregation, at the molecular level. 
 
3.2. Results and Discussion 
3.2.1. Rational Strategies for Peptide Modifications by Ir(III) Complexes 
To chemically modify A peptides in a photo-irradiation-dependent manner (Figure 3.1a), four Ir(III) 
complexes (Ir-Me, Ir-H, Ir-F, and Ir-F2; Figure 3.1b) were rationally designed and prepared. Iridium 
is a third row transition metal exhibiting strong spin-orbit coupling at the center of Ir(III) complexes 
with facile electronic transitions.38,39 This spin-orbit coupling can be further strengthened by fine-tuning 
ancillary ligands of Ir(III) complexes. As a result, Ir(III) complexes confer notable photophysical 





Figure 3.1. Chemical approaches to modify A peptides using rationally designed Ir(III) complexes. 
(a) Two types of modifying A peptides by Ir(III) complexes for control of A aggregation: (i) 
coordination to A peptides and (ii) oxidation of A peptides mediated by coordination and 
photoactivation ( = emission quantum yield). (b) Design criteria and chemical structures of Ir-F, Ir-









to generate reactive oxygen species (ROS) via electron or energy transfer.38,40–42 Incorporation of 2-
phenylquinoline derivatives as ligands yielded high emission quantum yield (F) and robust ROS 
generation.40 Thereby, the ancillary ligands of four complexes were constructed based on the 2-
phenylquinoline backbone by applying simple structural variations to provide appropriate structural and 
electronic environments to promote the photochemical activity of the corresponding Ir(III) complexes.40 
Moreover, fluorine atoms were introduced to the ancillary ligand framework, affording Ir-F and Ir-F2, 
to chemically impart the ability to interact with Ab through hydrogen bonding, alter photophysical 
properties of the complexes, and enhance the molecules’ biocompatibility.40,43–45 Two water (H2O) 
molecules were incorporated as ligands to enable covalent coordination to Ab via replacement with 
amino acid residues of the peptide, e.g., histidine (His).20,46,47 The four Ir(III) complexes were 
synthesized following the previously reported procedures with modifications (Scheme 3.1).20,48–50 
 
 
Table 3.1. Photophysical properties of Ir(III) complexes. 
 
 
3.2.2. Coordination-Dependent Photophysical Properties and Singlet Oxygen Production of Ir(III) 
Complexes 
Photophysical properties of the prepared Ir(III) complexes were investigated by UV-Vis and 
fluorescence spectroscopy. Effects of His coordination to the Ir(III) center on F of Ir(III) complexes, a 
measure of the molecules’ ability to produce singlet oxygen (1O2) with photoactivation, were 
comparatively evaluated. Upon addition of His, F of the Ir(III) complexes drastically increased (e.g., 
FIr-F = 0.0071 versus FIr-F + His = 0.26; Table 1), indicating His coordination of the complexes, which 
was further confirmed by electrospray ionization-mass spectrometry (ESI-MS) (Figure 3.2a). Ir-F 
showed the strongest binding affinity with His (Kd = 2.7 x 10-6 M; Figure 3.2b) and generated the largest 
amount of 1O2 upon photoactivation among four Ir(III) complexes (Figure 3.3). Based on these 
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amount of 1O2 upon photoactivation among four Ir(III) complexes (Figure 3.3). Based on these 
properties, we selected Ir-F as a representative candidate of our Ir(III) complexes and illustrated its 




Figure 3.2. Histidine binding of Ir(III) complexes. (a) ESI-MS analysis of Ir(III) complexes (gray dots; 
top) with and without His. The complex formation between His and Ir(III) complexes that do not contain 
two H2O molecules on the Ir(III) center [Ir(III) complexes - 2H2O] was observed (light green dots; 
bottom). Conditions: [Ir(III) complex] = 20 M; [His] = 200 M; room temperature; 2 h; no agitation. 
(b) His binding affinities of Ir(III) complexes. Dissociation constants (Kd) were determined through His 





Figure 3.3. Analysis of the amount of singlet oxygen (1O2) generated by Ir(III) complexes in the absence 
and presence of histidine. (a-d) Time-dependent absorbance of 9,10-anthracenediyl-
bis(methylene)dimalonic acid (ABDA) upon 1O2 generation triggered by (a) Ir-Me, (b) Ir-H, (c) Ir-F, 
and (d) Ir-F2. (e) Absorbance attenuation of ABDA with photoactivated Ir(III) complexes. (f) 
Correlation between the ability to produce 1O2 and the emission intensity of Ir(III) complexes upon His 
binding. Note that 1O2 generation is closely related to the triplet-to-singlet electronic transition of the 
complexes. Since 1O2 generation takes place through energy transfer, it is important that the energy 
donor (i.e., Ir(III) complex) can efficiently emit the photon (phosphorescence) by transferring its energy 
to the energy acceptor (ground state O2). Conditions: [Ir(III) complex] = 10 M; [His] = 0 or 10 M; 
[ABDA] = 100 M; room temperature; 40% of 1 sun light. 
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3.2.3. Photoirradiation-Dependent Peptide Modifications by Ir(III) Complexes 
Modifications of A peptides upon treatment with Ir-F were monitored via mass spectrometric 
techniques [i.e., ESI-MS, ESI-MS2, and ion mobility-mass spectrometry (IM-MS)]. The ESI-MS 
analysis of Ir-F-treated A samples revealed the complex formation between A and Ir-F’ (the Ir-F 
form that does not contain the two H2O ligands; Figure 3.4b) in the absence of light as an indication at 
1653 m/z (Figure 3.4a, middle; green). To identify the molecular species corresponding to 1653 m/z, the 
peak was further analyzed via ESI-MS2 in conjunction with collision-induced dissociation (CID; Figure 
3.4c). The detected ion fragments exhibited m/z values responsible for A40 and Ir-F’. Therefore, our 
MS results demonstrate the complexation between A and Ir-F with loss of two H2O molecules from 
the Ir(III) center (Figure 3.1b). Note that the m/z value of the Ir-F’–A40 complex is equal to that of 




Figure 3.4. Analysis of the A40 species generated upon treatment with Ir-F. (a) ESI-MS spectra of Ir-
F-incubated +3-charged A40 with and without light. The peak indicated in green corresponds to a 
complex of A40 and Ir-F’ [structure shown in (b)]. The peaks corresponding to oxidized A40 species 
are indicated with red dots. The number of red dots presents the number of oxygen atoms incorporated 
into A40. (c) Collision-induced dissociation (CID) spectrum at 1653 m/z [green peak from (a)]. (d) 
Arrival time distributions (ATDs) between nonoxidized and singly oxidized A40 monomers. (e) 
Sequence of A40 and CID spectrum of the singly oxidized A40 found in (a). Monooxidized b fragments 
are notated in red. Charges are omitted in the MS spectra. Conditions: [A40] = 100 M; [Ir-F] = 500 




Upon photoirradiation, the ESI-MS analysis of Ir-F-treated A40 samples led to the detection of 
oxidized A40 (Figure 3.4a, bottom). A40 oxidation manifested a conformational change as probed by 
IM-MS (Figure 3.4d). The most dominant arrival time distribution (ATD) of the singly oxidized A40 
treated with Ir-F showed a broad peak at 9.15 ms, while that of native A40 indicated a peak at 9.92 ms. 
These results suggest that A40 oxidation induced by Ir-F can alter the structural distribution of A40. 
Similar observations were observed with Ir-Me, Ir-H, and Ir-F2, where the complexes were able to 
oxidize A40 and consequently vary its structural distribution (Figures 3.5 and 3.6). In order to 
determine the location of peptide oxidation, the A fragment ions, generated by selectively applying 
collisional energy to singly oxidized A, were analyzed by ESI-MS2 (Figure 3.4e). All b fragments 
smaller than b13 were detected in their nonoxidized forms, while those larger than b34 were only  
 
 
Figure 3.5. ESI-MS spectra of +3-charged A40 treated with Ir-Me, Ir-H, and Ir-F2 in the (a) absence 
and (b) presence of light. The peaks [shown in (a)] corresponding to the complexes composed of A40 
and Ir(III) complexes are indicated in green. The peaks [shown in (b)] corresponding to oxidized A40 
species are highlighted with red dots. The number of red dots presents the number of oxygen atoms 
incorporated into A40. Conditions: [A40] = 100 M; [Ir(III) complex] = 500 M; 37 °C; 1 h (
a0.5 h 
for the sample of A40 with Ir-Me without light treatment); no agitation; 1 sun light for 10 min (for the 
samples treated with light); aerobic conditions. 
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monitored in their oxidized forms. The b fragments between b13 and b34 were indicated in both their 
oxidized and nonoxidized forms. Such observations, along with previous reports regarding A 
oxidation,19,51 suggest His13, His14, and Met35 of A as plausible oxidation sites. Collectively, our 
studies demonstrate that A peptides can be modified upon treatment with Ir-F [(i) coordination to A 
by replacing two H2O ligands with the peptide in the absence of light; (ii) coordination-mediated 
oxidation of A at three possible amino acid residues (e.g., His13, His14, and Met35) upon 




Figure 3.6. IM-MS spectra of +3-charged A40 incubated with and without Ir(III) complexes. Arrival 
time distributions (ATDs) for nonoxidized (top; the “A40 + Light” sample) and singly oxidized A40 
generated upon treatment of light-activated Ir(III) complexes were detected. 
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3.2.4. Effects of Peptide Modifications Triggered by Ir(III) Complexes on A Aggregation 
Based on the photoirradiation-dependent A modifications by Ir(III) complexes, the impact of such 
peptide variations on the aggregation pathways of A was determined employing A40 and A42, two 
main A isoforms found in the AD-affected brain.1–4,52–56 For these experiments, freshly prepared A 
solutions were treated with Ir(III) complexes with and without light under both aerobic and anaerobic 
conditions. The molecular weight (MW) distribution and the aggregate morphology of resultant A 
species were analyzed by gel electrophoresis with Western blotting (gel/Western blot) using an anti-A 




Figure 3.7. Change in the formation of A aggregate with incubation of Ir(III) complexes. (a) 
Sequences of A40 and A42 and Scheme of the inhibition experiments. (b,c,e) Analysis of the resultant 
A40 and A42 species generated under various conditions by gel/Western blot with an anti-A antibody 
(6E10). (d) TEM images of the A aggregates formed from (c) (scale bar = 100 nm). Conditions: [A] 
= 25 M; [Ir(III) complexes] = 250 M; 37 °C; 24 h; constant agitation; 1 sun light for 10 min (for the 
samples treated with light). 
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Under aerobic conditions (Figure 3.7b, left), the aggregation of A40 was affected with treatment 
of Ir-F prompting a shift in the MW distributions in the absence of light. Photoactivation of the Ir-F-
treated A40 sample resulted in a more diverse MW distribution compared to that of the corresponding 
sample without light (light, MW  100 kDa; no light, MW < 15 kDa). The distinct modulation of A40 
aggregation upon addition of Ir-F with photoirradiation is likely a consequence of the complex’s ability 
to generate 1O2 and oxidize A through photoactivation as observed in our spectrometric studies (vide 
supra; Figure 3.4). Therefore, the same experiments were performed under anaerobic conditions to 
 
 
Figure 3.8. Influence of Ir(III) complexes on the formation of A aggregates. (a) Scheme of the 
experiments. Analyses of the resultant (b) A40 and (d) A42 species produced from various 
experimental conditions by gel/Western blot with an anti-A antibody (6E10). Conditions: [A] = 25 
M; [Ir(III) complex] = 250 M; 1 sun light for 10 min (for the samples treated with light). (c) TEM 
images of the A40 aggregates produced from (b) (scale bar = 100 nm). 
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directly monitor the role of O2 in Ir-F’s modulative reactivity against A40 aggregation. In the absence 
of O2 (Figure 3.7b, right), A40 aggregation was also altered by Ir-F regardless of light treatment. Our 
results suggest that both light and O2 are important in the regulation of A40 aggregation through 
coordination-/photo-mediated peptide oxidation triggered by Ir-F. In addition, in the absence of light 
and O2, A40 aggregation is directed by the covalent interactions between Ir-F and the peptide. Similar 
modulation of A42 aggregation was observed upon incubation with Ir-F exhibiting different MW 
distributions compared to the A42 samples without Ir-F in the absence and presence of light and O2 
(Figure 3.7c). Moreover, smaller amorphous aggregates of both A40 and A42, reported to be less 
toxic,57,58 were visualized by TEM from the samples containing Ir-F regardless of irradiation (Figures 
3.7d and 3.8c). 
Furthermore, preformed A aggregates, generated at various preincubation time points (i.e., 2, 4, 
and 24 h), were disassembled and their aggregation pathways were altered, when Ir-F was introduced 
(Figure 3.9). Such Ir-F-induced effects on preformed A aggregates were observed to be dependent on 
photoirradiation. Moreover, the aggregation of both A40 and A42 was also changed with addition of 





Figure 3.9. Impact of Ir(III) complexes on the disassembly of preformed A42 aggregates produced at 
various incubation time points (i.e., 2 h, 4 h, and 24 h). (a) Scheme of the experiments. (b) Analysis of 
the resultant A42 species by gel/Western blot with an anti-A antibody (6E10). Conditions: [A42] = 





Figure 3.10. Viability of N2a cells upon 24 h treatment with A species produced by incubation with 
Ir(III) complexes for 24 h with and without light activation. Cell viability (%), measured by the MTT 
assay, was calculated compared with that treated with an equivalent amount of DMSO only. Conditions 
(final concentration): [A] = 20 M; [Ir(III) complexes] = 5 M. Error bars represent the standard error 
of the mean from three independent experiments. *P < 0.05. 
 
 
3.2.5. Cytotoxicity of A Species Generated upon Incubation with Ir(III) Complexes 
Moving forward, the toxicity of A species produced with treatment of our Ir(III) complexes was 
determined in murine Neuro-2a (N2a) neuroblastoma cells by the MTT assay [MTT = 3-(4,5-dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] (Figure 3.10). The cytotoxicity of A40 species 
incubated with our Ir(III) complexes was noticeably reduced in a photoirradiation-dependent manner. 
In the absence of light, the A40 samples incubated with our Ir(III) complexes exhibited a decrease in 
cytotoxicity (ca. 20%) than the sample of the complex-free A40. As for the photoirradiated samples, 
A40-induced toxicity was lowered by ca. 35% when being treated with our Ir(III) complexes. 
Furthermore, the cytotoxicity of A42 species formed with Ir(III) complexes was also diminished by ca. 
20% regardless of photoactivation. Note that the survival ( 80%) of cells added with our Ir(III) 
complexes under the concentration used for cell studies with A peptides was observed with and 




Figure 3.11. Viability of N2a cells with Ir(III) complexes. (a) Cell viability of Ir(III) complexes (5 M) 
in the absence and presence of light. (b) Survival of the cells treated with different concentrations of 
Ir(III) complexes (10-100 M; #the value was not obtained due to limited solubility) in the absence of 
light exposure. Cell viability (%), measured by the MTT assay, was calculated compared with cells 





Figure 3.12. Impact of Ir-F-preincubated A28 on the aggregation of A42. (a) Sequence of A28 and 
scheme of the experiments. (b) ESI-MS spectrum of +3-charged A28 upon incubation with Ir-F. The 
complex peak is indicated in green. (Inset) Fluorescence response of Ir-F to A28 (ex = 433 nm). 
Charges are omitted in the MS spectra. Conditions: [A28] = 100 M; [Ir-F] = 100 M; 37 °C; 1 h; no 
agitation; 1 sun light for 10 min (for the samples treated with light); aerobic conditions. (c) Analysis of 
the resultant A species, obtained by addition of A42 into Ir-F preincubated with A28, by gel/Western 
blot with (i) anti-A42 and (ii) anti-A (6E10) antibodies. (d) TEM images of the A aggregates 
produced from (c) (scale bar = 100 nm). Conditions: [A28] = 50 M; [Ir-F] = 10 M; [A42] = 20 M; 




3.2.6. Ternary Complexation with A and Intramolecular and Intermolecular A Oxidation 
Premised on Ir-F’s covalent bond formation with A and oxidation of A (vide supra), additional 
studies regarding ternary complexation and promotion of intermolecular oxidation of A were carried 
out employing Ir-F (Figure 3.12). A28, a fragment of A equipped with the metal binding and self-
recognition sites of A40 and A42 with a relatively less propensity to aggregate than the full-length 
peptide,1,59–61 was used to form a complex with Ir-F’ (Figure 3.4b) as evidenced by ESI- MS (1301 m/z; 
Figure 3.12b) and increased fluorescence (Figure 3.12b, inset). As shown in Figure 3.12a, following 
incubation, the sample of the A28–Ir-F’ complex was treated to freshly prepared A42 to monitor its 
effect on A42 aggregation. Based on the gel/Western blot and TEM analyses, the aggregation of A42 
was modulated by the A28–Ir-F’ complex (Figure 3.12c and d). Our mass spectrometric studies 
confirmed that such control of A42 aggregation by the A28–Ir-F’ complex was a result of the ternary 
complex formation with A42, i.e., (A28–Ir-F’)–A42, and (ii) oxidation of A42, both intramolecular 
and intermolecular, upon photoactivation (Figure 3.13). Based on previous reports detailing 
intermolecular interactions between A peptides, hydrophobic interactions between the self-recognition 
site (LVFFA) of A are likely responsible for ternary complexation,1,2,62 consequentially altering the 
 
 
Figure 3.13. ESI-MS spectra of Ir-F-incubated +4-charged A28 and A42 with and without light. The 
peak indicated in cyan refers to a ternary complex of A28, Ir-F’, and A42. The peaks corresponding to 
oxidized peptides (i.e., A28, A42, and A28 with A42) are indicated with red dots. The number of red 
dots presents the number of oxygen atoms incorporated into each peptide. Charges are omitted in the 
MS spectra. Conditions: [A28] = 100 M; [Ir-F] = 100 M; [A42] = 100 M; 37 °C; 2 h; no agitation; 
1 sun light for 10 min (for the samples treated with light); aerobic conditions. 
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aggregation pathways of A in the absence of photoirradiation. Furthermore, these studies indicate that 
intermolecular oxidation of A can be promoted by Ir-F upon photoactivation (Figures 3.13 and 3.14). 
This observation may explain the distinct difference between the modulation of A aggregation with 





Figure 3.14. ESI-MS spectra of +3-charged (a) A28 or (b) A42 treated with Ir-F in the absence and 
presence of light. The peak indicated in green refers to the complex generation between A and Ir-F’ 
(the Ir-F form that does not contain two H2O molecules). The peaks corresponding to oxidized A 
species are indicated with red dots. The number of red dots presents the number of oxygen atoms 
incorporated into A. Conditions: [A] = 100 M; [Ir-F] = 100 M; 37 °C; 1 h; no agitation; 1 sun 




Effective chemical strategies (i.e., coordination to A and coordination-/photo-mediated A oxidation) 
for modifications of A peptides using a single Ir(III) complex were rationally developed. Such changes 
in A peptides are able to lead to the noticeable modulation of their aggregation and toxicity in living 
cells. Our Ir(III) complexes can covalently bind to A by replacing two H2O ligands with A regardless 
of light and O2 [coordination to A; Figure 3.1a (i)]. In the presence of light and O2, Ir(III) complexes 
bound to A are capable of inducing the intramolecular and intermolecular oxidation of A at His13, 
His14, and/or Met35 [oxidation of A; Figure 3.1b (ii)]. Taken together, our multidisciplinary studies 
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demonstrate the feasibility of establishing new chemical approaches towards modifications of 
amyloidogenic peptides (e.g., A) by transition metal complexes designed based on their coordination 
and photophysical properties. In general, chemical modifications in peptides of interest can assist in 
furthering our understanding of principles in their properties, such as peptide assembly. 
 
3.4. Experimental Section 
3.4.1. Materials and Methods 
All reagents were purchased from commercial suppliers and used as received unless otherwise noted. 
Analyses of small molecules by nuclear magnetic resonance (NMR) spectroscopy, Fourier-transform 
infrared (FT-IR) spectroscopy, and mass spectrometry (MS) were conducted on a Bruker AVANCE III 
HD NMR spectrometer, Varian Cary 620/670 FT-IR spectrometer (UNIST Central Research Facilities, 
Ulsan, Republic of Korea), and a Thermo Scientific Q Exactive Hybrid Quadrupole-Orbitrap Mass 
Spectrometer, respectively. A40, A42, and A28 were purchased from Anygen (A40 = 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV; A42 = DAEFRHDSGYEVHHQ-
KLVFFAEDVGSNKGAIIGLMVGGVVIA; Nam-myun, Jangseong-gun, Republic of Korea) and 
AnaSpec (A28 = DAEFRHDSGYEVHHQKLVFFAEDVGSNK; Fremont, CA, USA), respectively. 
Double distilled H2O was obtained from a Milli-Q Direct 16 system (Merck KGaA, Darmstadt, 
Germany). 1 sun light (100 mWcm-2) was treated from a Newport IQE-200 solar simulator (Irvine, CA, 
USA). Anaerobic reactions were performed in a N2-filled glovebox (Korea Kiyon, Bucheon-si, 
Gyeonggi-do, Republic of Korea). Transmission electron microscopical images were taken by a JEOL 
JEM-2100 transmission electron microscope (UNIST Central Research Facilities, Ulsan, Republic of 
Korea). Analysis by electrospray ionization-ion mobility-mass spectrometry (ESI-IM-MS) was carried 
out using a Waters Synapt G2-Si quadrupole time-of-flight ion mobility mass spectrometer (DGIST 
Center for Core Research Facilities, Daegu, Republic of Korea) equipped with an ESI source. 
Photophysical properties were measured by a Shimadzu UV-2600 UV-visible (UV-Vis) 
spectrophotometer and a Varian Cary Eclipse fluorescence spectrophotometer (UNIST Central 
Research Facilities, Ulsan, Republic of Korea). Time-correlated single photon counting (TCSPC) was 
conducted for lifetime measurements with Ti:sapphire laser Mira900 (Coherent, Santa Clara, CA, USA), 
monochromator Acton Series SP-2150i (Princeton Instruments, Acton, MA, USA), and TCSPC module 
PicoHarp 300 (PicoQuant, Berlin, Germany), with micro channel plate photomultiplier tube (MCP-
PMT) R3809U-59 (Hamamatsu, Shizuika-ken, Japan) and fitted by PicoQuant FluoFit software 
(UNIST Central Research Facilities, Ulsan, Republic of Korea). A SpectraMax M5e microplate reader 
(Molecular Devices, Sunnyvale, CA, USA) was used to measure the absorbance for the MTT assay. 
 
3.4.2. Synthesis of Ir(III) Complexes 
3.4.2.1. Preparation of 2-Me 
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2-Me was synthesized by modifications of previously reported procedures.63 CH3(CH2)3Li (n-BuLi; 2.5 
M; 7.0 mL, 18 mmol) was slowly dropped to a solution of 4-bromotoluene (1-Me; 2.0 g, 12 mmol) in 
tetrahydrofuran (THF) under -78 °C, and the solution was vigorously stirred for 1 h. B(OCH3)3 (2.2 g, 
21 mmol) was slowly added to the solution, and the reaction mixture was stirred for additional 4 h. The 
reaction mixture was quenched with H2O. The product was extracted with CH2Cl2 three times. The 
collected organic solution was treated with MgSO4 and removed under the reduced pressure to obtain a 
white powder product. (1.2 g, yield 64%). 1H NMR [400 MHz, CDCl3,  (ppm)]: 8.13 (d, J = 7.9 Hz, 
2H), 7.31 (d, J = 7.5 Hz, 2H), 2.45 (s, 3H). 
 
3.4.2.2. Preparation of 2-F 
2-F was synthesized by the same procedure as 2-Me using 4-fluoroiodobenzene (1-F; 3.0 g, 14 mmol), 
n-BuLi (2.5 M; 8.1 mL, 20 mmol), and B(OCH3)3 (2.5 g, 24 mmol) (white powder; 820 mg, yield 
43%).63 1H NMR [400 MHz, CDCl3,  (ppm)]: 8.19-8.24 (m, 2H), 7.19 (t, J = 8.8 Hz, 2H). 
 
3.4.2.3. Preparation of 3-H 
3-H was synthesized by modifications of previously reported procedures.64 2-Chloroquinoline (400 mg, 
2.4 mmol), phenylboronic acid (2-H; 358 mg, 2.9 mmol), and Pd(PPh3)4 (141 mg, 0.12 mmol) were 
added to a mixture of degassed THF and K2CO3 (2 M, aq) (1:1). The solution was refluxed under N2 (g) 
overnight. After cooling down to room temperature, the solution was concentrated, and H2O was added 
into the resulting solution. The organic phase was extracted with ethyl acetate (EtOAc) three times. The 
collected organic solution was treated with MgSO4 and removed under the reduced pressure. The crude 
materials were purified by column chromatography (SiO2, 10:1 hexanes:EtOAc, Rf = 0.6; white powder; 
297 mg, yield 59%). 1H NMR [400 MHz, DMSO-d6,  (ppm)]: 8.45 (d, J = 8.8 Hz, 1H), 8.26 (d, J = 
7.2 Hz, 2H), 8.14 (d, J = 8.0 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.77 (t, J = 7.2 
Hz, 1H), 7.46-7.62 (m, 4H). 
 
3.4.2.4. Preparation of 3-Me 
3-Me was synthesized by the same procedure as 3-H using 2-chloroquinoline (600 mg, 3.7 mmol), 2-
Me (600 mg, 4.4 mmol), and Pd(PPh3)4 (212 mg, 0.18 mmol) (10:1 hexanes:EtOAc, Rf = 0.6; white 
powder; 733 mg, yield 91%). 1H NMR [400 MHz, DMSO-d6,  (ppm)]: 8.18 (t, J = 9.2 Hz, 2H), 8.08 
(d, J = 8.0 Hz, 2H), 7.86 (d, J = 8.4 Hz, 1H), 7.82 (dd, J = 8.1, 1.5 Hz, 1H), 7.72 (ddd, J = 8.4, 6.9, 1.5 
Hz, 1H), 7.52 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 7.34 (d, J = 8.1 Hz, 2H), 2.44 (s, 3H). 13C NMR [100 
MHz, DMSO-d6,  (ppm)]: 157.3, 148.3, 139.4, 136.9, 136.7, 129.7, 129.6, 129.4, 127.5, 127.1, 126.8, 
126.1, 118.9, 21.4. FT-IR (neat cm-1): 3055, 3026, 2958, 2914, 2858, 1597, 1552, 1496, 1431, 1373, 
1319, 1288, 1244, 1213, 1184, 1157, 1126, 1111, 1053, 1016, 974, 949, 814, 789, 746, 717. HRMS for 
[C16H13N + H]+ Calcd, 220.1121; found, 220.1116. 
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3.4.2.5. Preparation of 3-F 
3-F was synthesized by the same procedure as 3-H using 2-chloroquinoline (500 mg, 3.1 mmol), 2-F 
(500 mg, 3.6 mmol), and Pd(PPh3)4 (176 mg, 0.15 mmol) (10:1 hexanes:EtOAc, Rf = 0.7; white powder; 
616 mg, yield 90%). 1H NMR [400 MHz, DMSO-d6,  (ppm)]: 8.22 (d, J = 8.4 Hz, 1H), 8.17 (t, J = 8.0 
Hz, 3H), 7.83 (dd, J = 8.8 Hz, 2H), 7.73 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 7.53 (ddd, J = 8.1, 6.8, 1.2 Hz, 
1H), 7.21 (t, J = 8.8 Hz, 2H). 13C NMR [100 MHz, DMSO-d6,  (ppm)]: 168.8, 162.9, 160.4, 148.2, 
143.8, 143.8, 143.3, 140.9, 131.7, 129.1, 129.0, 128.9, 127.7, 127.1, 125.9, 119.7, 119.6, 117.5, 109.5, 
109.3. FT-IR (neat cm-1): 3067, 1736, 1594, 1558, 1515, 1495, 1432, 1324, 1286, 1270, 1230, 1162, 
1125, 1098, 1047, 1012, 977, 940, 852, 820, 789, 758, 710, 691, 673. HRMS for [C15H10FN + H]+ Calcd, 
224.0870; found, 224.0864. 
 
3.4.2.6. Preparation of 3-F2 
3-F2 was synthesized by the same procedure as 3-H using 2-chloroquinoline (860 mg, 5.3 mmol), 2,4-
difluorophenylboronic acid (2-F2; 996 mg, 6.3 mmol), and Pd(PPh3)4 (304 mg, 0.26 mmol) (10:1 
hexanes:EtOAc, Rf = 0.7; white powder; 742 mg, yield 59%). 1H NMR [400 MHz, DMSO-d6,  (ppm)]: 
8.46 (d, J = 8.8 Hz, 1H), 8.07-8.14 (m, 2H), 8.02 (d, J = 8.0 Hz, 1H), 7.88 (dd, J = 8.4, 2.4 Hz, 1H), 
7.80 (t, J = 7.6 Hz, 1H), 7.63 (t, J = 7.6 Hz, 1H), 7.43 (t, J = 9.2 Hz, 1H), 7.28 (t, J = 8.8 Hz, 1H). 13C 
NMR [100 MHz, DMSO-d6,  (ppm)]: 164.5, 162.0, 159.5, 152.8, 148.0, 137.3, 133.2, 130.5, 129.5, 
128.3, 127.3, 124.4, 122.3, 112.7, 105.1. FT-IR (neat cm-1): 3057, 2954, 2923, 2853, 1676, 1613, 1596, 
1497, 1456, 1430, 1418, 1318, 1294, 1264, 1134, 1096, 1053, 970, 942, 836, 808, 758. HRMS for 
[C15H9F2N + H]+ Calcd, 242.0776; found, 242.0772. 
 
3.4.2.7. Preparation of Ir-H 
Ir-H was synthesized by modifications of previously reported methods.49,50 3-H (859 mg, 4.2 mmol) 
was added to a solution of IrCl3∙nH2O (500 mg, 1.7 mmol) in a mixture of 2-methoxyethanol and H2O 
(3:1). The solution was refluxed under N2 (g) for 24 h. After cooling down to room temperature, brown 
precipitates were obtained by addition of H2O. The crude product (the cyclometalated chloride-bridged 
Ir(III) dimer, [Ir(-Cl)(3-H)2]2) was washed with hexanes and cold diethyl ether (Et2O) several times, 
dried, and used without further purification.48 
A solution of [Ir(-Cl)(3-H)2]2 (150 mg, 0.12 mmol) and AgOTf (91 mg, 0.35 mmol) was dissolved 
in a mixture of CH2Cl2 and CH3OH (1:1). The solution was stirred under inert conditions for 6 h. The 
reaction mixture was filtered through Celite to remove precipitates. The filtrate was concentrated in 
vacuo, and the resultant residues were solidified with hexanes. The target product (orange powder; 41 
mg, yield 22%) was collected by additional crystallization with CHCl3 and hexanes. 1H NMR [400 
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MHz, DMSO-d6,  (ppm)]: 9.12 (d, J = 8.8 Hz, 2H), 8.68 (d, J = 8.8 Hz, 2H), 8.46 (d, J = 8.8 Hz, 2H), 
8.16 (d, J = 8.0 Hz, 2H), 7.96 (d, J = 7.6 Hz, 2H), 7.87 (t, J = 8.4 Hz, 2H), 7.73 (t, J = 7.2 Hz, 2H), 6.86 
(t, J = 7.2 Hz, 2H), 6.55 (t, J = 7.2 Hz, 2H), 6.03 (d, J = 7.6 Hz, 2H). 
 
3.4.2.8. Preparation of Ir-Me 
Ir-Me was synthesized by the same procedure as Ir-H using 3-Me (700 mg, 3.2 mmol), IrCl3∙nH2O 
(433 mg, 1.5 mmol), [Ir(-Cl)(3-Me)2]2 (132 mg, 0.10 mmol), and AgOTf (77 mg, 0.30 mmol) (red 
powder; 72 mg, yield 44%). 1H NMR [400 MHz, DMSO-d6,  (ppm)]: 9.06 (d, J = 8.4 Hz, 2H), 8.66 
(d, J = 8.8 Hz, 2H), 8.41 (d, J = 8.8 Hz, 2H), 8.16 (dd, J = 8.1, 1.5 Hz, 2H), 7.83-7.90 (m, 4H), 7.72 
(ddd, J = 8.0, 6.8, 1.1 Hz, 2H), 6.72 (d, J = 8.8 Hz, 2H), 5.89 (s, 2H), 1.85 (s, 6H). 13C NMR [100 MHz, 
DMSO-d6,  (ppm)]: 169.8, 148.4, 144.0, 141.5, 140.2, 139.1, 134.8, 131.2, 128.7, 127.5, 126.6, 126.5, 
126.3, 123.0, 122.3, 119.1, 117.1, 21.2. FT-IR (neat cm-1): 3361 (br), 3088, 2916, 1606, 1579, 1554, 
1520, 1451, 1430, 1338, 1247, 1226, 1170, 1075, 1027, 988, 962, 876, 817, 785, 762, 734, 681, 662. 
HRMS for [M - 2H2O - OTf]+ Calcd, 629.1563; found, 629.1564. 
 
3.4.2.9. Preparation of Ir-F 
Ir-F was synthesized by the same procedure as Ir-H using 3-F (616 mg, 2.8 mmol), IrCl3∙nH2O (358 
mg, 1.2 mmol), [Ir(-Cl)(3-F)2]2 (134 mg, 0.10 mmol), and AgOTf (77 mg, 0.30 mmol) (orange powder; 
67 mg, yield 41%). 1H NMR [400 MHz, DMSO-d6,  (ppm)]: 9.08 (d, J = 8.8 Hz, 2H), 8.75 (d, J = 8.7 
Hz, 2H), 8.50 (d, J = 8.8 Hz, 2H), 8.21 (dd, J = 8.1, 1.5 Hz, 2H), 8.12 (dd, J = 8.7, 5.9 Hz, 2H), 7.92 
(ddd, J = 8.7, 6.8, 1.5 Hz, 2H), 7.78 (ddd, J = 8.0, 6.8, 1.1 Hz, 2H), 6.79 (td, J = 8.8, 2.6 Hz, 2H), 5.67 
(dd, J = 9.9, 2.5 Hz, 2H). 13C NMR [100 MHz, DMSO-d6,  (ppm)]: 168.8, 162.9, 160.4, 148.2, 143.8, 
143.8, 143.3, 140.9, 131.7, 129.1, 129.0, 128.9, 127.7, 127.1, 125.9, 122.3, 119.7, 119.6, 119.1, 117.5, 
109.5, 109.3. FT-IR (neat cm-1): 3359 (br), 3088, 2933, 2860, 1595, 1571, 1550, 1516, 1469, 1451, 1432, 
1395, 1341, 1297, 1232, 1194, 1182, 1149, 1070, 1025, 980, 962, 889, 864, 847, 834, 804, 782, 744, 
709, 675, 662. HRMS for [M - 2H2O - OTf]+ Calcd, 637.1062; found, 637.1060. 
 
3.4.2.10. Preparation of Ir-F2 
Ir-F2 was synthesized by the same procedure as Ir-H using 3-F2 (927 mg, 3.8 mmol), IrCl3∙nH2O (459 
mg, 1.5 mmol), [Ir(-Cl)(3-F2)2]2 (100 mg, 0.071 mmol), and AgOTf (54 mg, 0.21 mmol) (orange 
powder; 18 mg, yield 15%). 1H NMR [400 MHz, DMSO-d6,  (ppm)]: 8.89 (d, J = 8.8 Hz, 2H), 8.80 
(d, J = 9.2 Hz, 2H), 8.51 (d, J = 9.2 Hz, 2H), 8.22 (d, J = 8.4 Hz, 2H), 7.92 (t, J = 7.2 Hz, 2H), 7.79 (t, 
J = 7.2 Hz, 2H), 6.86 (t, J = 11 Hz, 2H), 5.63 (d, J = 8.8 Hz, 2H). 13C NMR [100 MHz, DMSO-d6,  
(ppm)]: 167.0, 166.9, 163.4, 162.4, 160.8, 160.7, 159.9, 159.8, 148.5, 145.3, 142.2, 137.6, 132.5, 132.0, 
131.9, 131.2, 130.7, 129.4, 128.4, 128.0, 127.9, 127.5, 126.6, 122.8, 120.4, 120.2, 119.6, 117.3, 117.1, 
99.7, 99.4, 99.1. FT-IR (neat cm-1): 3319 (br), 3081, 2935, 1597, 1556, 1518, 1433, 1411, 1317, 1295, 
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1216, 1190, 1162, 1106, 1019, 992, 830, 756. HRMS for [M - 2H2O - OTf]+ Calcd, 673.0868; found, 
673.0864. 
 
3.4.3. Photophysical Properties of Ir(III) Complexes 
Absorption and emission spectra of the solution of Ir(III) complexes (20 M in H2O; final 1% v/v 
DMSO) with or without histidine (His) or A28 (200 M in H2O) were recorded at 298 K by UV-Vis 
and fluorescence spectroscopy, respectively. Quantum yield () was calculated following previously 
reported procedures. [Ir(2-phenylquinoline)2(2,2’-bipyridine)]Cl (ref = 0.53 in H2O, 1% v/v DMSO) 
was used as a reference.40 For lifetime measurements, time-correlated single photon counting (TCSPC) 
was performed. The second harmonic generation (SHG = 420 nm) of a tunable Ti:sapphire laser with 
ca. 150 fs pulse width and 76 MHz repetition rate was used as an excitation source. The emission was 
spectrally resolved by using some collection optics and a monochromator. The TCSPC module with an 
MCP-PMT was used for ultrafast detection. The total instrument response function (IRF) for measuring 
the fluorescence decay was less than 150 ps, and the temporal time resolution was less than 10 ps. The 
deconvolution of the actual fluorescence decay and IRF was fitted by using the FluoFit software to 
deduce the time constant associated with each exponential decay. Radiative decay constant (kr) and 
nonradiative decay constant (knr) were calculated on the basis of previously reported equations.65 
 
3.4.4. Histidine Binding Affinities of Ir(III) Complexes 
The solution of Ir-Me, Ir-H, Ir-F, or Ir-F2 (20 M in H2O, 1% v/v DMSO) with or without His (200 
M) was measured by ESI-MS (Agilent 1200 and Bruker HCT). Dissociation constants (Kd) were 
determined through His titration experiments. Fluorescence intensity of the solution of Ir-Me, Ir-H, Ir-
F, or Ir-F2 (2 M in H2O; 1% v/v DMSO) with His (0-60 M) was measured after 2 h incubation 
without agitation at room temperature. The resultant titration points were fitted to the Hill’s equation [y 
= Vmax {xn / (xn + kn)}] [Vmax, emission intensity of complete saturation; n, cooperativity; k, half 
maximal effective concentration (EC50)] in non-linear curve fit (OriginPro 2015, OriginLab Corporation, 
Northampton, MA, USA) and the Kd values were calculated by the obtained constant [Kd = kn]. 
 
3.4.5. Singlet Oxygen (1O2) Generation by Ir(III) Complexes 
The amounts of singlet oxygen (1O2) generated upon treatment with Ir-Me, Ir-H, Ir-F, and Ir-F2 were 
determined according to the method reported previously.40 Solutions containing Ir(III) complexes (10 
μM in H2O, 1% v/v DMSO) and 9,10-anthracenediyl-bis(methylene)dimalonic acid (ABDA as a 1O2 
substrate, 100 μM) with or without His (10 μM) were irradiated with 40% of 1 sun light (40 mWcm-2; 
optimized intensity for ABDA not to be degraded). The absorbance of ABDA was measured for 7.5 min 
with a 2.5 min interval. 
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3.4.6. Electrospray Ionization-Ion Mobility-Mass Spectrometry (ESI-IM-MS) 
(i) [A40 (100 M) with Ir-Me, Ir-H, Ir-F, or Ir-F2 (500 M)] and (ii) [A28 and/or A42 (100 M) 
with Ir-F (100 M)] upon 10 min exposure to 1 sun light were incubated in H2O at 37 °C for 1 h without 
agitation. The incubated samples were diluted by 10 fold and then injected into a mass spectrometer. 
The capillary voltage, sampling cone voltage, and source temperature were set to 2.8 kV, 70 V, and 
60 °C, respectively. The backing pressure was adjusted to 3.2 mbar. Ion mobility wave height and 
velocity were adjusted to 10 V and 450 ms-1, respectively, and gas flow for the helium cell and ion 
mobility cell was set to 120 and 30 mLmin-1, respectively. Tandem MS (MS2) analysis was additionally 
performed on the +3-charged [A40 + Ir-F’] (m/z = 1656) and singly oxidized A40 (m/z = 1449). The 
ESI parameters and experimental conditions were same as above. Collision-induced dissociation was 
conducted by applying the collision energy in the trap. More than 200 spectra were obtained for each 
sample and averaged for analysis. 
 
3.4.7. A Aggregation Experiments 
A experiments were conducted as previously published.19 A peptides were dissolved with ammonium 
hydroxide (NH4OH, 1% v/v, aq), aliquoted, lyophilized, and stored at -80 °C. A stock solution (ca. 200 
M) was prepared by re-dissolving A with NH4OH (1% w/v, aq, 10 L) followed by dilution with 
H2O. The peptide concentration in solution was determined by measuring the absorbance of the solution 
at 280 nm ( = 1450 M-1cm-1 for A40;  = 1490 M-1cm-1 for A42 and A28). (i) For the inhibition 
experiments, A (25 M; H2O) was first treated with Ir(III) complexes (i.e., Ir-Me, Ir-H, Ir-F, or Ir-
F2; 250 M; 5% v/v final DMSO concentration) followed by exposure to 1 sun light for 10 min. The 
resulting samples were incubated at 37 °C for 24 h with constant agitation. (ii) For the disaggregation 
experiments, A (25 M; H2O) was initially incubated at 37 °C for 2, 4, or 24 h with steady agitation. 
Ir(III) complexes (250 M; 5% v/v final DMSO concentration) were added to the preincubated A 
samples with or without 1 sun light for 10 min followed by an additional 4 h of incubation at 37 °C with 
constant agitation. (iii) For A28 experiments, A28 (50 M; H2O) was treated with Ir-F (10 M; 1% 
v/v final DMSO concentration) and incubated at 37 °C for 1 h with steady agitation. A42 (20 M; H2O) 
was treated to the A28–Ir-F’ sample followed by exposure to 1 sun light for 10 min. The resulting 
samples were incubated at 37 °C for 1 h with constant agitation. For the experiments under anaerobic 
conditions, all samples were prepared following the same procedure described above for the aerobic 
samples in a N2-filled glovebox. 
 
3.4.8. Gel Electrophoresis with Western Blotting (Gel/Western Blot) 
The resultant A species from both inhibition and disaggregation experiments were analyzed by gel 
electrophoresis followed by Western blotting (gel/Western blot) using an anti-A antibody (6E10; 
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Covance, Princeton, NJ, USA) or anti-A42 antibody (Merck KGaA).19 Each sample (10 L) was 
separated using a 1020% gradient Tris-tricine gel (Invitrogen, Grand Island, NY, USA). The gel was 
transferred to a nitrocellulose membrane and blocked with a bovine serum albumin (BSA) solution (3% 
w/v; Sigma, St. Louis, MO, USA) in Tris-buffered saline (TBS; Fisher, Pittsburgh, PA, USA) containing 
0.1% Tween-20 (TBS-T; Sigma-Aldrich) for 3 h at room temperature. The membrane was treated with 
either an anti-A antibody [6E10; 1:2,000] or an anti-A42 antibody (1:2,000) in a solution of 2% BSA 
(w/v, in TBS-T) for 4 h at room temperature and then incubated with a horseradish peroxidase-
conjugated goat anti-mouse secondary antibody (Cayman Chemical, Ann Arbor, MI, USA; 1:5,000) for 
6E10-treated membranes or a horseradish peroxidase-conjugated anti-rabbit secondary antibody 
(Promega, Madison, WI, USA; 1:2,500) for anti-A42 antibody-treated membranes in 2% BSA in TBS-
T solution (w/v) for 1 h at room temperature. A self-made ECL solution (2.5 mM luminol, 0.20 mM p-
coumaric acid, and 0.018% H2O2 in 100 mM Tris, pH 8.6) was used to visualize the results on a 
ChemiDoc MP Imaging System (BioRad, Hercules, CA, USA). 
 
3.4.9. Transmission Electron Microscopy (TEM) 
Aβ samples for TEM were prepared following the previously reported methods.19 Glow discharged 
grids (Formvar/Carbon 300-mesh; Electron Microscopy Sciences, Hatfield, PA, USA) were treated with 
the resultant A (5 L) for 2 min at room temperature. Excess sample was removed with filter paper 
and the grids were washed with H2O three times. Each grid was stained with uranyl acetate (1% w/v 
H2O; 5 L) for 1 min. Uranyl acetate was blotted off and grids were dried for 20 min at room 
temperature. Images of samples were taken by a JEOL JEM-2100 transmission electron microscope 
(200 kV, 25000× magnification). 
 
3.4.10. Cytotoxicity Studies 
Mouse Neuro-2a (N2a) neuroblastoma cells were purchased from the American Type Cell Collection 
(ATCC, Manassas, VA, USA). Cells were maintained in the media containing 50% DMEM (GIBCO, 
Grand Island, NY, USA) and 50% opti-MEM (GIBCO), supplemented with 5% (v/v) fetal bovine serum 
(FBS; GIBCO), 1% (v/v) L-glutamine (GIBCO), 100 U/mL penicillin, and 100 mg/mL streptomycin 
(GIBCO). The cells were grown in a humidified atmosphere with 5% CO2 at 37 °C. Cell viability was 
determined by the MTT assay [MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide, Sigma-Aldrich]. The cells were seeded in a 96 well plate (15,000 cells in 100 μL per well). (i) 
To identify the cytotoxicity of Ir(III) complexes, the cells were treated with their various concentrations 
(5, 10, 25, 50, or 100 μM; 1% v/v final DMSO concentration) and incubated for 24 h. (ii) For the 
experiments with A, AA40 or A42; final concentration, 20 μM) was added with the Ir(III) 
complexes (final concentration, 5 μM) exposed to 1 sun light for 10 min, and incubated for 24 h at 
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37 °C. The resultant Aβ species were treated with cells. After 24 h incubation, MTT [25 μM; 5 mgmL-
1 in PBS (pH 7.4, GIBCO)] was incubated to each well and the plate was incubated for 3 h at 37 °C. 
Formazan produced by the cells was solubilized by addition of an acidic solution of N,N-
dimethylformamide (DMF, 50% v/v, aq, pH 4.5) and sodium dodecyl sulfate (SDS, 20% w/v) overnight 
at room temperature in the dark. The absorbance was measured at 600 nm using a microplate reader. 
Cell viability was calculated relative to cells containing an equivalent amount of DMSO. Error bars 
were calculated as standard errors of mean (S.E.M.) from three independent experiments. For 
comparisons between two groups, Student’s two-tailed unpaired t test was employed. Statistical 
difference was considered significant at *P < 0.05. 
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The number of aged people affected by neurodegenerative diseases has been increasing; however, the 
development of treatments for the diseases has not been successful due to the lack of understanding 
about their pathogenesis.1,2 The proposed risk factors of neurodegenerative diseases include metal ions 
[e.g., Zn(II)] and amyloidogenic peptides [e.g., amyloid- (A) and tau for Alzheimer's disease, -
synuclein for Parkinson's disease, and huntingtin for Huntington's disease].3–12 Toxic aggregates are 
formed upon aggregation of these amyloidogenic peptides, particularly in the presence of metal ions.2,13–
15 The aggregation and conformational changes of such amyloidogenic peptides have been previously 
studied by luminescence, including Förster resonance energy transfer (FRET).16–21 In addition, the 
interactions between amyloidogenic peptides and metal ions (e.g., binding affinity and coordination 
geometry) have been investigated through multiple physical methods.8,9,22–26 Such approaches, however, 
require high concentrations of peptides and metal ions (e.g., high M) presenting significant challenge 
in performing the experiments due to the aggregation-prone properties of amyloidogenic peptides. 
Unfortunately, detecting the formation of metal-bound amyloidogenic peptides with a straightforward 
and efficient method (e.g., monitoring a turn-on signal) at a low concentration (ca. nM) has not been 
reported. Herein, we report a FRET-based probe (A-1; Figure 4.1 and Scheme 4.1), composed of A1–
21 grafted with a pair of FRET donor and acceptor, for monitoring metal–A complexation at a 
nanomolar range with a turn-on FRET signal. The FRET intensity of A-1 was observed to increase upon 
binding to Zn(II) (green; Figure 4.2). Note that although other metal ions [particularly, Cu(II)] are 
reported to interact with A,10,24 the use of our probe, A-1, is limited for paramagnetic metal ions, such 
as Cu(II), because its fluorescence is quenched (Figure 4.2). Additionally, the FRET signal of A-1 was 
changed when (i) Zn(II) binding of A-1 was interfered by the metal chelator, EDTA (ethylenediamine  
 
 
Figure 4.1. Design principle and sequence of the FRET-based probe, A-1. (a) FRET responses of A-1 
in the absence and presence of Zn(II) with and without inhibitors. (b) Amino acid sequence of A-1. A-
1 is composed of Trp (blue box) at the C-terminus as a FRET donor and 1-naphthylethylenediamine 
conjugated to the side chain of the Asp (orange box) at the N-terminus as a FRET acceptor. Proposed 
amino acid residues for metal binding and a portion of the self-recognition site are indicated in green 
and red, respectively. 
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tetraacetic acid),29 or the compound, L2-b [N1N1-dimethyl-N4-(pyridin-2-ylmethyl)benzene-1,4-
diamine],30,31 capable of forming a ternary complex with Zn(II)–A; (ii) the probe was aggregated. 
Moreover, a library of natural products as inhibitors against metal–A interaction was screened based 
on the change in the FRET responses of Zn(II)-treated A-1. 8 out of 145 natural products were identified 
as effective inhibitors (> 80% inhibition) in vitro. Among the 8 molecules, 6 compounds were shown 
to lower the toxicity associated with Zn(II)–A in living cells. Our studies demonstrate the feasibility 
of developing an efficient tactic to probe metal–amyloidogenic peptide complexation, along with its 




Figure 4.2. Fluorescent response of A-1 (black) upon treatment with Zn(II) (green) or Cu(II) (orange). 
Conditions: [A-1] = 500 nM; [ZnCl2] = 100 M; [CuCl2] = 500 M; 10% DPBS; ex = 280 nm; em = 




Figure 4.3. Zn(II) binding of A-1, monitored by MS. Conditions: [A-1] = 20 M; [ZnCl2] = 2.0 mM; 
incubation for 1 h; 20 mM ammonium acetate, pH 7.4; room temperature; no agitation. 
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4.2. Results and Discussion 
4.2.1. Design and Preparation of A-1 
Our probe, A-1, was designed to have a FRET donor (Trp; ex = 280 nm, em = 350 nm) and an acceptor 
(1-naphthylethylenediamine conjugated to the side chain of an Asp; ex = 350 nm, em = 420 nm) for 
FRET at the C- and N-termini of the A1–21 sequence, respectively (Figure 4.1). A1–21 was selected as 
the main framework of A-1 to include the metal binding site of A (Figure 4.1b; proposed metal binding 
residues highlighted in green, e.g., Asp1, Glu3, His6, Asp7, Glu11, His13, and His14).10,26,32–35 Thus, 
A-1 itself can interact with metal ions like A. When A-1 was treated with Zn(II), the Zn(II)–A-1 
complex was formed which was confirmed by mass spectrometry (MS) (Figure 4.3). Additionally, the 
binding affinity [Kd = 5.6 (± 0.9) M] of A-1 (5 M) for Zn(II) was measured by a fluorescence 
measurement (Figure 4.4a), similar to the Kd values of Zn(II)–A obtained using the same method from 
previous studies.36–38 Moreover, the progression of peptide aggregation could be observed because A-1 
contains a portion of A’s self-recognition site (Figure 4.1b; red, Leu17–Phe20).10,33,39 A-1 was 
synthesized through solid phase peptide synthesis. The detailed synthetic routes are described in 
Scheme 4.1 and Experimental Section. 
 
 
Figure 4.4. Variation of the FRET intensity of A-1 (at 420 nm) upon titration with Zn(II). (a) Plot of 
F/Fmax of Zn(II)-bound A-1 (5 M) as a function of Zn(II) concentration. (b) Change in the 
fluorescence intensity of A-1 (500 nM) upon treatment with various concentrations of Zn(II) at 420 nm. 
Conditions: [A-1] = 5 M or 500 nM; [ZnCl2] = 0–100 or 0–150 M; 10% DPBS; ex = 280 nm; em = 
420 nm; room temperature. 
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Figure 4.5. FRET response of A-1 to Zn(II) and proposed structures of metal-free and Zn(II)-bound A-
1. (a) Change in fluorescence upon incubation of A-1 (black) with Zn(II) (green). Conditions: [A-1] = 
0.5 M; [ZnCl2] = 100 M; ex = 280 nm. (b) Proposed structures of metal-free A-1 (left) and Zn(II)-
bound A-1 (right). The structures were generated by modifications of the previously reported structures 
of metal-free A (PDB: 1AMC)27 and Zn(II)-bound A (PDB:1ZE9).28 The approximate distances 
between the FRET donor and acceptor were indicated with dashed lines. 
 
4.2.2. FRET Signal of A-1 upon Zn(II) Binding 
The presence of Zn(II) induced a significant turn-on FRET signal of A-1 by > 2 fold compared to Zn(II)-
free environment (Figure 4.5a). In order to minimize the aggregation of Zn(II)–A-1 (vide infra; Figure 
4.6), along with consideration of our probe’s Zn(II) binding property, 250–500 nM of the probe and 100 
M of Zn(II) were used for this study. As shown in Figure 4.4b, the fluorescence intensity of A-1 (500 
nM) at 420 nm was enhanced upon titration and was saturated at ca. 100 M of Zn(II). Since FRET 
occurs when a suitable donor and acceptor pair is in close proximity (1-10 nm) with the parallel 
orientation of the transition dipoles of the FRET donor and acceptor,40,41 an increase in the FRET 
intensity is indicative of A-1’s folding upon Zn(II) binding (Figure 4.5a). The possible conformations 
of metal-free and Zn(II)-bound A-1 were visualized by modeling with modifications of the previously 
reported structures of metal-free A and Zn(II)-bound A (PDB: 1AMC27 and 1ZE9,28 respectively; 
Figure 4.5b). Without Zn(II), although the indole ring of the FRET donor and the naphthalene ring of 
the FRET acceptor are close enough for energy transfer (ca. 2.7 nm), they are not facing each other and 
shown to be unfavorable to have a dipole–dipole interaction for FRET (Figure 4.5b; left). Upon 
interacting with Zn(II), however, the indole and naphthalene rings become closer (ca. 1.1 nm) than those 
in metal-free A-1 and are facing each other which could be favorable for the dipole–dipole interaction 
necessary for energy transfer, suggesting that an efficient FRET signal could be observed upon Zn(II) 
binding to the probe (Figure 4.5b; right). Additionally, the emission spectrum was blue shifted by ca. 
25 nm possibly due to an environmental change of the FRET acceptor, naphthylamine, when A-1 was 
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folded with Zn(II) treatment (Figure 4.5a; right). Note that we cannot rule out that intermolecular 




Figure 4.6. Time-dependent fluorescent response and aggregation progression of Zn(II)-treated A-1. (a) 
Change in the FRET signal of A-1 with Zn(II) as a function of incubation time. (b) TEM images of 
Zn(II)-added A-1 aggregates generated at various incubation time points (scale bar = 200 nm). 
Conditions: [A-1] = 0.25 M (for FRET) and 2.5 M (for TEM); [ZnCl2] = 100 M (for FRET) and 1 
mM (for TEM); ex = 280 mm; em = 420 nm; incubation up to 10 h; room temperature. 
 
 
4.2.3. Aggregation of Zn(II)-bound A-1 
In the absence of Zn(II), the FRET signal of A-1 reduced as a function of incubation time (ca. 70% and 
ca. 85% decrease after 1 and 3 h incubation, respectively; Figure 4.7). This lowered signal may be 
triggered by the aggregation of A-1 since the probe contains a portion of the self-recognition region of 
A.10,33,39 In contrast, following incubation time, the FRET signal of Zn(II)-treated A-1 decreased (ca. 
2% and ca. 18% decrease after 1 and 3 h incubation, respectively; Figure 4.6a) at a slower rate compared 
to that of Zn(II)-free A-1 (Figure 4.7). This indicates that the aggregation of A-1 could be delayed by 
the presence of Zn(II), as observed with full-length A40 (Figure 4.8). This difference could stem from 
the disparate conformations of A aggregates generated upon the aggregation of metal–A, distinct 




Figure 4.7. Change in the FRET signal of A-1 following the incubation time without Zn(II). Conditions: 




Figure 4.8. Time-dependent aggregation progression of A40 with and without Zn(II). (a) Aggregation 
kinetics of metal-free A40 and Zn(II)–A40, observed by the ThT assay. Conditions: [A40] = 20 M; 
[ZnCl2] = 20 M; [ThT] = 20 M; pH 7.4; 37 °C; constant agitation. (b) Morphologies of A40 
aggregates generated at various incubation time points, visualized by TEM (scale bar = 200 nm). 
Conditions: [A40] = 20 M; [ZnCl2] = 20 M; pH 7.4; 37 °C; constant agitation. 
 
aggregates.28,42 Thus, we analyzed the morphologies of Zn(II)–A-1 aggregates upon incubation by 
transmission electron microscopy (TEM). As depicted in Figure 4.6b, small and amorphous aggregates 
were observed after 1 h incubation of Zn(II)-added A-1 followed by the detection of larger and more 
structured aggregates with longer incubation. Based on the variation of the FRET intensity as the probe 
99 
aggregated, the aggregation process of Zn(II)–A-1 could be divided into three stages: (i) 0–1 h; (ii) 1–
3 h; (iii) 3–10 h (Figure 4.6a). Up to 1 h incubation, the FRET signal of Zn(II)–A-1 did not significantly 
decrease from the initial measurement. From 1 to 3 h, the FRET intensity of Zn(II)–A-1 dropped 
drastically and after 3 h incubation, the FRET responses of Zn(II)–A-1 were shown to be distinguishably 
reduced slower than those during the 1–3 h incubation period. This could be because Zn(II)–A-1 formed 
large-sized aggregates, including protofibrils and fibrils, which might restrict its rotation to limit the 
distance between the FRET donor and acceptor, along with its solubility in aqueous media. Thus, our 
FRET-based probe, A-1, could monitor the progression of Zn(II)–A aggregation, distinct from metal-
free A aggregation. 
 
4.2.4. Screening Inhibitors against Zn(II)–A Interaction 
To evaluate whether Zn(II)-bound A-1 is an effective identification tool for inhibitors against Zn(II)–
A interaction, alteration of the FRET signal of Zn(II)–A-1 was monitored upon addition of the metal 
chelator (i.e., EDTA) or the molecule capable of forming a ternary complex with Zn(II)–A (i.e., L2-
b) Table 4.1 and Figure 4.9a).29–31 When EDTA was introduced to Zn(II)–A-1, the FRET intensity was 
reduced by 83%, compared to the FRET signal of Zn(II)–A-1, and the emission spectrum was red shifted 
back to that observed under Zn(II)-free conditions (Figure 4.9, i). This suggests that Zn(II) was chelated 
out from A-1 by EDTA, causing the probe to be unfolded. Furthermore, the treatment of L2-b to Zn(II)–
A-1 exhibited a noticeably weaker FRET signal than Zn(II)–A-1 by 82%, but did not present the same 
emission spectrum as that of Zn(II)-free A-1 (Figure 4.9a, ii). The fluorescence behavior of L2-b-added 
Zn(II)–A-1 implies that a ternary complex [e.g., L2-b–Zn(II)–A-1] could be formed and thus Zn(II) 
still interacts with A-1, but the distance between the FRET donor and acceptor may not be in close 
proximity. Note that the emission of Trp was not significantly changed at ca. 350 nm which was not 
absorbed by the FRET acceptor upon addition of EDTA and L2-b (Figure 4.9a), indicating that the 
compounds did not affect the absorption and emission of the FRET donor. Together, our probe, A-1, 
demonstrates the ability to identify molecules with inhibitory activity towards metal–A interaction. 
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Table 4.1. Chemical structures of EDTA, L2-b, and the natural products in our chemical library and 
their inhibition values (%) of the interaction between Zn(II) and A-1. The inhibition values (%) are 
presented in parenthesis. 
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141 (23%) 142 (33%) 143 (3.6%) 
  
144 (38%) 145 (20%) 
 
Moving forward, to confirm the screening capability of our FRET-based method to verify 
molecules as potential inhibitors against metal–A interaction, we built up a chemical library containing 
145 natural products that do not absorb the FRET signal of Zn(II)–A-1 at ca. 420 nm, similar to EDTA 
and L2-b (Figure 4.10 and Table 4.1). The FRET signal of Zn(II)–A-1 upon addition of natural products 
was compared to that of Zn(II)–A-1 to calculate % inhibition (Figures 4.9b, 4.11, and Table 4.1). In our 
library, (i) 15 molecules could not affect Zn(II) binding to A-1; (ii) 103 compounds showed 0 to 50% 
inhibition; (iii) 27 natural products induced a significant decrease in the fluorescence of Zn(II)–A-1 by 
> ca. 50% (Figure 4.9b and Table 4.1). Furthermore, among the 27 natural products (> ca. 50% 
inhibition), 8 compounds (i.e., 9, 37, 61, 71, 73, 84, 106, and 139) demonstrated > 80% inhibitory 
activity against Zn(II)–A-1 interaction. Three compounds (i.e., 61, 71, and 84 out of 8 potent inhibitors; 
Figure 4.9b and Table 4.1) contain both -amyrin moiety and ,-unsaturated carbonyl groups, 
previously reported for controlling metal–A aggregation.43 Note that the compounds containing an 
,-unsaturated carbonyl moiety could form a covalent adduct with A possibly by reacting with Lys 
or His.44,45 To verify the covalent bond formation between one of the effective inhibitors, 61, and an A  
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Figure 4.9. Change in the FRET signal of Zn(II)-bound A-1 upon treatment with inhibitors against 
Zn(II)–A interaction. (a) Fluorescent responses of A-1 in the presence of both Zn(II) and compounds: 
[(i) EDTA and (ii) L2-b]. (b) Inhibition (%) of Zn(II)–A-1 interaction by incubation with the natural 
products. Full data sets regarding the inhibition (%) of 145 natural products are summarized in Table 
4.1. 61, 71, and 84 that contain both -amyrin and ,-unsaturated carbonyl groups and show > 80% 
inhibition against Zn(II)–A-1 interaction are labeled in blue. Conditions: [A-1] = 0.3 M; [ZnCl2] = 
100 M; [inhibitor] = 100 M; incubation for 10 min; room temperature; ex = 280 nm; em = 420 nm. 
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fragment (A28), the sample containing 61 and A28 was monitored by MS. The MS measurement 
presented a covalent A28–61 adduct at 1244 m/z (blue peak; Figure 4.12a). In addition, the tandem MS 
analysis of the peak at 1244 m/z indicated A28 (at 1088 m/z) and 61 (at 471 m/z) confirming the 
formation of the covalent A28–61 adduct (Figure 4.12b). Thus, our inhibitors containing an ,-
unsaturated carbonyl moiety have the potential to bind A-1. Overall, inhibitors against Zn(II)–A 
interaction could be screened and identified by our probe, A-1, showing a variation in its FRET signal 




Figure 4.10. Absorption spectra of EDTA, L2-b, and the selected natural products in the absence (black) 
and presence (green) of Zn(II). Conditions: [compound] = 100 M; [ZnCl2] = 100 M. Note that the 




Figure 4.11. FRET responses of A-1 (black) to Zn(II) without (green) and with (purple) the selected 
natural products. The FRET intensities of the selected natural products showing noticeable inhibition 
(9, 61, 73, 84, 106, and 139) or no significant inhibition (7 and 48) against Zn(II)–A interaction were 
monitored. Conditions: [A-1] = 300 nM; [ZnCl2] = 100 M; [compound] = 100 M; ex = 280 nm. 
 
 
Figure 4.12. Mass spectrometric analysis of the sample containing A28 with the natural product, 61. 
(a) ESI-MS spectra of A28 incubated without (top) and with (bottom) 61. (b) Tandem MS (ESI-MS2) 
spectrum of the +3-charged A28–61 complex (blue, [(A28 – H) + (61 – H) + 3H]3+, 1244 m/z). The 
ESI-MS2 results support the formation of a covalent complex composed of A28 and 61. Conditions: 





Figure 4.13. Effect of the selected natural products on the cytotoxicity triggered by Zn(II) and Zn(II)–
A. (a) Toxicity of the selected natural products with and without Zn(II) in 5Y cells. Cells were treated 
with compounds (10 M) in the absence (light gray) and presence (light green) of Zn(II) (same 
equivalent to compounds; 10 M) for 24 h at 37 °C. (b) A40 (left) or A42 (right; 10 M) with Zn(II) 
(10 M) was pre-incubated at room temperature for 1 h and then treated to 5Y cells with compounds 
(10 M) for 24 h. Cell viability (%) was determined by the MTT assay compared to that obtained upon 
treatment with a volume of H2O (1% v/v DMSO) equal to the samples added. Error bars represent the 
standard error of the mean from three independent experiments. *P < 0.05. 
 
4.2.5. Influence of Inhibitors on Toxicity Associated with Zn(II) and Zn(II)–A 
The effect of the 8 natural products that showed > 80%inhibition against Zn(II)–A-1 interaction on the 
toxicity triggered by metal-free and Zn(II)-treated A40 and A42 (two major isoforms of A)6,10 was 
determined in living cells. We first examined the toxicity of 10 natural products (i.e., 8 effective natural 
products: 9, 37, 61, 71, 73, 84, 106, and 139; 2 compounds which may not be able to disrupt Zn(II)–A-
1 interaction: 7 and 48) in human neuroblastoma SH-SY5Y (5Y) cells. The tested compounds, except 
for 37 and 71, were not relatively toxic (> ca. 80% of cell viability at more than 10 M) in the absence 
and presence of Zn(II) (Figures 4.13a and 4.14). Employing the relatively less toxic natural products 
(i.e., 7, 9, 48, 61, 73, 84, 106, and 139) with and without Zn(II), their impact on the toxicity induced by 
pre-incubated A40 and A42 with and without Zn(II) for 1 h at room temperature was analyzed. The 
natural products could not ameliorate the toxicity induced by metal-free A (Figure 4.15). On the other 
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hand, as depicted in Figure 4.13b (purple), cell survival was improved by 6 natural products, determined 
as effective inhibitors against metal–A-1 interaction, even with the species of Zn(II)–A. As expected, 
the compounds, 7 and 48, shown to hinder Zn(II) binding to A by less than ca. 5% (Figure 4.9b and 
Table 4.1), were not able to mitigate the toxicity induced by both metal-free and Zn(II)-associated A 
(Figures 4.13b and 4.15; gray). Thus, our FRET-based method employing A-1 demonstrates its practical 





Figure 4.14. Toxicity of the selected natural products with and without Zn(II) in 5Y cells. (a) Cells were 
treated with various concentrations (5, 10, 20, and 50 M) of compounds for 24 h at 37 °C. (b) 
Compounds (5 M) in the absence (gray) and presence (green) of Zn(II) (same equivalent to the 
compounds; 5 M) were added to cells and incubated for 24 h at 37 °C. Cell viability (%) was 
determined by the MTT assay. The viability value was calculated compared to that of the cells added 
with DMSO only (1%, v/v). Error bars represent S.E.M. from three independent experiments. *P < 0.05 




Figure 4.15. Effect of the selected natural products on the toxicity triggered by metal-free A in 5Y 
cells. (a) A40 or (b) A42 (10 M) was pre-incubated at room temperature for 1 h and then treated to 
5Y cells with compounds (10 M) for 24 h. Cell viability (%) was determined by the MTT assay 
compared to that of the cells treated with a volume of H2O (1% v/v DMSO) equal to the samples added. 
Error bars represent S.E.M. from three independent experiments. *P < 0.05. 
 
4.3. Conclusions 
Since metal ions and amyloidogenic peptides (e.g., A) can interact with each other and induce 
neurotoxicity, our understanding of such complexation is important to reveal their effects in the 
pathogenesis of neurodegenerative diseases. In order to verify the feasibility of monitoring metal–
amyloidogenic peptide interactions, we employed A as an example of amyloidogenic peptides to 
develop a FRET-based probe, A-1, to detect the metal binding of A and the progression of metal–A 
aggregation effectively and efficiently. Upon addition of Zn(II), the FRET signal of A-1 was 
significantly increased due to the folding of our probe. In addition, when the probe aggregated with 
Zn(II), its fluorescent response was altered in a distinct manner from that of metal-free case. 
Furthermore, by utilizing our FRET-based probe to screen a chemical library (total 145 compounds), 
we identified 6 natural products capable of significantly modulating metal–A interaction (> 80% 
inhibition) in vitro and diminishing cytotoxicity associated with Zn(II)–A in living cells. Our overall 
studies illustrate the development of a strategy to monitor metal–A interaction and its applicability 
towards searching potent inhibitors against metal–A interaction. In the near future, for biological 
applications, new and optimized probes will be developed to monitor the interaction between A and 
Zn(II) or other metal ions, including Cu(II), showing more sensitive fluorescent responses with lower 
energy profiles for excitation and emission (e.g., near-infrared region). Applying our tactic to other 
amyloidogenic peptides, their interactions with metal ions could be, and the inhibitors against metal–
amyloidogenic peptide interaction could be identified. 
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4.4. Experimental Section 
4.4.1. Materials and Methods 
All chemical reagents (reagent grade) were purchased from Sigma Aldrich or Tokyo Chemical Industry 
(Tokyo, Japan) and used as received. Fmoc-protected amino acids were purchased from Chemimpex 
(Wood Dale, IL, USA) and GL biochem (Shanghai, China). Full length A (i.e., A40 and A42) peptides 
were purchased from Anaspec (Fremont, CA, USA) (A40 = DAEFRHDSGYEVHHQKLVFFAEDVG-
SNKGAIIGLMVGGVV; A42 = DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVI-
A). Reaction products were analyzed using high performance liquid chromatography (HPLC), matrix 
associated laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), and nuclear 
magnetic resonance spectroscopy (NMR). HPLC analysis was performed using the Waters photodiode 
array detector 996, separation module 2695, and XBridgeTM C18 column (5 m, 4.6 x 250 mm). 
Peptide purification was performed by the Waters XBridgeTM Prep C18 column (5 m, 19 x 250 mm). 
Purified peptide samples and their Zn(II) binding studies were analyzed by a Bruker MALDI-TOF mass 
spectrometer (Sogang University, Seoul, Republic of Korea) and a Q Exactive Plus Orbitrap mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA), respectively. Fluorescence was recorded 
on a PerkinElmer LS55 fluorescence spectrometer (PerkinElmer, Waltham, MA, USA) and HORIBA 
PTI QuantaMaster 8000 fluorescence spectrometer (HORIBA, Kyoto, Japan). TEM images were taken 
by a JEOL JEM-2100 transmission electron microscope [UNIST Central Research Facilities (UCRF), 
Ulsan, Republic of Korea] and a Tecnai F30 (FEI) transmission electron microscope [KAIST Analysis 
Center for Research Advancement (KARA), Daejeon, Republic of Korea]. Absorbance values of 
compounds and the MTT assay and the fluorescence intensity of ThT were measured using a Molecular 
Devices SpectraMax M5e microplate reader (Sunnyvale, CA, USA). The complex formation between 
A fragments and the natural product was analyzed by the MicrOTOF-QII Hybrid Quadrupole-Time of 
Flight mass spectrometer (Bruker, Billerica, MA, USA) equipped with an ESI source [KARA, KAIST, 
Republic of Korea]. 
 
4.4.2. Synthesis and Purification of A-1 
A-1 was synthesized through solid phase peptide synthesis (SPPS) using the 2-chlorotritylchloride resin 
(loading = 1.2 mmol/1 g resin). The resin was swelled with dry dichloromethane (DCM) for 30 min at 
room temperature. Immobilization of the Fmoc-amino acid was carried out on 1 g resin using 2 equiv 
of the Fmoc amino acid (2.4 mmol) and 4 equiv of N,N-diisopropylethylenediamine (DIPEA) for 1 h at 
room temperature. Fmoc deblocking was achieved twice for 10 min at room temperature using 20% 
(v/v) piperidine in N,N-dimethylformamide (DMF) followed by washing with DMF. Peptide coupling 
reactions were executed according to a pre-activation (10 min) protocol using 4 equiv of the appropriate 
amino acid, 4 equiv of 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU), 4 equiv of 1-hydroxy-benzotriazole (HOBt), and 8 equiv of DIPEA. Then, the preactivated 
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solution was added to the resin and allowed to shake for 2 h at 30 °C. Using the above protocol, the 21-
mer peptide, A-1 (DDnapEFRHDSGYEVHHQKLVFFW), composed of natural amino acids and/or a 
side chain-modified aspartic acid with 1-naphthylethylenediamine (Dnap) was synthesized. Cleavage 
of the final peptide from the resin and deprotection of the acid-labile protective groups were 
accomplished using a mixture of trifluoroacetic acid (TFA), thioanisole, ethanedithiol, and double-
distilled water (ddH2O) (94/1/2.5/2.5, v/v/v/v). The crude peptide was precipitated from the cleavage 
solution and thoroughly washed with ice-cold diethyl ether (Et2O). After preparative HPLC purification 
using a gradient of acetonitrile (CH3CN) with 0.075% TFA in ddH2O containing 0.1% TFA, the product 
fractions were pooled and lyophilized to give a white powder. The identity of A-1 was confirmed using 
MALDI-TOF MS (Calcd, 2860.342; found, 2860.206). 
 
4.4.3. Side Chain-Functionalized Fmoc-Asp(Nap)-OH (Fmoc-Dnap) 
Fmoc-Asp(Nap)-OtBu: Orthogonal protected Fmoc-Asp-OtBu (2.0 g, 4.9 mmol) was dissolved in 
DCM (0.2 M), and subsequently 1-hydroxy-7-azabenzotriazole (HOAt, 1 equiv, 0.65 g, 4.9 mmol), 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, 2 equiv, 1.9 g, 9.7 mmol), and DIPEA (3 equiv, 
2.5 mL, 15 mmol) were added. The reaction mixture was stirred for 10 min at 0 °C followed by the 
addition of N-naphthylethylenediamine (Nap; 2 equiv, 2.5 g, 9.7 mmol) and DIPEA (2 equiv, 1.7 mL, 
9.7 mmol). The reaction mixture was stirred for 20 min at 0 °C and stirring was continued at room 
temperature for additional 4 h. After complete disappearance of the starting material was confirmed by 
thin layer chromatography (TLC), the reaction mixture was diluted with DCM and subsequently washed 
with 1 M HCl (aq, 3x), saturated NaHCO3 (aq, 3x), and brine (3x), dried Na2SO4, filtered, and 
concentrated in vacuo. The residue was purified using silica gel column chromatography [hexanes/ethyl 
acetate (EtOAc) = 2/1 → 1/1) to give the titled compound as a greenish solid (2.2 g; yield = 79%). 1H 
NMR [500 MHz, CDCl3, δ (ppm)]: 7.78 (s, 1H), 7.67 (d, J = 7.3 Hz, 3H), 7.46 (d, J = 7.4 Hz, 2H), 7.35 
(s, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.23 (dd, J = 14.3, 7.2 Hz, 2H), 7.14 (d, J = 8.1 Hz, 1H), 6.47 (d, J = 
7.5 Hz, 1H), 6.13 (s, 1H), 5.94 (d, J = 7.4 Hz, 1H), 5.22 (s, 1H), 4.41 (s, 1H), 4.22-4.31 (m, 1H), 4.21-
4.14 (m, 1H), 4.06 (t, J = 7.0 Hz, 1H), 3.58 (d, J = 4.1 Hz, 2H), 3.33 (s, 2H), 2.74-2.85 (m, 1H), 2.70 
(dd, J = 15.4, 2.5 Hz, 1H), 1.39 (s, 9H). 13C NMR [125 MHz, CDCl3, δ (ppm)]: 171.1, 170.0, 156.2, 
143.8, 143.2, 141.3, 134.3, 128.6, 127.7, 127.1, 126.5, 125.9, 125.2, 124.9, 123.4, 120.3, 120.0, 117.5, 
103.8, 82.7, 67.2, 51.5, 47.0, 44.8, 39.0, 38.4, 27.9. HRMS: Calcd, 524.2180; Found, 524.2181. 
 
Fmoc-Asp(Nap)-OH: Fmoc-Asp(Nap)-OtBu (1, 1.5 g, 2.6 mmol) was co-evaporated with DCM and 
dissolved in a solution of 30% TFA in DCM at 0 °C. The reaction mixture was allowed to warm up to 
room temperature for 2 h, after which the volatiles were removed in vacuo. The residue was subjected 
to silica gel column chromatography (hexanes/EtOAc 1/5 → 1/15) to give the titled compound as a 
light greenish solid (1.3 g; 93%).1H NMR [500 MHz, DMSO-d6, δ (ppm)]: 12.73 (s, 7H), 8.18 (t, J = 
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5.7 Hz, 35H), 8.08 (d, J = 8.1 Hz, 34H), 7.88 (d, J = 7.5 Hz, 68H), 7.67-7.77 (m, 100H), 7.62 (d, J = 
8.3 Hz, 30H), 7.35-7.47 (m, 136H), 7.23-7.35 (m, 103H), 7.10 (d, J = 8.1 Hz, 7H), 6.57 (t, J = 10.7 Hz, 
34H), 6.21 (s, 33H), 4.43 (td, J = 8.1, 5.6 Hz, 6H), 4.26 (dd, J = 7.0, 2.6 Hz, 11H), 4.21 (dd, J = 14.3, 
7.5 Hz, 8H), 3.32-3.46 (m, 37H), 3.27 (d, J = 3.8 Hz, 15H), 2.67 (d, J = 5.4 Hz, 3H), 2.64 (d, J = 5.3 
Hz, 4H), 2.51-2.61 (m, 7H), 1.13-1.40 (m, 5H). 13C NMR [125 MHz, DMSO-d6, δ (ppm)]: 173.6, 170.2, 
156.3, 144.3, 144.3, 144.3, 141.2, 134.5, 128.4, 128.1, 127.6, 127.3, 126.1, 125.7, 124.5, 123.4, 121.9, 
120.6, 116.0, 103.2, 66.1, 51.2, 47.1, 43.4, 38.2, 37.6. HRMS: Calcd, 580.2806; Found, 580.2811. 
 
4.4.4. Preparation of the Samples Containing A-1 
A-1 was dissolved in hexafluoroisopropanol (HFIP, 1 mM) and allowed to stand for 1 h at room 
temperature. The resultant solution of A-1 was aliquoted, lyophilized, and stored at -20 °C. The obtained 
powder was dissolved in a mixture of DMSO/ddH2O (1:1, v/v) to give the final concentration of 1 mM. 
To aid the solvation of the peptide, the mixture was vortexed for 1 min followed by sonication for 10 
min at room temperature. The resultant solution was allowed to be at room temperature for specified 
incubation time points. During fluorescence experiments, the solution of A-1 was stored at 4 °C. 
 
4.4.5. Zn(II) Binding Studies of A-1 
The solution of A-1 (20 M) and ZnCl2 (2.0 mM) was prepared in 20 mM ammonium acetate buffer 
(pH 7.4) and incubated for 1 h without agitation at room temperature. The MS analysis was performed 
using the Q Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific) with an electrospray 
ionization (ESI) source. 
 
4.4.6. Modeling of A-1 with and without Zn(II) 
The structures of metal-free A-1 and Zn(II)-bound A-1 were generated with modifications of the 
previously reported structures of metal-free A (PDB: 1AMC)27 and Zn(II)-bound A (PDB: 1ZE9)28 
by Discovery Studio Visualizer. 
 
4.4.7. Fluorescent Measurements 
A-1 (250-500 nM) and ZnCl2 (100 M) with and without compounds (i.e., L2-b, EDTA, natural 
products; 100 M) were mixed in 10% DPBS for 10 min without agitation. The mixture was excited at 
280 nm. The FRET signal of Zn(II)-treated A-1 was recorded from 300 to 600 nm. Particularly, the 
emission of A-1 at 420 nm showed > ca. 2-fold increase in the presence of ZnCl2, relative to that of A-
1 itself. The buffer for our measurements was selected based on (i) the solubility and (ii) aggregation 
rate of A-1 as well as (iii) no presence of other divalent metal ions. In addition, based on Zn(II) titration 
experiments, the concentration of Zn(II) for fluorescence measurements was chosen. The fluorescence 
intensity of A-1 (500 nM) at 420 nm was enhanced upon titration with Zn(II) and was saturated at ca. 
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100 M of Zn(II). Thus, 500 nM of A-1 and 100 M of Zn(II) were used for fluorescence measurements. 
Moreover, Zn(II) titration to A-1 (5 M) was conducted in order to determine the dissociation constant 
(Kd) of Zn(II)–A-1. The Kd value was determined following previously reported methods.36–38,46 
Furthermore, the fluorescent response of A-1 (500 nM) in the presence of Cu(II) (1 equiv to A-1) was 
monitored. Upon incubation with Cu(II), the fluorescent intensity of A-1 was quenched. 
 
4.4.8. Time-dependent Fluorescence Measurements 
A-1 (250 nM) was dissolved in 10% DPBS and incubated with and without ZnCl2 (100 M) for 10 h. 
Fluorescence was recorded for 10 h with an interval of 5 min at room temperature. 
 
4.4.9. Morphologies of the Aggregates of A-1 and A40 with and/or without Zn(II) 
A-1 (2.5 M) was incubated with ZnCl2 (1.0 mM) in 10% DPBS at room temperature for 10 h without 
agitation. In addition, A40 (20 M) was incubated with and without ZnCl2 (20 M) in a buffered 
solution (20 mM HEPES, pH 7.4, 150 mM NaCl) at 37 °C for 10 h with constant agitation. The samples 
for TEM were prepared according to previously reported methods.30,31 Glow-discharged grids 
(Formvar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) were treated with the 
samples from different incubation time points [1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 h for Zn(II)-treated A-1 
(10 L); 0.5, 3, 5, 7, and 10 h for metal-free A40 and Zn(II)-added A40 (5 L)] for 2 min at room 
temperature. Excess sample was removed with filter paper and washed with ddH2O. Each grid was 
treated with uranyl acetate (1% w/v ddH2O; 5 L) for 1 min. Excess stain was blotted off and the grids 
were air dried for at least 20 min at room temperature. Images from each sample were taken at 200 kV 
with 25,000x magnification [UCRF, Ulsan, Republic of Korea (for Zn(II)-treated A-1 samples)] and 
29,000x magnification [KARA, Daejeon Republic of Korea (for the samples of metal-free and Zn(II)-
bound A40)]. 
 
4.4.10. Thioflavin-T (ThT) Assay 
The kinetics of the formation of -sheet-rich A40 aggregates were monitored by the ThT assay 
according to previous reported methods.47,48 Each A40 sample (20 M) was obtained after different 
incubation time points (up to 12 h) at 37 °C with constant agitation (in 20 mM HEPES, pH 7.4, 150 
mM NaCl) followed by treatment with ThT (20 M). After 20 min incubation, the fluorescence intensity 
of ThT (ex = 440 nm; em = 490 nm) was measured using a microplate reader, and normalized compared 
to that of 12 h incubated metal-free A40 samples. 
 
4.4.11. Absorption Spectra of Inhibitors 
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The solutions of the inhibitors, i.e., EDTA, L2-b, 7, 9, 48, 61, 73, 84, 106, and 139 (100 M; 2% v/v 
DMSO), were prepared in 10% DPBS. Absorption spectra of the inhibitors with and without ZnCl2 (100 
M) were obtained by a microplate reader at room temperature. 
 
4.4.12. Analysis of the Covalent Bond Formation between A28 and the Inhibitor (61) 
A28 (20 M) was incubated with 61 (100 M; 2% v/v DMSO; containing an ,-unsaturated carbonyl 
group) in 20 mM ammonium acetate (pH 7.4) for 2 h at room temperature without agitation. The 
incubated samples were injected into the MicrOTOF-QII Hybrid Quadrupole-Time of Flight mass 
spectrometer (Bruker, Billerica, Massachusetts, USA) equipped with an ESI source (KARA, KAIST, 
Republic of Korea). 
 
4.4.13. Cell Studies 
The human neuroblastoma SH-SY5Y (5Y) cell line was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). The cell line was maintained in media containing 50% 
minimum essential medium (MEM) and 50% F12 (GIBCO), and supplemented with 10% fetal bovine 
serum (Sigma-Aldrich) and 100 U/mL penicillin (GIBCO). Cells were grown and maintained at 37 °C 
in a humidified atmosphere with 5% CO2. The cell culture used in this work did not indicate 
mycoplasma contamination. Cell viability upon treatment with compounds was determined by the MTT 
assay [MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. Cells were seeded in a 
96 well plate (15,000 cells in 100 L per well). Cells were treated with pre-incubated samples containing 
Zn(II) and/or A for 1 h at room temperature without agitation followed by addition of the selected 
natural products. After 24 h incubation, MTT [25 L of 5 mg/mL in PBS (pH 7.4, GIBCO)] was added 
to each well and the plate was incubated for 4 h at 37 °C. Formazan produced by cells was solubilized 
using an acidic solution of N,N-dimethylformamide (DMF, pH 4.5, 50% v/v, aq) and sodium dodecyl 
sulfate (SDS, 20% w/v) overnight at room temperature in the dark. The absorbance was measured at 
600 nm by a microplate reader. Cell viability was calculated relative to that of the cells containing a 
volume of ddH2O (containing 1% DMSO) equal to the volume of protein sample added. 
 
4.4.14. Statistical Analysis 
All data present mean ± standard error of the mean (S.E.M.). For comparisons between two groups, 
Student’s two-tailed unpaired t test was employed. Statistical difference was considered significant at 
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